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ABSTRACT 
Sarcopenia, the loss of muscle mass and function as we age, affects all 
individuals from approximately the 4th decade of life and results in a poor quality of 
life. The mechanisms responsible for sarcopenia are unclear and it is likely that it is a 
multifactorial disease. However, it is hypothesised that an increase in systemic and/or 
muscle pro-inflammatory cytokine levels play a major role. Interferon induced protein 
10 (IP10) is a chemokine that has been shown to be increased in serum as we age. 
Polyphenols are extracts from plants and have been shown to have anti-inflammatory 
effects with benefits in multiple diseases. Therefore, the main aim of this thesis was to 
establish an in vitro model to study the effect of increased levels of IP10 on muscle 
atrophy and inflammation and to examine whether resveratrol treatment was able to 
protect against IP10 induced effects on skeletal muscle atrophy or inflammation. 
Primary myoblasts were isolated from rat muscles and treated with 0.1µM, 
1µM and 10µM of resveratrol to identify a functional concentration. Treatment of cells 
with 1µM of resveratrol increased myoblast growth, increased myotube diameter and 
decreased production of hydrogen peroxide of the cell media. Furthermore, treatment 
of myoblasts with 1µM resveratrol led to increases in the protein content of known 
resveratrol targets; MnSOD and catalase and caused transient increases in Sirt1 protein 
content. Treatment of cells with 1µM resveratrol also increased MnSOD and catalase 
content of myotubes and resulted in a decrease in the content of Sirt1, coupled with an 
increase in the acetylation status of proteins compared with untreated myotubes. As 
these data suggested that 1µM of resveratrol was functional in myotubes, this 
concentration was used to pre-treat myotubes before IP10 treatment. Treatment of 
myotubes with IP10 at levels found in older people (200pg/ml) led to decreases in 
myotube diameter and increases in the atrophy marker, Atrogin1. Pre-treatment of 
myotubes with resveratrol provided protection against both of these effects. 
Treatment of myotubes with a concentration of IP10 found in the young (150pg/ml) 
had no effect on markers of atrophy. Both concentrations of IP10 were found to have 
similar effects on cytokine release by myotubes and resveratrol treatment had only 
marginal effects on this.  
The second aim of this study was to identify an effective concentration of 
resveratrol in vivo and examine the effect of this on skeletal muscle force generation in 
adult and old mice. Treatment of mice with 125mg resveratrol/kg/day resulted in an 
increase in MnSOD and Sirt1 contents of skeletal muscle from young mice but had no 
effect on skeletal muscle force generation by EDL muscles of either adult or old mice. 
Overall data suggest that the increase in IP10 levels seen in ageing contributes 
to sarcopenia; however it is unlikely this acts through changes to the cytokine profile of 
muscle. Resveratrol prevented some atrophic effects induced by IP10, suggesting that, 
the mechanism through which resveratrol may protect against sarcopenia may be 
through the prevention of increases in atrophic pathways.  
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1.1. Skeletal Muscle Structure and Function 
Skeletal muscle accounts for approximately 40% of total body weight and is 
characterised by multi peripheral nuclei and striations. The striations seen in skeletal 
muscle are due to the arrangement of the sub cellular contractile components; actin 
and myosin. Skeletal muscle is comprised primarily of contractile materials but also 
contains nerves, blood vessels and connective tissue – all of which contribute to the 
function of skeletal muscle. There are 640 skeletal muscles in the body that are 
attached to the bones via tendons throughout the body and have important roles 
including locomotion, stabilising body positions and producing heat.  
1.1.1. Skeletal muscle structure 
Mature skeletal muscle consists of numerous multi nucleated muscle fibres 
(Figure 1.1). Each of these muscle fibres is composed of bundles of myofibrils that can 
run the entire length of the fibre (Figure 1.1). The number of parallel myofibres 
determines the force generating ability of the fibre. The number of these myofibres in 
a muscle is determined at birth and little change occurs during life span (Alnaqeeb et 
al., 1986; Klein et al., 2003). However, the cross-sectional area of a muscle fibre is 
very dynamic and is able to change throughout life in response to numerous stimuli 
such as exercise (Maughan et al., 1984), unloading (Berg et al., 1991) and ageing 
(Lexell et al., 1988; Frontera et al., 2000). Myofibrils consist of sarcomeres (Figure 1.1) 
which contain thick and thin protein filaments named myosin and actin that are 
arranged in a longitudinal repeated banding pattern (Figure 1.1). 
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 Figure 1.1 Structure of skeletal muscle (Adapted from Vasilaki et al 2003). 
 
1.1.2. Skeletal muscle molecular structure  
A single sarcomere is composed of repetitions of dark A bands and light I 
bands, it is this orientation that causes the striations that are characteristic of skeletal 
muscle. The light I bands contain the thin filaments, actin, the H zone contains solely 
a. Bundle of 
muscle fibres  
b. Single 
muscle fibre  
c.Myofibril 
e.Actin and 
Myosin filaments 
d. Sarcomere 
Myosin 
Actin 
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myosin and the dark A band is where myosin and actin overlap. The A band is 
separated by a dark line known as the M line and it is this distance between two Z discs 
that is known as a sarcomere. Skeletal muscle contraction involves the sarcomere, ATP, 
troponin and tropomyosin (Bailey, 1948; Ebashi, 1963; Hartshorne et al., 1967).  
   
  
Figure 1.2 Molecular structure of the sarcomere. The sarcomere is made of thick and thin 
filaments known as myosin and actin and the orientation gives skeletal muscle its striated 
appearance (Adapted from Vasilaki et al, 2003). 
 
1.1.3. Sliding filament theory of muscle contraction 
The basic mechanism of skeletal muscle contraction is known as the sliding 
filament theory and was first proposed by Huxley in 1954 (Huxley et al., 1954) and 
confirmed in 1957 (Huxley, 1957). The sliding filament theory describes the action of 
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Z disc Z disc 
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actin binding to and overlapping with myosin in the H Zone with the Z discs making 
contact with the A band. The ability of the sarcomere to act in such a way is due to 
presence and organisation of the actin and myosin filaments in the sarcomere.  
At rest, actin and myosin are not cross-linked due to the presence of the 
troponin-tropomyosin complex. Tropomyosin occupies the groove in the actin filament 
which contains the myosin binding region (Parry et al., 1973). Skeletal muscle 
contraction occurs when an action potential which has exceeded the threshold arrives 
at the neuromuscular junction of a skeletal muscle fibre and ATP is available. The 
arrival of an action potential causes the release of Ca2+ from the sarcoplasmic reticulum 
(Ashley et al., 1968). The Ca2+ will then bind to troponin, causing a change in formation 
that will initiate the movement of tropomyosin away from the myosin binding site 
(Lehman et al., 1994). This allows the myosin head to form a cross-bridge with the actin 
filaments. If ATP is available, ATP will bind to the head of myosin and will be hydrolysed 
into ADP and inorganic phosphate, releasing the energy needed to activate the myosin 
head and for the actin to move across the myosin. This hydrolysis of ATP strengthens 
the cross-link between actin and myosin, and this ATPase activity of myosin dictates 
the speed of the contraction (Bárány, 1967). The myosin head then undergoes a 
conformational change that propels the actin approximately 10nm along the 
sarcomere towards the H Zone; this is known as a power stroke (Figure 1.3). Following 
the power stroke, an ATP molecule will again bind to the myosin head and release actin 
from the myosin head ready to repeat the cycle.  
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Figure 1.3 Sliding Filament Theory. The action of skeletal muscle contraction is known as the 
sliding filament theory. Following activation by an action potential, Ca2+ will bind to troponin 
causing tropomyosin to rearrange and expose the myosin binding site of the actin filaments.  
 
1.1.4. Skeletal muscle fibre types  
Skeletal muscle is a very versatile organ with a range of different requirements 
for different tasks. To meet these demands there are two types of skeletal muscle 
fibres; type I and type II. The skeletal muscle fibres are identified by the presence of 
different isoforms of myosin heavy chain (MHC) and they are generally classified into 3 
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groups; MHCI, MHCIIa and MHCIIx which correspond to different isoforms of myosin 
ATPases; I, IIa and IIx (Brooke et al., 1970).  
Type I fibres are known as slow oxidative fibres and primarily use oxidative 
phosphorylation of triglycerides as a source of energy (MacIntosh et al., 2006). These 
fibres produce ample amounts of ATP and have a high resistance to fatigue and are 
therefore capable of producing low level contractions for a long period of time under 
aerobic conditions. Characteristics of type I muscle fibres include high capillary density, 
mitochondria and myoglobin content (Ingjer, 1979; Jansson et al., 1983; Dueya et al., 
1997) and type I fibres are commonly a red colour. Type I fibres have lower maximum 
shortening velocity, maximum power output, optimal velocity, optimal force, specific 
tension and isometric tension/cross-sectional area than type II fibres (Bottinelli et al., 
1996). Type I fibres are innervated by slow motor neurons.  
Type IIB (also known as Type IIx) fibres are known as fast-twitch glycolytic 
fibres and are generally whiter in colour. In contrast to type I fibres, type IIB fibres have 
low levels of mitochondria, myoglobin and capillaries (Ingjer, 1979) and rely mostly on 
glycolysis of ATP and creatine phosphate for energy. Type IIB fibres are used for short 
anaerobic exercises that require rapid high forces and quickly become fatigued. Type 
IIB fibres are innervated by fast fatigue motor neurons.  
Type IIA (also known as Type IIA) fibres are known as fast-twitch oxidative 
fibres and are usually classed as intermediate fibres. These fibres contain moderate 
levels of mitochondria, capillaries and myoglobin (Ingjer, 1979; Jansson et al., 1983) 
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and use both glycolysis and oxidative phosphorylation of glycogen and creatine 
phosphate as sources of energy and are fairly resistant to fatigue. These fibres are used 
during long term anaerobic exercises. Type IIA fibres are innervated by fatigue resistant 
motor neurons. 
Table 1.1. Characteristics of skeletal muscle fibre types.  
 
In humans, most muscles are classified as type I or II however the majority of 
muscles contain both type I and type IIA/B fibres (Edgerton et al., 1975; Soukup et al., 
2002). Furthermore, the muscle fibre type proportion can change following certain 
activities such as exercise (Simoneau et al., 1985), primarily this occurs if fibres are lost, 
although fibre type per se can only change if changes in innervation occur. 
1.2. Plasticity of Skeletal Muscle  
1.2.1. Satellite cells  
It has been known since the 1800s that skeletal muscle has the ability to 
regenerate following injury. The process of regeneration is similar to the development 
of muscle, and depends on satellite cells. Satellite cells were first identified in 1960’s 
(Katz, 1961; Mauro, 1961) when it was postulated that these cells were involved in 
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muscle regeneration, but it was not until later on in that decade that this was 
confirmed (Shafiq et al., 1965; Reznik, 1969).  
Satellite cells are usually mitotically quiescent until they are required (Schultz 
et al., 1978). These cells reside in between the basal lamina and the sarcolemma 
(skeletal muscle cell cytoplasm) (Mauro, 1961) and become mitotically activated 
following signals from damaged muscle, or other signals such as inflammation (Li, 
2003) or exercise (Crameri et al., 2004). Activated satellite cells migrate to the site of 
injury (Reznik, 1969), where they fuse to existing myofibrils to repair damage or fuse 
with each other to form new myofibrils. Satellite cells also replenish the reserve 
population of satellite cells (Zammit et al., 2004). Approximately 80% of activated 
satellite cells will be used for repair and 20% will replenish the satellite cell population 
(Schultz, 1996). Despite satellite cells being well accepted as major contributors to 
repair and regeneration, their involvement in hypertrophy is debated; some studies 
have shown satellite cells are involved in hypertrophy (Schultz et al., 1978; Crameri et 
al., 2004) whereas others have found there was no effect on hypertrophy with the 
prior ablation of satellite cells (McCarthy et al., 2011). 
1.2.2. Culture of primary skeletal muscle cells  
Satellite cells can be isolated from muscles of humans and animals to allow 
cell culture studies on skeletal muscle (Simoneau et al., 1985; Larkin et al., 2006). Once 
activated, satellite cells will enter myogenic development were they become single 
nucleated muscle cells known as myoblasts (Figure 1.4). Following proliferation, 
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myoblasts can be induced to fuse with other myoblasts to become multinucleated 
myotubes (Figure 1.4) (Capers, 1960).  
 
Figure 1.4 Myogenesis: Representative bright field images of primary rat (a) myoblasts, (b) 
immature myotubes and (c) mature myotubes in cell culture. 
 
1.2.3. Skeletal muscle atrophy 
Skeletal muscle atrophy is characterised by a decline in protein content and 
fibre diameter. Both lead to the decline in force production. Skeletal muscle atrophy 
can be caused by numerous situations such as disuse, injury and denervation and is 
common in the ageing population. 
The correct balance between protein synthesis and protein degradation is 
essential for the maintenance of muscle protein homeostasis. Although different 
models of atrophy (disuse, cachexia etc.) can act through different mechanisms, they 
all lead to the same common end result of fibre and muscle atrophy. The two main 
systems involved in protein degradation are the ubiquitin-proteasomal system (UPS) 
and the autophagy-lysosome system.  
b. a. c. 
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1.2.3.1. Ubiquitination of proteins  
Ubiquitination is a post-translational modification that labels proteins for 
degradation. Ubiquitins are small highly conserved molecules that are activated by 
ubiquitin activating enzymes (E1) (Sharp et al.). Following activation of the ubiquitin, 
the ubiquitin molecule is transferred to an ubiquitin-conjugating enzyme (E2). Finally 
the ubiquitin ligases (E3) bind to E2 and the protein substrate to catalyse the 
movement of the ubiquitin from the E2 to the protein to be degraded. This cycle 
repeats so the protein will be polyubiquitinated, and labelled for proteasomal 
degradation (Hershko et al., 1983).  
The UPS is used for the remodelling of sarcomere proteins in response to 
muscle use (Murton et al., 2008) and it is well established that, during atrophy, the UPS 
is upregulated. The involvement of the UPS in skeletal muscle atrophy was shown in 
elegant studies by Goldberg’s (Gomes et al., 2001) and Glass’s groups (Bodine et al., 
2001b), who identified genes whose expression had changed in numerous models of 
atrophy. These genes were termed “atrogenes”. Two of the most upregulated genes 
during atrophy were muscle specific ubiquitin ligases Atrogin1 and Murf1 (Section 
1.4.4.2). The role of Atrogin1 and Murf1 in atrophy have been shown in genetically 
modified mice, with deletion of Murf1 and Atrogin1 leading to an atrophy resistant 
mouse (Murton et al., 2008). Furthermore, Atrogin1 specifically targets the key muscle 
transcription factor MyoD (Tintignac et al., 2005; Lagirand-Cantaloube et al., 2009) and 
the protein synthesis activator elF3f (Csibi et al., 2009) for degradation. Murf1 has also 
been shown to target structural muscle proteins such as troponin (Kedar et al., 2004) 
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and myosin heavy and light chain (Clarke et al., 2007). There is a role for other E3 
ligases in skeletal muscle atrophy such as Tripartite motif-containing protein 32 
(TRIM32) which causes degradation of structural muscle proteins (Cohen et al., 2012). 
These data demonstrate that the UPS leads to protein degradation and inhibition of 
synthesis of important muscle proteins, signifying the importance of the UPS in muscle 
atrophy.  
1.2.3.2. Autophagy 
Autophagy is the process of “self-eating” and is crucial for the turnover of cell 
components, both in normal circumstances as well as in cellular stress such as 
starvation (Pfeifer et al., 1983). A portion of the cell cytoplasm, including organelles, is 
engulfed by a phagophore (a double membrane that engulfs the cytoplasmic 
components during autophagy) and leads to the formation of an autophagosome. 
Subsequently, the outer membrane of the autophagosome fuses with the endosome (a 
membrane bound compartment derived from the golgi body) this is followed by the 
fusion with the lysosome leading to the degradation of the internal components 
(Arstila et al., 1968) (Figure 1.5).  
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Figure 1.5 Autophagy is a self-degradative process that involves the formation of a 
phagophore which engulfs cytoplasmic compartments to form an autophagosome. The 
autophagosome will fuse with an endosome and a lysosome which will lead to degradation 
(Glick et al., 2010). 
Autophagy has been shown to play a role in skeletal muscle atrophy of 
genetically modified animals, such as mice with the transgenic deletion of CuZnSOD. 
This deletion results in muscle atrophy this was, at least partially, caused through 
upregulation of autophagy (Dobrowolny et al., 2008). Fox03 induced atrophy was also 
shown to occur through autophagy (Mammucari et al., 2007).  
The role of autophagy in skeletal muscle atrophy is further characterised by 
autophagy of the mitochondria (mitophagy). In many models of muscle atrophy, the 
mitochondria are dramatically remodelled. One of the systems activated during this 
remodelling is fission (the breakdown of the mitochondrial reticulum into multiple 
mitochondria) (Hoppins et al., 2007). Inhibition of fission leads to the protection 
against denervation-induced atrophy and the upregulation of fission leads to atrophy 
in mice (Romanello et al., 2010).  
One of the pathways regulating the UPS and autophagy is the IGF1-Akt 
pathway (Section 1.2.4) which can inhibit Atrogin1, Murf1 and other genes required for 
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autophagy (Stitt et al., 2004). An increase in inflammation, and in particular an increase 
in the master inflammation regulator, NF-κB (Section 1.4.8) leads to an increase in 
Murf1 expression (Wu et al., 2014), whereas the genetic down-regulation of NF-κB 
results in a reduction in denervation-induced atrophy (Cai et al., 2004). TNF-α has also 
been shown to regulate Atrogin1 and Murf1 (Wang et al., 2014). Myostatin is a well-
known negative regulator of skeletal muscle mass and deletion of myostatin genes in 
young and old mice results in hypertrophy (Latres et al., 2015). Furthermore, myostatin 
is able to inhibit the IGF-Akt pathway, as Akt can inhibit Atrogin1 and Murf1; an 
increase in myostatin results in the indirect upregulation of Atrogin1 and Murf1 by 
preventing their inhibition by Akt. This myostatin induced upregulation of Atrogin1 and 
Murf1 has been shown to induce autophagy in C2C12 cells (Wang et al., 2015a). 
1.2.4. Skeletal muscle hypertrophy  
Skeletal muscle hypertrophy is an increase in muscle mass due to an increase 
in cross-sectional area of muscle fibres and is usually achieved when the muscle is 
continuously exposed to work that is beyond its current capacity, e.g. resistance 
training (Donnelly et al., 1993; Abe et al., 2003). For hypertrophy to occur, protein 
synthesis must exceed protein degradation. The main pathway involved in protein 
synthesis and muscle hypertrophy is the IGF1-PI3K-Akt-mTOR pathway (Bodine et al., 
2001a; Lai et al., 2004). Insulin growth factor 1 (IGF1) is a small protein similar to 
insulin. A major role for IGF-1 in muscle hypertrophy has been demonstrated 
extensively, whereby inhibition of IGF-1 reduces proliferation and fusion of myoblasts 
in vitro and in vivo (Mavalli et al., 2010) and overexpression of IGF-1 in skeletal muscle 
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of mice results in hypertrophy (Musaro et al., 2001). Evidence that the PI3K-Akt 
pathway acts downstream of IGF-1 is found in studies where activation of P13K and Akt 
pathway led to hypertrophy (Lai et al., 2004) and IGF-1 dependent protein synthesis 
has been shown to require P13K (Mendez et al., 1996; Welsh et al., 1997a).  
Hypertrophy occurs when IGF-1 binds to the IGF-1 receptor (IGFR-1). This 
causes activation of P13K resulting in the conversion of phosphatidylinositol (3, 4)-
bisphosphate (PIP2) lipids to phosphatidylinositol (3, 4, 5)-trisphosphate (PIP3). Akt 
binds to PIP3, which results in phosphorylation of Akt by PDK1. Akt then 
phosphorylates and activates mammalian target of rapamycin (mTOR), which further 
phosphorylates and activates p70s6k leading to increased protein synthesis. mTOR also 
phosphorylates eukaryotic translation binding factor 4E- binding protein 1 (4E-BP1). 
Phosphorylation of 4E-BP1 results in release from the protein synthesis inhibitory 
complex with eLF-4E (Eukaryotic initiation factor 4E), allowing the binding of eLF-4E to 
eLF4G (Eukaryotic initiation factor 4G) thus promoting protein translation initiation 
(Bodine et al., 2001a). PI3K/Akt has also been shown to increase protein synthesis 
through the phosphorylation and inhibition of glycogen synthase 3β (GSK-3β) (Welsh et 
al., 1997b) (Figure 1.6).  
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 Figure 1.6 Mechanism of hypertrophy. P13K phosphorylates and activates Akt. Akt activates 
mTOR and mTOR phosphorylates p70s6k resulting in increased protein synthesis. mTOR also 
inhibits the translation suppressors’ 4E-BP1 and GSK-3β leading to further increases in 
protein synthesis. One of the common activators of this pathway is mechanotransduction.  
 
1.3. Reactive oxygen species (ROS) and ROS defences 
Reactive oxygen species (ROS) are extremely reactive molecules that are 
derived from molecular oxygen. ROS are thought to be predominantly produced by the 
mitochondria as a product of the electron transport chain (Chen et al., 2003b). The 
main source of ROS is thought to be the mitochondria; however recent studies have 
identified other sources of ROS (Sakellariou et al., 2013). ROS have vital roles in cell 
signalling; however in excess they can also cause damage to macromolecules (Powers 
et al., 2010). ROS production is relatively high in skeletal muscle, as skeletal muscle has 
high oxygen consumption and it is well known that ROS, in particular superoxide, are 
40 
 
produced during skeletal muscle contraction (Reid et al., 1992; Sakellariou et al., 2013). 
To contend with the production of ROS skeletal muscle cells have an antioxidant 
defence system which converts ROS into none or less damaging products to prevent 
any deleterious effects. The antioxidant defence system includes antioxidant defence 
enzymes such as the superoxide dismutases (SODs) and catalase. 
1.3.1. Superoxide dismutase   
Superoxide dismutase was first discovered by McCord and Fridovich (McCord 
et al., 1969) and is responsible for the dismutation of superoxide radical into hydrogen 
peroxide (H2O2) and oxygen through the following reaction:  
2O2
+ 2H+ SOD  H2O2 + O2 
Mammalian skeletal muscle contains two prominent types of SOD; copper zinc 
and superoxide dismutase (CuZnSOD) and manganese superoxide dismutase (MnSOD). 
MnSOD is also known as SOD2 and is located in the mitochondria (Weisiger et al., 
1973) with a manganese ion attached to its active site whereas CuZn is also known as 
SOD1 and contains copper and zinc. CuZnSOD is localised to the inter mitochondrial 
space and in the cytoplasm (Crapo et al., 1992). Mammalian skeletal muscle also 
expresses a third superoxide; extracellular SOD (Folz et al., 1994), which scavenges 
extracellular produced O2
 however much less is known about its function. 
1.3.2. Catalase  
The dismutation of the superoxide anion produces hydrogen peroxide (H2O2). 
Although H2O2 is more reactive than O2
- it is not as damaging, but it is still capable of 
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causing cell damage to skeletal muscle cells. Therefore, the role of catalase is to further 
protect the cell from damage by converting H2O2 into oxygen and water (Ji, 1993). 
2H2O2  Catalase 2 H2O + O2 
1.4. Skeletal muscle ageing  
Sarcopenia is the loss of muscle mass and function as we age (Rosenberg, 
1989) and has been shown to occur in human and animal models (Lushaj et al., 2008; 
Sousa-Victor et al., 2014). In humans, sarcopenia will affect individuals from 
approximately the 4th decade of life (Lexell et al., 1988), with a decrease of 30-50% in 
skeletal muscle mass and function by the time individuals reach approximately 80 years 
of age (Akima et al., 2001). However this percentage loss varies depending on personal 
characteristics (Gallagher et al., 1997) as well as the use of different criteria for 
defining sarcopenia (Coin et al., 2013). Sedentary people are most affected by 
sarcopenia and this is worsened by unloading of muscle in inactive old subjects 
(Bamman et al., 1998; Breen et al., 2013). Lifelong exercise is associated with modest 
improvements in muscle mass in the quadriceps of mice (McMahon et al., 2014) and 
lifelong triathlon training is able to preserve muscle mass in the mid-thigh of humans 
(Wroblewski et al., 2011) (Figure 1.7). However, the benefits of exercise on muscle 
function are controversial since lifelong exercise has not been capable of preventing 
loss of strength, since master athletes still undergo a loss in strength, power and 
endurance with age (Grassi et al., 1991; Kayani et al., 2008).  
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Figure 1.7 MRI of a cross sectional area of a (a) sedentary 74 year old man and (b) a lifelong 
triathlon 70 year old man (Wroblewski et al., 2011). 
 
The ageing population is growing substantially with demographic analysis 
predicting that the world population of over 60’s will reach 2 billion by 2050, nearly 
tripling from the beginning of the millennium, resulting in the over 80’s being the 
fastest growing sub-population in the developed world (WHO, 2014). Although there 
have been improvements in lifespan, the same advances have not been made in 
health-span, meaning that the extra years of living are under poor health. Sarcopenia is 
a major contributor to frailty in the older population resulting in further immobility 
with a loss of independence, as well as increasing the risk of other chronic diseases and 
morbidity (Coin et al., 2013). Thus sarcopenia has major socio-economic costs – in 2000 
the US spent 1.5% of their national budget ($18.5 billion) on sarcopenia (Janssen et al., 
2004). This means just a 10% reduction in sarcopenia prevalence would result in a 
saving of $1.1 billion per year in U.S healthcare costs, signifying the importance of 
finding a treatment or preventative therapy for sarcopenia. The mechanisms that 
cause sarcopenia are not completely understood and it is likely that it is a multi-
factorial disease with a network of interacting dysfunctional systems. There are several 
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proposed processes; decrease in protein synthesis (Welle et al., 1993), infiltration of fat 
and connective tissue into skeletal muscle (Brack et al., 2007; Addison et al., 2014), 
dysregulation of proteasomal degradation pathways (Chondrogiannia et al., 2000; 
Cuervo et al., 2000), mitochondrial dysfunction (Short et al., 2005; Sakellariou et al., 
2013), reduced number of satellite cells, increased ROS production (Broome et al., 
2006; Palomero et al., 2013) and increased inflammation (Fagiolo et al., 1993). These 
dysfunctions are proposed to lead to a decrease in fibre number, decreased muscle 
cross sectional area and poor regeneration seen in old humans (Figure 1.8) (Lexell et 
al., 1988). Type II fibres have been shown to be more susceptible than type I fibres to 
sarcopenia (Larsson et al., 1978; Lexell et al., 1988; Nilwik et al., 2013). There is also 
evidence for increases in the ratio of type I to type II fibres (Larsson et al., 1978; 
Holloszy et al., 1995; Andersen, 2003; Lee et al., 2006). However there are some 
conflicting results with other studies providing evidence of no difference in the 
percentage of type I and type II fibres with age (Lexell et al., 1988). The technique used 
to identify fibre type is mainly for identification of myosins, therefore, an explanation 
for these differences could be differential expression of the different myosins along the 
length of the fibre since there is evidence of an increase in the number of mixed fibres 
in old humans (Andersen, 2003). Mixed fire types have been shown in chronically 
stimulated tibialis anterior of the rabbit (Staron et al., 1987). Therefore specific fibre 
typing would depend on analysis of the whole fibre for full fibre typing. Nevertheless, 
total numbers of muscle fibres are lost in older individuals (Figure 1.8).  
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Figure 1.8 Relationship between the total number of fibres in the vastus lateralis muscles and 
age in males (Faulkner et al., 2007). 
 
1.4.1. Changes in satellite cells during sarcopenia  
Satellite cells (Section 1.1.4) are stem cells present in muscle and are 
necessary for skeletal muscle to regenerate following injury (Shafiq et al., 1965). During 
ageing, the number of satellite cells have been shown to decline (Day et al., 2010; 
Chakkalakal et al., 2012) in a fibre type specific manner; in humans there was a 
decrease in satellite cells in type II fibres, with no differences seen in type I fibres 
(Verdijk et al., 2014). Furthermore, a decline in the satellite cell content of EDL muscles 
(primarily type II fibre) of mice is seen at 1 year of age, whereas a decline was not seen 
in the satellite cell content of the soleus muscle (predominately type I fibre) until mice 
were 2.5 years old (Shefer et al., 2006). Remarkably this study also showed the 
presence of whole myofibres with no satellite cells present in 2.5 year old mice (Shefer 
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et al., 2006) . However, there are also studies that show no change in satellite cell 
number in the soleus of rats (Brooks et al., 2009) and a study by Carlson et al (2001) 
showed that satellite cell number was increased in muscles of old rats suffering from 
hind-limb neuropathy (Carlson et al., 2001). These studies used different species as 
well as different muscles and suggest that changes to satellite cell number may be 
specific to the muscle and species used. Furthermore, the proliferation of satellite cells 
from mice is not grossly affected during ageing (Ballak et al., 2015), however the initial 
proliferation rate of isolated satellite cells from old mice in culture has been shown to 
be lower than in cells isolated from younger mice (Shefer et al., 2006). 
Satellite cells self-renew the quiescent pool of satellite cells (Zammit et al., 
2004). During ageing the ability of satellite cells to self-renew is reduced (Shefer et al., 
2006) due to the loss of inactivation and increase in proliferation (Chakkalakal et al., 
2012) which can lead to apoptosis or senescence (Sousa-Victor et al., 2014). This loss in 
the ability to self-populate the reserve population of satellite cells may contribute to 
sarcopenia and this is associated with poor regeneration of muscle of aged animals 
(Carlson et al., 2001).  
The role of this modified behaviour of satellite cells as a cause of sarcopenia is 
unclear, as depletion of satellite cells had no effect on the cross-sectional area seen in 
the muscle of old mice (Fry et al., 2015) or on muscle growth after unloading (Jackson 
et al., 2012). Parabiosis studies showed that muscle of old mice can regenerate 
successfully when placed in a young host (Carlson et al., 1989; Conboy et al., 2005). 
Furthermore, cell culture studies have shown that satellite cells isolated from old mice 
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can fully differentiate into mature myotubes (Shefer et al., 2006) and when 
supplemented with fibroblast growth factor (FGF) showed there was no difference in 
the ability of satellite cells to proliferate ex vivo compared with those from young mice. 
These data suggest that the change in the environment during ageing causes the 
dysfunction in satellite cells rather than loss of function within satellite cells per se 
(Shefer et al., 2006). However, the ablation of satellite cells results in increased fibrosis 
suggesting satellite cell function may play a role in preventing fibrosis. Further studies 
have also shown that satellite cells are essential for regeneration following damage in 
muscle since ablation of these cells had profound effects on the ability of muscles to 
successfully regenerate (Fry et al., 2015). 
1.4.2. Changes in protein synthesis during sarcopenia  
A balance between protein synthesis and degradation is vital to maintain 
muscle mass and the relevant gains or losses in protein synthesis and degradation rates 
are required for hypertrophy (Section 1.2.4) and atrophy (Section 1.2.3). Much 
research has focused on the basal protein synthesis rates in the muscles in the old. 
These studies have shown contradicting results with some studies showing a decreased 
rate of overall protein synthesis in the muscle of old compared with muscle of adult 
humans, (Hasten et al., 2000) and decreased rates of synthesis of individual muscle 
proteins such as myosin heavy chain proteins (Balagopal et al., 1997). Other studies 
showed no difference in protein synthesis in muscles of old humans compared with 
muscles of adults (Volpi et al., 2001; Wall et al., 2015). Thus there is a lack of evidence 
for differences in basal protein synthesis between young and old people. Therefore 
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research has focused on studying protein synthesis in the post-prandial state to 
identify whether older subjects can utilise protein as efficiently as younger people. 
These studies have shown that older subjects have a blunted protein synthesis 
response to nutrients (Cuthbertson et al., 2005; Wall et al., 2015) and to exercise (Fry 
et al., 2011); this is known as anabolic resistance. Data by Kooperman et al (2009) 
demonstrated that there was no difference in either digestion or absorption of 
proteins between the old and young people so it was proposed that anabolic resistance 
is likely to be due to an increase in the amount of protein required to reach a 
‘threshold’ for protein synthesis to occur (Koopman et al., 2009). This is further 
evidenced by studies that show blunted mTOR activation following protein intake in 
the muscle of older people (Cuthbertson et al., 2005). Additional studies have shown 
that this anabolic resistance could be overcome by giving >40g of protein to older men 
(Moore et al., 2015). This has led to researchers to suggest that the recommended 
quantity and daily intake of protein for older individuals to be increased from 0.8g/kg 
per day to up to 1-1.5g/kg (Morley et al., 2010). However it should be noted that a 90g 
dose of protein did not cause an increase in protein synthesis any more than a 30g 
dose suggesting just an increase in overall protein content is not sufficient to overcome 
anabolic resistance. Furthermore higher doses of protein intake (3g protein x kg fat-
free mass (FFM)(-1) x day(-1) have been linked with a decrease in the glomerular 
filtration rate in older people, suggesting that high levels of protein may have 
damaging effects on the kidney (Walrand et al., 2008) and thus prescribing increased 
intake of protein in old people is controversial. Increases in protein synthesis have also 
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been seen if the protein supplement contains a high percentage of leucine (Katsanos et 
al., 2006) or essential amino acids (Paddon-Jones et al., 2004). Increased protein 
synthesis was also achieved by inhibiting co-ingestion of carbohydrates and protein 
(Katsanos et al., 2006). This increase in the amount and quality of protein needed to 
activate protein synthesis in older people may be the reason that some studies have 
found no indication of anabolic resistance in the old (Koopman et al., 2009).  
1.4.3. Infiltration of fat and fibrosis during sarcopenia 
Fibrosis is the accumulation of extracellular matrix (Alnaqeeb et al., 1984; 
Goldspink et al., 1994) and it is well established that during ageing fibrosis and the 
infiltration of adipose tissue (Evans et al., 1995; Song et al., 2004) occurs in skeletal 
muscle. This decrease in the quality of skeletal muscle is thought to contribute to the 
age-related impairment in force generation, particularly in lateral transfer of force 
throughout the muscle fibres (Ramaswamy et al., 2011). 
The accumulation of extracellular matrix, particularly collagen, seems to be 
the result of incomplete repair of muscle following damage (Serrano et al., 2010). 
Skeletal muscle regeneration following injury depends upon a series of well-co-
ordinated events involving numerous cell types that modify the microenvironment of 
the damaged muscle. Infiltration of inflammatory cells and remodelling of the 
extracellular matrix is essential for normal muscle regeneration to preserve muscle 
architecture. During ageing, this remodelling becomes dysregulated possibly due to 
changes in the inflammatory response to damage (Mann et al., 2011). Dysfunction in 
remodelling is coupled with a switch in myogenic progenitor cells from a myogenic to 
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fibrotic fate (Shefer et al., 2006; Brack et al., 2007) or an adipogenic fate (Vettor et al., 
2009; Pisani et al., 2010) suggesting satellite cells as a possible source of intramuscular 
fat deposition. This change in cell fate is possibly due to changes in the Wnt signalling 
pathway which has been shown to be involved in the myogenic fate of satellite cells 
and increased Wnt signalling has been shown to occur in ageing (Vertino et al., 2005; 
Brack et al., 2007). Alternatively changes in the inflammatory response such as those 
seen during ageing may also play a role in determining cell fate (Wang et al., 2015b).   
Increases in collagen deposition leads to an increase in advanced glycation 
end (AGE) products in skeletal muscle in humans (Haus et al., 2007). AGE is the non-
enzymatic crosslinking of collagen; this crosslinking increases the strength of the 
collagen leading to stiffness within the muscle. Goldspink et al (2004) showed no 
difference in the transcription levels of collagen in the muscle of old mice (Goldspink et 
al., 1994). Given that total collagen levels are elevated in muscle of old mice these data 
suggest that there may be a reduction in collagen degradation likely due to the 
increased crosslinking, making the collagen somewhat resistant to degradation by 
collagenase. 
1.4.4. Changes in protein degradation during sarcopenia 
The appropriate quality control of protein is vital for the correct functioning of 
the cell. The two most common mechanisms responsible for this are autophagy and 
the proteasomal degradation pathway. These two pathways have been shown to be 
dysregulated in ageing and therefore are hypothesised to contribute to the loss of 
muscle mass with age.  
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1.4.4.1. Autophagy during sarcopenia 
There is evidence that autophagy (Section 1.2.3.2) is dysregulated in the 
muscle of old rodents (Russ et al., 2012; Joseph et al., 2013b; Russ et al., 2015a) and 
studies in drosophila show that there is an accumulation of protein aggregates that 
lead to impaired muscle function (Demontis et al., 2010) providing evidence for 
autophagic dysregulation in the development of sarcopenia.  
Impairment of mitophagy (autophagy of the mitochondria) is detrimental to 
muscle homeostasis, and leads to the accumulation of damaged and dysfunctional 
mitochondria (Grumati et al., 2010). Dysfunctional mitophagy has been shown to occur 
in the muscle of old men (Gouspillou et al., 2014) and women (Drummond et al., 2014) 
and is therefore hypothesised to play a role in the mitochondrial dysfunction that is 
thought to be one of the major contributors to sarcopenia (Section 1.4.7).  
1.4.4.2. Proteasomal degradation during sarcopenia  
The role of the ubiquitin-proteasome system (UPS) (Section 1.2.3.1) is to 
regulate protein degradation and maintain protein homeostasis. Proteins are labelled 
with ubiquitin molecules for degradation and are passed to the proteasome where 
they are degraded.  
There are numerous ligases that are able to carry out protein degradation; 
however Atrogin1 and Murf1 are muscle specific ligases that have been shown to play 
a role in numerous models of atrophy (Bodine et al., 2001b). Despite the evidence for a 
role of the UPS in muscle atrophy, the role of the UPS in muscle ageing is controversial. 
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Some studies show upregulation of both muscle specific ligases Atrogin1 and Murf1 in 
the muscle of old rats (Clavel et al., 2006), whilst others show no difference between 
age groups (Gaugler et al., 2011) or the upregulation of only one of the atrogenes 
(Altun et al., 2010). Others have shown that Atrogin1 and Murf1 are down regulated in 
the muscle of old rats (Edström et al., 2006). Although these results from rodent 
studies show contradicting results, it is generally thought that these two atrogenes and 
the UPS play a role in sarcopenia.  
1.4.5. Changes to the neuromuscular system during sarcopenia 
During ageing there is a decrease in motor unit number in rodents (Ling et al., 
2009) and humans (Figure 1.9) (Piasecki et al., 2015) and this has been shown to occur 
in various muscles (McComas et al., 1993). A decrease in the number of motor axons 
innervating fibres has been observed in rodents (Ansved et al., 1990) and humans 
(Tomlinson et al., 1977). Denervation leads to the sprouting of axons of existing 
functional nerves to innervate fibres in close proximity. This is known as motor unit 
remodelling and is evidenced by an increase in reinnervation is old mice (Holloszy et 
al., 1995). Reinnervation is speculated to cause some of the age-related fibre type 
switching that occurs (Larsson et al., 1978; Andersen, 2003; Lee et al., 2006), as slow 
motor neurons may be more adapted to reinnervation which leads to an age-related 
loss in fast motor neurons (Kadhiresan et al., 1996). If reinnervation does not occur it is 
likely that the muscle fibre will eventually undergo cell death (Borisov et al., 2000; 
Borisov et al., 2001). Research has provided evidence that neuromuscular remodelling 
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is a pre-requisite for muscle atrophy (Deschenes et al., 2010), however this is still 
poorly understood.  
 
Figure 1.9 The relationship between the number of motor units in the extensor digitorum 
brevis muscles and the age of men between 5 and 88 years of age. The number of motor 
units remained constant from 5 years to 50 years of age, but then decreased linearly with an 
apparent zero intercept at approximately ninety-five years of age (Faulkner et al., 2007) 
 
1.4.6. Increases in reactive oxygen species and alterations in antioxidant defence 
systems during sarcopenia 
Reactive oxygen species are extremely reactive molecules and have important 
roles in metabolism and cell signalling (Thannickal et al., 2000), particularly during 
muscle contraction (Reid et al., 1993). Though ROS have important functions in cells, 
when in excess, ROS can be damaging to the marcomolecules of the cells such as lipids, 
proteins and DNA, leading to cell death, if not eliminated by the antioxidant defence 
system (Section 1.3.1).  
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The role of ROS in ageing was first hypothesised by Harman in the 1950s who 
proposed the ‘free radical theory of ageing’. This theory states that ageing occurs due 
to the accumulation of damage to the cellular marcomolecules by ROS over time 
(Harman, 1956). This is particularly relevant to skeletal muscle, as ROS are produced at 
a high rate in skeletal muscle due to the large amount of oxygen consumption and this 
increase in ROS is proposed to be one of the master regulators of sarcopenia. There is 
evidence that ROS are increased in the satellite cells of older subjects (Minet et al., 
2012) which may contribute to the loss of regeneration potential in muscles of older 
animals and humans. One possible mechanism for this is a decrease in myogenic 
regulatory factors (Ardite et al., 2004). ROS are also increased at basal levels in mouse 
muscle (Palomero et al., 2013) and this is hypothesised to be due to mitochondria 
dysfunction (Section 1.4.7). This increase in ROS in older skeletal muscle has been 
shown to be detrimental to skeletal muscle as is reflected by increases in markers of 
oxidative damage such as an increase in protein carbonyl and malonaldehyde (Broome 
et al., 2006) and oxidation of lipids, DNAs and proteins in the muscles of old mice 
(Mecocci et al., 1999). This modified redox status has also been shown to be 
detrimental for processes such as calcium transport (Fulle et al., 2003) and increased 
degradation of important proteins such as myogenin. These changes result in impaired 
autophagy (Scherz-Shouval et al., 2007) and differentiation of muscle cells (Ardite et 
al., 2004). These impairments are possibly due to increased inflammation as well as an 
increase in proteasomal degradation (Li et al., 2003). ROS are also thought to play a 
role in the chronic inflammation state seen in old humans and animals (Section 1.4.8). 
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 ROS are eliminated by the antioxidant defence system (Section 1.3). During 
ageing, it has been shown there is a constituent upregulation of the antioxidant 
defence system activity in skeletal muscle (Vasilaki et al., 2006; Palomero et al., 2013; 
Sullivan-Gunn et al., 2013). Following a stress such as muscle contraction, there is no 
further increase in antioxidant defence enzyme activities in the muscle of old humans 
and animals (Vasilaki et al., 2006; Ryan et al., 2008) leaving the cells exposed to 
oxidative damage.  
The contribution that ROS play in the ageing process remains unclear. Over-
expression of CuZnSOD extends the lifespan in Drosophila melanogaster (Sun et al., 
1999). However the deletion of the SOD antioxidant enzymes did not affect the 
lifespan of C.Elegans (Honda et al., 2008) whereas the lifespan of the C.Elegans with 
deleted MnSOD was increased (Van Raamsdonk et al., 2009). Furthermore, the oral 
intake of juglone, a ROS generator that comes from the plants and leaves from the 
Juglandacaeae family, increased the lifespan of C.Elegans (Ji et al., 2012). Over 
expression of CuZnSOD in muscle led to increased oxidant production and resulted in 
atrophy (Rando et al., 1998). The deletion of CuZnSOD resulted in a decrease in 
modified ROS generation, inability of muscle to adapt and decreased muscle force 
(Muller et al., 2006; Vasilaki et al., 2010; Larkin et al., 2011; Sakellariou et al., 2014b) 
suggesting the correct balance of ROS as an important modulator of sarcopenia.  
1.4.7. Mitochondria dysfunction during sarcopenia 
Mitochondria are essential for providing the ATP required for muscle 
contraction and are also central to the redox regulation and quality control of the cell 
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and therefore essential for the viability of muscle cells. Given this essential role of 
mitochondria in skeletal muscle maintenance and survival, alterations in mitochondria 
are considered one of the primary contributors driving the sarcopenic process. 
Due to the high levels of oxidative phosphorylation in skeletal muscle, 
mitochondria are proposed to be responsible for the majority of ROS produced. The 
role of the mitochondria in sarcopenia was proposed by Miquel in the mitochondrial 
free radical theory of ageing (Miquel et al., 1980). This stated that mitochondrial 
dysfunction in ageing occurs from the increase in ROS and blunted antioxidant 
defences, these damaging effects change the redox status of the cell which in turn 
leads to mutations in the mitochondrial DNA (mtDNA) leading to the production of 
dysfunctional components of the electron transport chain (ETC). Impairment of the ETC 
leads to compromised oxidative phosphorylation which causes a further rise in ROS, 
causing a vicious circle which will exacerbate the ageing phenotype (Miquel et al., 
1980). 
This hypothesis was confirmed in skeletal muscle by studies showing that 
during ageing there was an increase in ROS, mtDNA deletions and mitochondrial 
dysfunction which were associated with skeletal muscle atrophy in non-human 
primates (Lee et al., 1998a) rodents (Wanagat et al., 2001) and humans (Bua et al., 
2006). Interestingly, these observations were not seen in the phenotypical normal 
regions of the muscle fibres. Furthermore mice which contain error prone mtDNA 
polymerase accumulate high levels of mtDNA mutations and show severe muscle 
atrophy due to increased apoptosis (Kujoth et al., 2005). Further studies show that 
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mtDNA mutations lead to increased ROS production (Logan et al., 2014), and 
overexpression of antioxidants have been shown to protect against some of the 
oxidative and nucleic acid damage as well as changes to mitochondrial respiration and 
ATP production in skeletal muscle (Lee et al., 2010) which prevent age related 
mitochondrial dysfunction. Furthermore, the overexpression of PGC1-α, the master 
mitochondrial regulator, led to improved mitochondrial function and protection 
against sarcopenia in mice (Wenz et al., 2009). These data suggests that both ROS and 
mitochondrial dysfunction are likely to contribute to sarcopenia. However, more 
recently the theory of mitochondrial free radical theory of ageing has become 
debatable as non-mitochondrial sources of ROS generation have been identified 
(Sakellariou et al., 2013; Sakellariou et al., 2014a; Jackson et al., 2016).  
Mitochondria in the muscle of sarcopenic individuals also show increased 
fusion and decreased fission (Yoon et al., 2006) and impairment of mitochondrial 
autophagic (Gouspillou et al., 2014) and proteasomal machinery (Marzetti et al., 2008). 
The release of damaged mitochondrial components into the extracellular matrix 
correlates with increases in pro-inflammatory cytokines in the plasma of elderly 
humans (Pinti et al., 2014). Mitochondria undergo complex morphological changes 
during age which are also likely to affect their function (Leduc-Gaudet et al., 2015) and 
thus give further evidence of a role for dysfunctional mitochondria in sarcopenia.  
1.4.8. Increased inflammation during sarcopenia 
The inflammatory response is the secretion of pro-inflammatory mediators in 
response to the appropriate stimuli such as toxins, bacteria and damage. Primarily, 
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neutrophils migrate to the site of injury/infection (Zhang et al., 2004); during later 
stages the infiltration of other inflammatory cells such as leukocytes, lymphocytes and 
eosinophils contributes to the breakdown and removal of any damaged or foreign 
tissue. The inflammatory response is then resolved by the production of anti-
inflammatory cytokines such as IL4 and IL13 which can then initiate repair to the site of 
damage(Marie et al., 1996). The migration of the immune cells to the site of damage is 
regulated by the production of growth factors, chemokines and cytokines. Therefore 
the inflammatory response prevents damage, infection, restores homeostasis and 
initiates repair. 
The acute pro-inflammatory state is vital for the protection of cells but too 
much for too long can be detrimental; for example chronic low grade inflammation has 
been associated with ageing and has been implicated in numerous diseases such as 
diabetes (Duncan et al., 2003), cardiovascular disease (Lagrand et al., 1999) and 
neurodegenerative disease (Frischer et al., 2009).  
Immunosenescence is the decline in the function of the immune system with 
age (Lazuardi et al., 2005; Gruver et al., 2007). Immunosenescence has been 
implemented in the cause of chronic low state of inflammation that occurs with age 
(Khodr et al., 2001). This constant state of inflammation is due to the systemic 
decrease in anti-inflammatory cytokines and increases in the pro-inflammatory 
cytokines, TNF-α, IL6 and C-reactive protein (CRP) (Alley et al., 2007; Giovannini et al., 
2011). Such changes are correlated with an increased risk of mortality and morbidity 
although ageing without co-morbidities is still shown to be associated with low grade 
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inflammation (Krabbe et al., 2004). The increase in ROS that occurs with age (Section 
1.4.6) is thought to be one of the major causes of this chronic low grade inflammation, 
due to the activation of redox sensitive inflammatory markers such as the transcription 
factor NF-κB.  
NF-κB is a transcription factor that is expressed in skeletal muscle (Bar-Shai et 
al., 2005) and has been shown to increase with age in skeletal muscle (Vasilaki et al., 
2006). In muscles of adult mice, non-damaging isometric contractions result in 
activation of NF-κB and this is related to an increase in transcription of cytoprotective 
proteins (Vasilaki et al., 2006). In contrast to this, muscle of old mice and humans has 
constitutively active NF-κB and no there is no further activation following contractions 
(Vasilaki et al., 2006; Buford et al., 2009). This increase in NF-κB has been associated 
with increases in muscle content of pro-inflammatory cytokines and skeletal muscle 
atrophy (Cai et al., 2004; Hunter et al., 2004) and the inability of muscles to regenerate 
in old mice (Broome et al., 2006).  
Low level chronic inflammation coupled with immunosenescence that occurs 
in ageing has been termed ‘inflamm-ageing’ (Franceschi et al., 2000). Inflamm-ageing 
has been associated with numerous age-related diseases (Chung et al., 2009) such as 
obesity-related diabetes (Xu et al., 2003), Alzheimer’s disease (Leea et al., 2008) and 
has been implicated as a major contributor to sarcopenia (Schaap et al., 2006; Schaap 
et al., 2009). 
Serum levels of TNF-α, IL6 and C-reactive protein (CRP) are all increased in 
ageing and have been proposed to be important mediators of sarcopenia as changes 
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are correlated with a decrease in muscle mass (Pedersen et al., 2003; Aleman et al., 
2011), performance (Thalacker-Mercer et al., 2010), function (Bautmans et al., 2011), 
strength (Tiainen et al., 2010; Norman et al., 2014) and fitness (Levinger et al., 2010). It 
should be noted however that TNF-α, IL6 and CRP have all been shown to have 
beneficial effects in skeletal muscle growth; IL6 and TNF-α at low levels has been 
shown to cause satellite cell proliferation and differentiation (Li, 2003; Kurosaka et al., 
2013), therefore it is likely that the effect of systemic inflammation on muscle mass 
and function during ageing may only occur when it surpasses a certain threshold and/ 
or persists for an extended period (Degens, 2010). 
The increase in inflammation leads to a further increase in ROS production by 
skeletal muscle (Li et al., 1998). As well as an increase in skeletal muscle cell apoptosis 
(Phillips et al., 2005), inflammation has also been shown to play a role in the anabolic 
resistance that leads to a lack of increase in protein synthesis following protein 
ingestion that is correlated to Akt and IGF-1 levels (Del Aguila et al., 2000; Mercier et 
al., 2002). High levels of inflammation have been associated with catabolism in the 
skeletal muscle (Li et al., 1998) . 
1.4.8.1. The role of IP10 during sarcopenia 
The majority of studies examining a role of cytokines in muscle atrophy have 
focused on the effect of IL6, TNF-α and CRP (Pedersen et al., 2003; Phillips et al., 2005; 
Cartier et al., 2009). However, recent research into interferon-gamma induced protein 
10 (IP10) has shown the importance of this chemokine in both systemic ageing and 
sarcopenia. IP10 is also known as CXCL10 and is a small chemokine. IP10 binds to the 
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CXCR3 receptor and is induced by IFN-y (Luster et al., 1985) and other cytokines. 
Following induction, IP10 acts as a chemo-attractant for CXCR3 positive cells such as 
activated T-lymphocytes. This is evidenced in IP10 deficient mice that have an impaired 
contact hypersensitivity response and a reduction in inflammatory cell infiltrates 
(Dufour et al., 2002). Furthermore IP10 levels are increased in humans and mice 
infected with viruses (Haeberle et al., 2001) and bacteria (Azzurri et al., 2005).  
Increases in IP10 is associated with numerous diseases such as Behcet’s 
syndrome (Ambrose et al., 2015), hepatitis C (Reiberger et al., 2008) and has been 
shown to have both beneficial (Kobayashi et al., 2015) and negative effects in cancer. 
IP10 has also been implicated in inflammatory diseases (Medoff et al., 2002; Grebel et 
al., 2013) as well as increasing apoptosis in virus infected (Klein et al., 2004) and 
healthy cells (Vinet et al., 2010). Furthermore, IP10 has a prominent role in numerous 
autoimmune diseases (Antonelli et al., 2014).  
Unpublished work from our laboratory and other studies have shown an 
increase in IP10 in the plasma (Chen et al., 2003a) and other tissues (Duan et al., 2008) 
during ageing. Most importantly, a study that took into consideration other co-
morbidities showed that IP10 was still significantly upregulated in the plasma of older 
people, when many cytokines that had previously been associated with ageing were 
not elevated (Miles et al., 2008). These data suggest that IP10 is correlated directly 
with ageing whereas changes in other cytokines are potentially due to the presence of 
aged-related diseases. However, it should be noted that contrary to the above data 
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Banerjee et al (2011) found a decrease in the IP10 content in the plasma of older men 
compared with younger men (Banerjee et al., 2011). 
 In skeletal muscle, IP10 has been shown to be upregulated in unloading 
induced atrophic muscle, likely through activation of NF-κB (Wang et al., 2013). IP10 
and its receptor are upregulated in the serum of humans suffering from myositis 
(Limongi, 2015) and in vitro work on human skeletal muscle cells show that an increase 
in IP10 is likely to be one of the first stages of self-promoted muscular inflammation in 
myositis (Crescioli et al., 2012). Furthermore, therapeutics to decrease IP10 have 
decreased inflammation in a mouse model of myositis (Kim et al., 2014).  
Despite the evidence for changes in levels of IP10 during ageing and muscular 
diseases, only a sparse amount of work has been undertaken on the role of IP10 in 
sarcopenia. As it is now evident in numerous diseases, it is possible that IP10 could be 
used as a therapeutic target for sarcopenia.  
1.5. Current therapeutics for sarcopenia 
Sarcopenia is a massive economic burden with billions of dollars being spent 
on direct and indirect effects of the condition every year (WHO, 2014). Current 
treatments for sarcopenia include both pharmacological and lifestyle interventions 
with evidence showing that loss of muscle function is at least partially reversible, 
particularly if interventions are started at the early stages of the onset of sarcopenia.  
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1.5.1. Physical exercise 
The importance of physical activity in sarcopenia has been shown in studies 
where people who are less physically active have a higher chance of developing a 
decrease in skeletal muscle mass and strength and thus sarcopenia (Lee et al., 2007). It 
is generally thought that exercise is beneficial and may slow down the progression of 
sarcopenia as well as the detrimental effects of unloading and bed rest on muscle loss 
in adult and old individuals. There are various different exercise programmes that are 
recommended for the older population in an attempt to combat sarcopenia. 
1.5.1.1. Resistance training 
There is mutual agreement that resistance exercise is effective at improving 
muscle function and the overall quality of life of older people. Resistance training is the 
requirement to generate force to move or resist weight such as weight lifting/push 
ups/leg press. Numerous studies have shown beneficial effects of resistance training in 
the function of skeletal muscle of the old; increasing muscle mass and strength 
(Fiatarone et al., 1994; Maltais et al., 2015) as well as cross-sectional area of myofibres 
(Fiatarone et al., 1994; Leenders et al., 2013) and motility (Fiatarone et al., 1994). 
Interestingly, Raue et al (2012) carried out analysis of the skeletal muscle 
transcriptome in young and old humans and the results suggested that the gene 
response following resistance exercise was most pronounced in type II rich fibres (Raue 
et al., 2012).  
Studies have used a variety of different intensities and training programmes 
but there is data to suggest that just one bout of resistance exercise training per week 
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is sufficient to gain the same benefits as training up to three times a week (Taaffe et 
al., 1999). Although higher intensity resistance training leads to bigger muscle size than 
at a lower intensity, lower intensity is still capable of instigating increases in muscle 
mass (Bemben et al., 2000; Beneka et al., 2005; Csapo et al., 2015). However, it is 
worth noting that some studies have shown no correlation between physical activity 
and muscle mass (Mitchell et al., 2003) and only a higher level of physical activity and 
not ‘leisure-time’ activity are able to prevent or delay some sarcopenic effects (Raguso 
et al., 2006).  
Improvements in muscle function following resistance training are thought to 
be due to an improved neuromuscular system (Taaffe et al., 1999), increased protein 
synthesis and attenuation of anabolic resistance (Schulte et al., 2001) and an increase 
in the satellite cell content of type II fibres (Verdijk et al., 2009a; Leenders et al., 2013).  
1.5.1.2. Aerobic training 
Aerobic training stimulates the heart and blood flow and provides 
cardiovascular conditioning. Examples of aerobic exercises include running, cycling and 
swimming. Although, the majority of the beneficial effects of aerobic exercise are 
cardiovascular, aerobic exercise has shown to increase the cross-sectional area of 
muscle fibres and can result in hypertrophy of old human muscles (Schwartz et al., 
1991; Konopka et al., 2013). However the effects of aerobic exercise are not as well 
established as resistance exercise and it is likely that the hypertrophic effects of 
aerobic exercise depend on the frequency, intensity and length of exercise.  
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 The effects of aerobic exercise on skeletal muscle are primarily through 
increases in mitochondrial proteins such as cytochrome C in the electron transport 
chain, and, the master of mitochondria biogenesis PGC-1α (Short et al., 2003; Konopka 
et al., 2013). Increases in mitochondrial biogenesis result in improved mitochondrial 
function, metabolic control and respiratory capacity (Coggan et al., 1992; Short et al., 
2003) consequently increasing the endurance of the individual. Furthermore, long term 
aerobic exercise programmes have shown an ability to reduce ROS production by 
muscle in old people (Ghosh et al., 2011). Aerobic exercise has also been shown to 
decrease anabolic resistance (Section 1.4.2) through the upregulation of protein 
synthesis through the Akt/mTOR pathway (Fujita et al., 2007), as well decreasing 
inflammation (Kohut et al., 2006). 
1.5.1.3. Other forms of physical activity  
Other forms of physical activity include power training. Power declines at a rate 
of 3-4% per year in older people and this is detrimental for everyday activities such as 
climbing stairs. To improve power, fast shortening resistance training is implemented. 
Improvements in skeletal muscle power (Fielding et al., 2002; Henwood et al., 2005; 
Reid et al., 2008) and in the ability to carry out every day activities in older people have 
been seen following power exercises (Henwood et al., 2005). These improvements are 
thought to be due to changes in the neuromuscular junction that allow a greater motor 
unit recruitment and firing rate of fast twitch fibres (Fielding et al., 2002; Reid et al., 
2008). Some studies have shown power training to be more effective than slow 
velocity resistance training (Reid et al., 2008). 
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Many suggested physical activities may be too intense for older adults to 
maintain over a prolonged time. To combat this, less impact exercises such as whole-
body vibrations and whole body electromyostimulation have been developed. These 
techniques use impulses that cause involuntary contractions of the muscles to 
preferentially recruit the fast twitch fibres that are most affected by ageing and this 
approach has been shown to increase maximum isometric strength and muscle mass 
(Kemmler et al., 2010; Kemmler et al., 2014) and grip strength (Stengel et al., 2015) in 
older women. These low impact exercises may be more suited for subjects who are 
unable to perform intense exercise programmes during sarcopenia.  
Despite the evidence for some benefits of different types of exercise on muscle 
mass, even lifelong exercise is not the complete answer as a treatment or preventative 
for sarcopenia as lifelong exercise does not prevent sarcopenia (Kayani et al., 2008).   
1.5.2. Nutrition 
Protein and other nutrients are vital for the protein synthesis required for 
muscle growth and maintenance. The effects that changes in protein synthesis and 
degradation have on sarcopenia have been discussed previously (Section 1.4.2). It is 
likely that nutritional intake may play a role in sarcopenia and altering nutritional 
intake may be able to relieve some symptoms of sarcopenia. 
1.5.2.1. Increase in protein intake  
Anabolic resistance is the inability of nutritional protein to be translated into 
protein synthesis effectively by muscle and this inability to increase protein synthesis 
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contributes to sarcopenia. In addition to anabolic resistance, around 30-40% of women 
over 50 and 20-40% of men over 50 do not reach the recommended daily intake of 
protein and it is has been shown a low protein diet can be detrimental to muscle mass 
(Oumi et al., 2000). Therefore, a considerable number of studies examining 
interventions against sarcopenia have focused on increasing protein intake.  
Studies using whole protein supplementation have shown that increasing the 
amount of overall protein intake can overcome the anabolic resistance in older people 
leading to an increase in protein synthesis, muscle mass and decrease proteolysis in 
rodents (Mosoni et al., 2014) and humans (Norton et al., 2015; Verreijen et al., 2015). 
Protein supplementation was also shown to increase SOD content (Shahar et al., 2013) 
in the blood of humans and glutathione concentrations in mice (Pouget et al., 2015), 
suggesting that increased protein supplementation may indirectly protect against 
oxidative damage. Furthermore a correlation between higher protein intake and 
muscle mass was found in women over 65 (Genaro et al., 2015) and it has been shown 
that protein intake of mothers during the pregnancy and lactation can affect the 
autophagy mechanism in the muscle of the offspring, demonstrating the importance of 
early life protein intake on muscle mass retention throughout life (Wanga et al., 2015).  
The essential amino acid profile, digestibility and bioavailability of ingested 
protein are important elements of the anabolic potential of protein. This was 
demonstrated in studies where anabolic resistance was overcome by increasing the 
percentage of leucine contained in the ingested protein rather than the total amount 
of protein (Volpi et al., 2003). The mechanism through which leucine achieves this 
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improvement in anabolic resistance in the old is likely to be through the upregulation 
of the Akt/mTOR pathway as well as decreasing proteolysis and autophagy (Volpi et al., 
2003). Increases in Akt/mTOR pathway and decreases in proteolysis have also been 
shown in vitro (Sato et al., 2014) and in vivo which led to an increase in muscle mass 
when used as a single supplement of leucine or in combination with other nutrients 
(Sato et al., 2013b; Sato et al., 2015). Leucine supplementation leads to improved 
muscle regeneration in old rats through a decrease in inflammation and an increase in 
satellite cell proliferation resulting in an increase in the cross-sectional area of 
regenerated fibres compared with control animals (Pereira et al., 2015). 
In contrast, meta-analysis of protein supplementation (Xu et al., 2014) showed 
no difference between the effect of protein supplementation and that of placebo 
groups on muscle mass, protein synthesis and muscle strength in older men (Dirks et 
al., 2014) or women (Zhu et al., 2015). Furthermore, Russ et al (2015) showed that 
protein supplementation attenuated muscle degradation through decreasing Murf1 
expression, this did not translate to any functional benefits to muscles of old rats (Russ 
et al., 2015b). 
One of the explanations of these negative studies may be the times at which 
intake of protein occurred. Symons et al (2007) showed that a 90g of protein meal in 
humans does not offer any more protein synthesis than a 30g meal in humans (Symons 
et al., 2007), suggesting that ingestion of more than 30g of protein in one meal is an 
energetically inefficient means of protein synthesis and that protein intake should be 
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spread out throughout the day to optimise muscle protein synthesis as shown below 
(Figure 1.10). 
 
Figure 1.10 Optimal distribution of protein intake throughout the day to maximise protein 
synthesis (Paddon-Jones et al., 2009) 
 
Benefits have been seen in muscle following protein supplementation 
however it is important to note the potential detrimental effects of a high protein diet. 
The most cited harmful effect of a high protein diet is the effect on renal function. 
Although it has been shown that high protein diets are relatively non-toxic to healthy 
kidneys (Manninen, 2004), it is possible that where other conditions are evident there 
may be detrimental effects on the kidney. High protein diets led to low glomerular 
filter rates in older humans (Walrand et al., 2008) and in mice where a high protein diet 
led to hypertrophy and increases in the size of the kidney (Hammond et al., 1998). A 
high protein diet can also be detrimental to the musculoskeletal system as high protein 
diets have shown negative calcium balance that could lead to osteoporosis in men 
(Allen et al., 1979). Other side effects of a high protein diet include weakness, nausea, 
diarrhoea problems and even death. Despite this, it is generally believed that 25-30g of 
high quality protein in a single meal is adequate to stimulate skeletal muscle protein 
synthesis in the old and that this may be beneficial as a treatment against sarcopenia.  
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1.5.3. Protein supplementation paired with exercise  
There is considerable evidence for beneficial effects of exercise and protein 
intake together on sarcopenia; therefore there are several studies that have combined 
the two as a potential therapeutic option for sarcopenia. These studies have shown 
that combined together, protein and exercise can increase muscle strength and mass in 
the old (Tieland et al., 2012; Shahar et al., 2013; Maltais et al., 2015; Palop et al., 2015), 
as well as increasing IGF1 and decreasing serum levels of IL6.  
The ability of protein supplementation to increase muscle mass and strength 
further than with exercise alone is debateable. Some research groups suggest that 
protein supplementation will only enhance exercise-induced muscular improvements if 
there is an existing protein deficiency (Verdijk et al., 2009b). Thus there is increasing 
evidence that an increase in protein intake may be beneficial for attenuating 
sarcopenia where protein intake is sub optimal. This is particularly relevant in those 
who do not already reach the recommended daily intake of protein, where the amount 
and distribution of protein throughout the day alongside an effective exercise plan may 
play an essential part in whether the supplement will be effective.  
1.5.4. Calorie restriction 
Calorie restriction is thought to be one of the most effective interventions of 
attenuating ageing, long term 30% reduction in calorie intake changed the 
transcriptional profile of an older individual similar to that of a younger subject, 
increased the production of antioxidants and decreased inflammation (Mercken et al., 
2013). Restriction of the number of calories eaten has been proved to be life-extending 
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in numerous species (Weindruch et al., 1986; Lakowski et al., 1989; Jiang et al., 2000) 
as well as reducing all-cause mortality in rhesus monkeys (Colman et al., 2014).  
The benefits of calorie restriction have been extended into sarcopenia. In rats, 
a 6 week 20% reduction in calorie intake led to an attenuation of age-related loss of 
muscle mass and function in the soleus and gastrocnemius muscles through an 
upregulation of PGC-1α (Joseph et al., 2013a). Calorie restriction also preserved fibre 
number and type and protected mitochondrial DNA from deletion (Lee et al., 1998b). 
In rats, calorie restriction decreased apoptosis and protected from oxidative stress 
(Dirks et al., 2004) as well as a decrease in the overall oxidation (Hepple et al., 2008) in 
skeletal muscle. These data suggest that calorie restriction prevents sarcopenia 
potentially through an inhibition of apoptosis and enhancement of the mitochondrial 
function and this has been shown to occur through the upregulation of the NAD-
deacetylase Sirt1 (Cohen et al., 2004). Sarcopenia was also attenuated by calorie 
restriction in the rhesus monkey (Colman et al., 2008).  
1.6. Polyphenols 
Polyphenols are secondary metabolites of plants, where their role is 
predominantly protection from UV radiation and pathogens (Manach et al., 2004). 
Polyphenols are found in various foods and drinks such as fruits, vegetables, cereals 
and teas (Manach et al., 2004). There are thousands of molecules with a polyphenolic 
structure (aromatic rings with several hydroxyl groups) and depending on their 
structure, these polyphenolic molecules are further classified into flavanoids, phenolic 
acids, lignans and stilbenes (Bravo, 1998). The majority of polyphenols cannot be 
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absorbed in their native form and are therefore metabolised by intestinal enzymes or 
colonic microflora and further modified to allow entry into the blood and tissues, 
therefore the state of the polyphenols that are present in food are often very different 
to the ones that reach the blood and tissues (Scalbert et al., 2002).  
Recent research in health and disease has focused on polyphenols as 
therapeutics for many diseases due to their apparent antioxidant (Young et al., 1999; 
Sies et al., 2005) and anti-inflammatory (Scoditti et al., 2012) effects, with fruit and 
vegetable intake associated with decreased IL6, CRP, TNF-α levels in the blood and 
reduced oxidative stress in adolescents (Holt et al., 2009) and adults (Folchetti et al., 
2014). Therefore, polyphenols are thought to be beneficial in the fight against 
numerous diseases such as cardiovascular diseases for example, pomegranate juice 
reduced LDL oxidation in humans and mice (Aviram et al., 2000) and in mice this led to 
a decrease in the size of atherosclerotic lesion (Aviram et al., 2000). Black tea was 
found to lower blood pressure (Hodgson et al., 2012). Polyphenol intake has also 
shown to reduce the number of tumours in different types of cancer; green tea and 
quercetin both prevented proliferation of breast cancer (Sartippour et al., 2001; Deng 
et al., 2013) in vitro and curcumin inhibited prostate cancer in humans (Dhillon et al., 
2008). Although numerous polyphenols have been shown to have anti-carcinogenic 
effects, the mechanisms of action are thought to differ. For example, curcumin 
decreased NF-κB activity in pancreatic cancer in humans (Dhillon et al., 2008), whereas, 
in vitro, a treatment of Du145 prostate carcinoma cells with black tea inhibited 
proliferation of the cancerous cells by inhibiting IGF-1 signalling (Klein et al., 2002) and 
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quercetin inhibited breast cancer cell expansion by retaining cells in the G0/G1 phase 
of cell proliferation (Deng et al., 2013). This and many other in vitro and in vivo studies 
provide a strong rationale in support of the use of dietary polyphenols as a human 
cancer chemoprevention. Polyphenols have been shown to be beneficial in diabetes, 
with quercetin (Rizvi et al., 2009) and tea catechins (Rizvi et al., 2005) reducing 
oxidation in blood cells isolated from diabetic patients and ferulic acid has been shown 
to lower blood glucose and increase plasma insulin levels leading to decreased 
cholesterol levels in diabetic mice (Jung et al., 2007).  
Polyphenols have also been shown to have protective effects in 
neurodegeneration with a 10 year period of flavonoid supplementation negatively 
correlating to cognitive decline (Letenneur et al., 2007). A Mediterranean diet, which 
contains high amount of polyphenols, also correlates with a lower risk of Alzheimer’s 
disease and Alzheimer’s disease mortality (Scarmeas et al., 2006). 
The anti-oxidative and anti-inflammatory effects of polyphenols have also led 
researchers to propose that polyphenols can be used as an ‘anti-ageing’ treatment 
(Maurya et al., 2009).  
1.6.1. Polyphenols and sarcopenia  
Since beneficial effects of polyphenols have been shown in some diseases, 
research has focused on the effect of polyphenols on sarcopenia. An 8 week treatment 
of rats with catechins resulted in an increase in muscle mass and cross-sectional area 
which was associated with decreases in the levels of muscle specific ubiquitin ligases 
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Murf1 and Atrogin1 and therefore in proteasomal degradation (Meadori et al., 2015), 
as well as increasing protein synthesis (Mirza et al., 2014). Catechins also led to 
increased muscle mass following recovery of hind limb unloading in the rat plantaris 
through activation of satellite cells and a decrease in apoptosis (Alway et al., 2014). 
Treatment of old rats with green tea extract has prevented the acute loss of muscle 
mass and force generation and the decrease in cross-sectional area following hind limb 
suspension through an increase in satellite cell proliferation and differentiation 
coupled with a decrease in oxidative stress and apoptosis markers in the plantaris 
muscle (Alway et al., 2015). These data provide evidence for polyphenols as potential 
treatments for sarcopenia, since increased in intake of polyphenols may be more 
achievable than other current treatments available such as exercise (Section 1.5).   
1.7. Resveratrol 
Resveratrol was first isolated from the roots of white hellebore (Takoka, 1940) 
and is found in high abundance in grapes and wine. Interest in resveratrol as a 
therapeutic agent began is 1992 when it was recognised as the beneficial component 
of wine that led to cardio-protective effects (Siemann et al., 1992). Resveratrol has also 
been linked with the ‘French paradox’. The French paradox is the hypothesis that 
although the French nationals ingest high amounts of fat in their diet, the 
cardiovascular incidence does not represent the effects of this and this is thought to be 
due to the high intake of resveratrol through the high amount of wine the French 
consume (Renaud et al., 1992). 
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Despite this interest in resveratrol, research into the beneficial effects of 
resveratrol (Figure 1.11) only began once Jang et al (1997) identified that resveratrol 
could act as a chemo-protective agent at different stages of cancer progression (Jang et 
al., 1997) and in 2007 a cross-sectional study by Block et al (2007) showed that of all 
people who take regular supplements, 50% of people take resveratrol supplements 
(Block et al., 2007). Since research into resveratrol acting as a therapeutic agent began, 
resveratrol has been shown to be able to improve the symptoms of numerous diseases 
such as obesity (Baur et al., 2006), diabetes (Movahed et al., 2013; Asadi et al., 2015), 
cardiovascular diseases (Cheng et al., 2015), Alzheimer’s disease (Porquet et al., 2014) 
and muscular dystrophy (Hori et al., 2011) and has been shown to increase memory 
(Witte et al., 2014). Thus, it is generally accepted that resveratrol has health benefits 
however the life extension properties of resveratrol are still unclear.  
Evidence that resveratrol can increase lifespan has been shown in 
Saccharomyces cerevisiae (Howitz et al., 2003), Caenorhabditis elegans, Drosophila 
melanogaster (Wood et al., 2004) and Nothobranchius furzeri fish (Valenzano et al., 
2006), however others show no difference in lifespan compared with controls (Bass et 
al., 2007; Pearson et al., 2008). Studies have shown life extension effects in organisms 
under oxidative stress but not normal conditions (Chen et al., 2013) and in mice on a 
high fat diet (Baur et al., 2006) suggesting the health status of the organism may be a 
determinant of the beneficial effects of resveratrol. For example Zou et al (2009) 
showed that the pro-longevity effects of resveratrol were dependent on calorie intake 
in the fruit fly (Zou et al., 2009). However, a meta-analysis of the ability of resveratrol 
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to cause life extension shows considerable variation between studies and few studies 
showed consistency within life extension properties thus it is concluded it is unlikely 
that resveratrol can increase lifespan (Hector et al., 2012).  
 
 
 
Figure 1.11: Yearly publications with resveratrol in the title (1990–2014). The original search 
with the chemical structure of RSV (CAS number 501-36-0) and the removal of duplicate 
articles which yielded 15,782 references which was accessed July 18, 2014 (Park et al., 2015). 
 
1.7.1. Mechanisms of action of resveratrol 
Similar to other polyphenols, resveratrol has also been shown to have 
antioxidant and anti-inflammatory properties and it is through these properties that 
resveratrol is proposed to offer beneficial effects to cells and tissues. Resveratrol is 
proposed to mimic calorie restriction (Wood et al., 2004; Pearson et al., 2008). These 
properties of resveratrol are thought to occur through direct activation of Sirt1 (Howitz 
et al., 2003; Wood et al., 2004; Borra et al., 2005; Lagouge et al., 2006; Cote et al., 
2015). This is evidenced in transgenic mice with a Sirt1 deletion, where the effects of a 
resveratrol treatment where absent (Price et al., 2012).  
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Sirt1 is a member of the sirtuins family. Sirtuins are a conserved family of 
(NAD+) dependent deacetylases that are involved in the ageing process. Sirt1 resides 
mostly in the nucleus where it acts as a functional transcriptional repressor through 
histone deacetylation (Vaquero et al., 2004). One of the most repeatable and robust 
effects of resveratrol treatment is an increase in mitochondrial mass and biogenesis 
which is hypothesised to act through Sirt1 activation of the mitochondrial master 
regulator PGC1-α (perisome proliferator-activated receptor gamma co-activator 1 
alpha) (Lagouge et al., 2006). Activation of PGC1-α will then lead to the activation of 
numerous transcription factors such as nuclear respiratory factor 1 (NRF1), PPARy 
(peroxisome proliferator-activated receptor), ERRα (oestrogen-related receptor α) and 
Gabpα (GA binding protein transcription factor)/NRF2 (Wu et al., 1999; Mootha et al., 
2004) which consequently leads to the increases in mitochondrial proteins such as 
COXIV, mitochondrial transcription factor A and cytochrome C (Wu et al., 1999) and in 
mitochondrial DNA. These increases in mitochondrial components lead to increases in 
total mitochondrial biogenesis, mass and function (Wu et al., 1999; Lehman et al., 
2000). These changes in important mitochondria transcription factors also lead to 
increased antioxidant enzymes expression (Bellaver et al., 2014), increases in proteins 
responsible for alleviating stress from the endoplasmic reticulum (ER) and restoring 
homeostasis in the ER (Viswanathan et al., 2005), decreased apoptosis (Bournival et al., 
2009) and thus protecting cells from oxidative damage and promoting cell survival 
(Figure 1.12). 
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Figure 1.12 Postulated mechanism through which resveratrol carries out its antioxidant and 
anti-inflammatory effects.  
 
Despite the evidence for a role of Sirt1 activation in the cellular response to 
resveratrol there have been recent debates as to whether Sirt1 is activated by 
resveratrol (Beher et al., 2009; Guarente, 2012). These authors argue that evidence of 
Sirt1 activation following resveratrol treatment was a technical artefact of the 
fluorophore used (Beher et al., 2009). Furthermore, studies have shown no difference 
in Sirt1 activation following resveratrol treatment (Pacholec et al., 2010), others also 
believe AMPK (Dasgupta et al., 2007) or cAMP (Park et al., 2012) are the direct targets 
of resveratrol and these can consequently activate Sirt1. However, it is worth 
considering that the effects of resveratrol are likely to be dose dependent, with high 
and low doses of resveratrol having opposite effects (Calabrese et al., 2010). For 
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example <5mg/kg/day caused weight gain in mice on a high fat diet (Pearson et al., 
2008) whereas treatment of mice with 400mg/kg/day resulted in weight loss in mice 
(Lagouge et al., 2006). Therefore, to date the mechanism of action of resveratrol is still 
highly controversial. This biphasic effect of resveratrol may account for some of the 
differences seen in studies and suggests that different concentrations may act through 
different pathways. This is an important for when considering resveratrol as a 
therapeutic agent, particularly when very high doses of resveratrol have been shown to 
have negative effects such as blunting beneficial cardiovascular effects of exercise 
(Gliemann et al., 2013), increasing the growth of mammary gland cancer (Castillo-
Pichardo et al., 2013) and causing apoptosis in smooth muscle cells (Mnjoyan et al., 
2003). Resveratrol also exacerbated multiple sclerosis (Sato et al., 2013a). High doses 
of resveratrol in human clinical trials have also caused diarrhoea, nausea and 
abdominal pain (Brown et al., 2010) and resveratrol has also been shown to cause cell 
senescence in dermal fibroblasts, however, where this occurred there was a down 
regulation of Sirt1 (Kilic Eren et al., 2015), suggesting that for the beneficial effects to 
occur Sirt1 must be activated. As well as a dose dependent effect, resveratrol has been 
shown to have the opposite effects when studied in cancerous cells compared to non-
tumour cells (Baarine et al., 2011) suggesting that resveratrol also acts in a cell specific 
type manner.  
Some of the downstream pathways shown to be affected by resveratrol 
include IGF-1 P13K/Akt (Jing et al., 2015), NRF2/ARE (Cheng et al., 2015), cAMP 
signalling (Zhang et al., 2015b), ERK (Wakabayashi et al., 2013) and Wnt signalling 
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(Zhou et al., 2015). Resveratrol has also been shown to directly scavenge ROS (Leonard 
et al., 2003; Ungvari et al., 2007). 
1.7.2. Resveratrol and inflammation 
The anti-inflammatory effects of resveratrol are well established with 
resveratrol having the ability to decrease pro-inflammatory cytokines such as TNF-α, 
IL6, MCP-1, IL8 (Feng et al., 2002; Csaki et al., 2009; Wakabayashi et al., 2013) and 
increase anti-inflammatory cytokines (Song et al., 2014a) in many different cells and 
tissues and in the plasma.  
The majority of cytokines mediate their effects through the transcription 
factor NF-κB and most anti-inflammatory agents diminish NF-κB activation in cells. The 
decreases in inflammatory markers by resveratrol have been shown occur through the 
suppression of NF-κB activation (Csaki et al., 2009). These anti-inflammatory effects of 
resveratrol have been shown in numerous cell types, as well as the ability of 
resveratrol to inhibit FOXO (Motta et al., 2004) and p53 (Eo et al., 2013), lead to a 
decrease in apoptosis and prevent cell death (Csaki et al., 2009). Resveratrol has also 
been shown to decrease inflammatory mediated production of ROS (Martinez et al., 
2000). These decreases in inflammation have shown to attenuate inflammatory related 
diseases such as rheumatoid arthritis (Arend et al., 1995) and asthma (Royce et al., 
2011).  
80 
 
1.8. Resveratrol and sarcopenia 
Evidence for resveratrol as a therapeutic intervention for sarcopenia was 
provided with studies showing that resveratrol can be beneficial to skeletal muscle in 
number of ways. From a functional aspect, resveratrol prevented the loss of muscle 
mass and force and cross-sectional area in muscle in an unloaded model in rats 
(Jackson et al., 2010; Dolinsky et al., 2012). Resveratrol fed mice also had increased 
grip strength, increased time to fatigue and a decrease in biochemical markers of 
muscle fatigue such as ammonia and lactate (Wu et al., 2013). Furthermore, 
resveratrol was able to prevent myotube atrophy following treatment of C2C12 cells 
with TNF-α (Wang et al., 2014) and dexamethasone (Alamdari et al., 2012) through the 
suppression of Murf1 and Atrogin1 and also ameliorated motor neuron loss, thus 
leading to an improved survival rate in an Amyotrophic Lateral Sclerosis (AML) mouse 
model (Song et al., 2014b).  
Similar to other tissues, resveratrol is proposed to act through improved 
mitochondrial function (Lagouge et al., 2006; Momken et al., 2011; Joseph et al., 
2013a) thus, decreasing oxidative stress through increases in MnSOD and catalase 
activities, decreasing hydrogen peroxide production and lipid peroxidation and 
inhibiting apoptosis by decreasing p53, FOXO03, caspase 3 and 9, bax and increasing 
Bcl2 (Jackson et al., 2010; Jackson et al., 2011; Sin et al., 2015). There is also evidence 
that resveratrol is able to prevent age-related changes in fibre type percentages 
(Jackson et al., 2011; Zhang et al., 2015a) and protein degradation (Russell et al., 2006; 
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Wilson et al., 2015) as well as resulting in an increase synthesis of muscle contractile 
proteins (Lagouge et al., 2006).  
The anti-inflammatory effects of resveratrol on other tissues are well known, 
however the anti-inflammatory effects of resveratrol on skeletal muscle are less clear. 
Resveratrol had no effect on CRP content in the blood of marathon runners 
(Laupheimer et al., 2011; Olesen et al., 2014). Whereas, in mdx mice, there was a 
decrease in inflammation cell infiltrates into the muscle following resveratrol 
treatment compared with non-treated mdx mice (Gordon et al., 2014). Resveratrol also 
attenuated cancer mediated cachexia through the down regulation of NF-κB in muscle 
leading to a decrease in inflammation and a reduction in proteolysis of the sarcomere 
(Shadfara et al., 2011). However research into the anti-inflammatory effects of 
resveratrol on skeletal muscle is sparse and more work is needed in this area. 
Resveratrol induced differentiation and hypertrophy in skeletal muscle cells 
(Montesano et al., 2013). Hypertrophy is likely caused by an increased IGF-1/Akt/mTOR 
pathway induction by resveratrol (Montesano et al., 2013; Wang et al., 2014). 
Resveratrol down-regulated microRNA 133, which is involved in muscle skeletal 
proliferation (Kaminskia et al., 2012b), and decreased cell proliferation, p21 and cyclins 
expression in C2C12 cultures following resveratrol treatment compared with untreated 
C2C12 cells. However resveratrol treatment also resulted in the increased of the 
myogenic regulators Myf-5, MyoD, myogenin and important structural proteins in 
C2C12 cells (Montesano et al., 2013). Importantly, this shows that it is unlikely that 
resveratrol is toxic to muscle cells and the decrease in cell number seen by Kaminskia 
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et al (2012) is likely due to the fusion of myoblasts into myotubes. These data suggest 
that resveratrol is potentially a differentiating agent, and may be beneficial during 
muscle regeneration. This has been further evidenced by treatment of C2C12 cells with 
low doses of resveratrol promoting muscle regeneration (Bosutti et al., 2015) and in 
vivo (Bennett et al., 2013). Whether this improved regeneration was due to increases 
in satellite cells number (Bennett et al., 2013) or not (Ballak et al., 2015) is debateable, 
although increased Sirt1 has been shown to increase proliferation of satellite cells 
(Rathbone et al., 2009). Some studies have found that resveratrol was not able to 
protect against muscle wasting or fatigue (Busquetsa et al., 2007; Jackson et al., 2011), 
improve mitochondrial function (Joseph et al., 2013a) or have any beneficial effects on 
muscle regeneration (Rogers et al., 2015). Olesen et al (2014) showed that resveratrol 
was prevented the beneficial exercise-induced effects on protein oxidation and 
inflammation in older men (Olesen et al., 2014). However, treatment with resveratrol 
in senescence-accelerated prone (SAMP1) mice with resveratrol resulted in increased 
endurance and mitochondrial function-related enzymes (cytochrome oxidase III/IV, 
MCAD) (Murase et al., 2009).  
Similar to other tissues, the mechanisms by which resveratrol was able to offer 
protection is debatable. Some studies showed that treatment with resveratrol resulted 
in an increase in muscle expression of Sirt1 (Joseph et al., 2013a) and PGC1-α 
(Kaminskia et al., 2012b) whereas others showed no change in the protein expression 
of Sirt1 (Ringholm et al., 2013), PGC1-α (Barger et al., 2008), mitochondrial genes or 
mitochondrial DNA content (Ringholm et al., 2013). In a similar manner to other 
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tissues, a lot of these discrepancies can possibly be explained by the difference in 
doses of resveratrol treatment, for example 10µM resveratrol was shown to be able to 
protect C2C12 muscle cells from oxidative damage, but higher doses were not (Bosutti 
et al., 2015). Also a 25mg/kg/day dose of resveratrol was more beneficial at protecting 
muscle against fatigue than 50mg resveratrol/kg/day or 125mg resveratrol/kg/day (Wu 
et al., 2013). There is considerable variability in doses and time courses of treatments 
with resveratrol within studies which reach contrasting conclusions.  
Interestingly, although resveratrol was able to protect old mice from losing 
muscle mass and function during unloading, resveratrol had no effect on muscle mass 
or force generation in young mice (Jackson et al., 2010) suggesting that the signalling 
pathways involved may be different during ageing. Some of these discrepancies may 
also be explained by to the different fibre type compositions of these muscles. For 
example, Sirt1 protein expression was increased in the white (type II) portion of the 
gastrocnemius following treatment with resveratrol, whereas there was no effect of 
resveratrol on Sirt1 protein expression in the red (type I) portion (Joseph et al., 2013a). 
These data provides further evidence that the health status of the subject may be a 
major determinant of the outcome of resveratrol treatment, as it is type II fibres which 
are primarily affected during ageing. This would therefore explain why treatment with 
resveratrol could provide protection to type II fibres but not type I fibres.  
These data suggests that resveratrol may be able to attenuate some of the 
effects of sarcopenia and may have the potential to be a therapeutic agent; however it 
is vital to validate the effects of different doses of resveratrol and to optimise the 
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length of treatment. Furthermore, the concentrations used in these studies, 
particularly in vivo, are extremely high and not achievable by diet; it is therefore a 
priority to identify whether physiological doses of resveratrol can provide these 
beneficial effects.  
1.9. Aims and Objectives 
The main objectives of this study were to: 
1. Establish an in vitro model to test the effects of resveratrol on primary muscle 
cells in culture and identify a concentration of resveratrol that was effective in 
both undifferentiated (myoblasts) and differentiated (myotubes) primary 
skeletal muscle cells. 
2. Establish an in vitro model to study the effect of increased levels of IP10 on 
muscle cell atrophy and inflammation. 
3. Examine whether a treatment of primary myotubes with resveratrol is able to 
protect against IP10 induced effects on skeletal muscle cell atrophy or 
inflammation. 
4.  Identify an effective dose of resveratrol in mice in vivo and examine the effect 
of this concentration on skeletal muscle force generation in adult and old mice. 
5. Establish a 3D muscle construct model that could potentially be used to study 
the direct effects of compounds on skeletal muscle function in vitro. 
The overall hypothesis of this thesis is that the increase in serum IP10 levels 
during ageing contributes to sarcopenia and causes an increase in markers of atrophy. 
85 
 
Due to the potential health benefits of resveratrol, a further hypothesis is that 
resveratrol is able to protect against some of these negative effects through its 
antioxidant and anti-inflammatory properties.  
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2. MATERIALS AND METHODS 
  
87 
 
2.1. Project overview 
 
Figure 2.1 Schematic diagram showing overall experimental approach of thesis. 
 
2.2. Animals  
2.2.1. Animal husbandry & Home Office licence permissions 
All experiments followed UK Home Office Animal Licensing Laws for the care 
and use of laboratory animals. All animals were housed in the specific pathogen free 
Biomedical Services Unit at the University of Liverpool where they were monitored on 
a daily basis. The animals had standardised lighting system (12 hr light cycles), 
controlled temperatures (22±2°C) and access to food and water ad libitum. 
2.2.2. Rat studies  
3-4 week old wild type Wistar rats were used to generate primary muscle 
cells. Rats were used for these studies as it has not been possible to make 3D muscle 
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constructs (also known as myooids) using cells isolated from mice (Larkin Lab, 
University of Michigan, unpublished).  
2.2.3. Mouse studies  
Young (approximately 6 months) and old (approximately 24 months) C57BL/6 
male mice were used for the mouse studies.  
2.3. Cell culture and treatment of primary cells isolated from rats 
2.3.1. Isolation of primary skeletal muscle cells  
Reagents: 
 Dissociation medium (for 200mg of tissue): 
 
o 0.4 units/mg Collagenase type IV (Invitrogen, Paisley, UK) 
o 239 units/mg Dispase (Invitrogen, Paisley, UK) 
o 35ml Hams-F12 (Invitrogen, Paisley, UK) 
 Ethanol 
 
 DPBS (Sigma Aldrich, Dorset, UK) 
 
 Attachment factor protein (Invitrogen, Paisley, UK) 
 
 Growth medium:   
o 60% v/v Hams F-12 nutrient mix (Invitrogen, Paisley, UK) 
o 25% v/v Dulbecco’s modified eagle’s medium (DMEM, Sigma Aldrich, 
Dorset, UK) 
o 15% v/v foetal bovine serum (FBS, Sigma Aldrich, Dorset, UK) 
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o 100µmol/ml penicillin and 0.1mg/ml streptomycin (Sigma Aldrich, 
Dorset, UK) 
Protocol: 
This method of rat primary cell isolation was adapted from a well-established 
protocol (Larkin et al., 2006) and results in a high myoblast to fibroblast ratio. Rats 
were sacrificed using CO2, cleaned with ethanol and the diaphragm and both the left 
and right soleus and EDL muscles were dissected and placed in DPBS.  
The removed muscle was cleaned in ethanol and then washed in DPBS. Visible 
connective tissue was removed and the muscle minced in Hams F-12 nutrient mix using 
a razor blade. Approximately 200mg portion of muscle was placed in dissociation 
medium and another 15ml of Hams-F12 was added to each muscle portion to make a 
final volume of 35ml. The muscle was incubated for 1.5H at 37oC and was dissociated 
by pipetting every 15 minutes. After incubation, the solution was further dissociated by 
repetitive pipetting and the dissociated tissues were filtered through a 70µm mesh. 
The solution was centrifuged for 10 minutes at 250g and the pellet was re-suspended 
in growth medium. Cells were plated into a 25cm2 tissue culture flask that had been 
previously coated with attachment factor for 1H to enhance the adhesion of the cells 
to the flask. Cells were left for 48H in a 37°C, 5% CO2 incubator. A schematic 
representation of isolation of primary cells from skeletal muscle is shown in Figure 2.2.  
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Figure 2.2 Flow diagram showing the dissociation and isolation of primary skeletal muscle 
cells. Cells are isolated, connective tissue removed and placed in dissociation medium for 
1.5H. When cells reached 80% confluence, depending on the experiment, cells were then 
plated on laminin coated sylgard plates or were split for further culture.  
 
2.3.2. Culture of primary muscle cells from rat 
A large number of cells were required for several different experiments 
therefore, the cells were cultured until adequate numbers were reached. For each 
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primary cell isolation, cells were used between passage 1 and 6 as myoblasts did not 
differentiate into myotubes adequately if passaged further (data not shown).  
Reagents: 
 DPBS 
 
 0.025% Trypsin (Sigma Aldrich, Dorset, UK) 
 
 Growth medium:   
o 60% v/v Hams F-12 nutrient mix  
o 25% v/v Dulbecco’s modified eagle’s medium  
o 15% v/v foetal bovine serum  
o 100µmol/ml penicillin and 0.1mg/ml streptomycin  
 Differentiating medium: 
o 70% v/v Medium 199 (Invitrogen, Paisley, UK) 
o 24% v/v Dulbecco’s modified eagle’s medium 
o 6% v/v FBS (Sigma Aldrich, Dorset, UK) 
All media were stored at 4oC until use and warmed to 37oC in a heated water bath for 
20 minutes before use.  
Protocol: 
Forty eight hours after isolation, myoblasts were washed with DPBS and new 
growth medium was added to flasks. Once myoblast had reached 80% confluence, they 
were washed with DPBS and incubated in 3ml of trypsin at 37oC for 5 minutes to aid 
detachment from culture flasks. Detachment was confirmed by viewing the myoblasts 
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under the microscope. Myoblasts were re-suspended in approximately 1ml of growth 
medium (this volume varied depending on the size of the cell pellet) and 10µl of cell 
suspension was pipetted into a cell counter slide and counted using a TC-20 automatic 
cell counter (Biorad, Hertfordshire, UK) and plated at the appropriate density (2x104 
per well) or split into adequate flasks (4 T25 flasks for each concentration at each time 
point).  
2.4. Treatment of rat primary muscle cells with resveratrol 
 
Reagents:  
 Growth medium 
 Resveratrol (Sigma Aldrich, Dorset, UK) 
Protocol: 
Following culture of myoblasts (Section 2.3.2), myoblasts were placed into 6 
well plates at a density of 2x104 for myoblast studies and 5x104 for myotube studies 
and were left overnight to adhere. Resveratrol (Sigma Aldrich, Dorset, UK) that had 
been previously dissolved in distilled water and stored at -20oC at a concentration of 
5mM, was further diluted in growth medium or differentiation medium to reach a final 
concentration of 0.1, 1 or 10µM. For myoblast experiments, resveratrol was added to 
myoblasts for 3, 6, 12, 24 or 48H. For myotube experiments, myotubes were treated 
daily for 3, 5, 7 or 10 days. A detailed experimental plan is given in the appropriate 
chapter.  
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2.5. IP10 treatment of rat myotubes 
Reagents:  
 IP10 (Sigma Aldrich, Dorset, UK) 
Protocol: 
Murine IP10 was reconstituted in dH20 and stored at -20
oC at a concentration 
of 0.1mg/ml. IP10 was further diluted with differentiation medium to reach a final 
concentration of 150pg/ml or 200pg/ml. Recombinant IP10 was purified by the 
manufacturer and contained less than <0.2EU/ml. 
2.6. Cell counts  
Trypan blue is routinely used in cell culture for analysing the viability of cells. 
Trypan blue is an impermeable dye and cannot penetrate the intact cell membranes of 
live cells, therefore will only stain unviable cells blue, allowing dead and live cells to be 
distinguished. The TC-20 automated cell counter (Biorad, Hertfordshire, UK) analyses 
multiple focal planes to identify the optimal plane of view of the cells. This optimal 
focal plane is then used for the cell counting algorithm to determine the number of 
cells. Using this automated machine is thought to improve the accuracy of cell counts 
by preventing the incorrect focal plane to be selected by user error. Automatic cell 
counters also allow users to set the width of the cell type to eliminate any artefacts 
that may be miscounted as cells.  
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Reagents: 
 DPBS 
 
 0.025% Trypsin containing EDTA (Sigma Aldrich, Dorset, UK) 
 
 Growth Medium 
 
 0.4% Trypan Blue (Invitrogen, Paisley, UK) 
 
Protocol: 
Following the appropriate treatment and time points (Section 2.4), myoblasts 
were detached using trypsin (Section 2.3.2). Trypsin was neutralised with growth 
medium and cells were centrifuged at 100g for 5 minutes. Supernatant was removed 
and the cell pellet was re-suspended in 1ml of growth medium. Fifty microlitres of cell 
suspension was then mixed 1:1 with trypan blue. For manual counting, 10µl of cell 
suspension was mixed with trypan blue and added into each side of a cover slipped 
haemocytometer and 4 measurements were taken from each corner of the 
haemocytometer (Figure 2.3). For automatic cell counting, 10µl of sample and trypan 
blue mix was added into a cell counter slide and placed in the TC-20 automated 
counter and this repeated 4 times to gain 4 measurements for each sample.  
For analysis of the effect of resveratrol on cell number, each measurement per 
well was averaged and all wells with the same treatment were then averaged to give 
an overall cell number per treatment. This was repeated for each time point.  
For all further experiments only TC-20 automatic cell counter was used to 
identify cell number.  
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Figure 2.3 Heamocytometer: X marks where measurements were taken for each sample.   
 
2.7. Live and Dead assay 
Live and dead cells were visualised using a LIVE/DEAD® Reduced Biohazard 
Viability/Cytotoxicity Kit (Life technologies, Warrington, UK). The live and dead kit tests 
the viability of cells by distinguishing between the permeability of dead and live cell 
membranes. SYTO10 is a cell permeable dye which will penetrate all cell membranes 
staining all cells nuclei green. DEAD Red is a cell impermeable dye which can only stain 
cells with compromised membranes, and therefore will only stain the nuclei of dead 
cells (red). Thus, live cells stain green and dead cells stain red (Figure 2.4).  
 
Figure 2.4 Representative image of live and dead stained myoblasts. Scale bar, 100µm.  
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Reagents: 
 SYTO10 Green fluorescent Nucleic Acid Stain (Molecular Probes, Eugene, 
Oregon) 
 
 DeadRed fluorescent nucleic acid stain (Molecular probes, Eugene, Oregon) 
 
 Hepes Buffer Saline Solution (HBSS):  
 
o 135mM NaCl (Sigma Aldrich, Dorset, UK) 
 
o 5mM KCl (Sigma Aldrich, Dorset, UK) 
 
o 1mM MgSO4 (BDH Prolabo, Leicestershire, UK) 
 
o 10mM Hepes (Sigma Aldrich, Dorset, UK) 
 
o 1.8mM CaCl2 (Sigma Aldrich, Dorset, UK) 
 
o 4% glutaraldehyde (Sigma Aldrich, Dorset, UK) 
 
Protocol: 
Following treatment, cell media was removed and cells were washed in HBSS. 
Two microlitres of SYTO10 and 2µl of DeadRed was added to 1ml of HBSS (1:500 
dilution of each) and mixed thoroughly by vortexing. Five hundred microlitres of the 
mixture was added to each well and incubated at room temperature for 15 minutes in 
the dark. Following incubation, media was removed and cells washed with HBSS. Cells 
were then fixed in 4% glutaraldehyde and placed at 4oC until viewing with the Nikon 
Eclipse TE2000 (Nikon, Kingston upon Thames, UK).  
 
97 
 
2.8. Measurement of myotube diameter 
Myotubes were viewed using a Nikon Eclipse TE2000 (Nikon, Kingston upon 
Thames, UK) at X20 magnification and 6 images taken from 6 different areas in each 
well. Each image was then analysed using ImageJ (US National Institutes of Health, 
Maryland, USA). For each image, every myotube was measured 3 times along its length 
to give an average diameter per myotube, each myotube was then pooled to give an 
average per well. The average per well was then used to determine an average for the 
treatment groups.  
2.9. Harvesting of cells for protein extraction  
 
Reagents 
 DPBS 
 1% SDS (Sigma Aldrich, Dorset, UK)  
 Protease inhibitors (Sigma Aldrich, Dorset, UK) 
Protocol: 
Cell media was removed and myoblasts were washed and scraped in PBS and 
centrifuged at 14000g for 5 minutes at 4oC. The supernatant was aspirated and cells 
were re-suspended in 50µl of 1% SDS containing protease inhibitors. Cells were 
sonicated on ice for 15 seconds and centrifuged at 14000g for 5 minutes at 4oC. The 
pellet of the sonicated samples was discarded and a BCA assay was carried out on the 
supernatant to determine protein concentration. 
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2.10. Analysis of protein content of samples using the bicinchoninic acid assay    
Bicinchoninic acid assay (BCA) (Smith et al., 1985) is an assay used to detect 
the concentration of proteins in a sample and is based on the method developed by 
Smith et al (1985). The principle of the BCA assay is based on Cu2+ protein complex 
formation. The reduction of Cu2+ to Cu1+ is proportional to protein content of the 
sample, resulting in the formation of a purple coloured complex with Cu1+ which can be 
quantified using a spectrophotometer (BMG laboratories, Buckinghamshire, UK) 
Reagents: 
 Bicinchoninic acid (BCA) solution (Sigma Aldrich, Dorset, UK, Dorset UK) 
 Copper sulphate (Sigma Aldrich, Dorset, UK, Dorset UK) 
 Distilled water  
Protocol: 
The BCA assay was carried out using a 96 well plate. A standard curve was 
generated from a 1mg/ml stock solution of protein standard (Sigma Aldrich, Dorset, 
UK, Dorset UK) as shown in Table 2.1.  
Table 2.1 Typical concentrations of a standard curve for protein determination using the BCA 
assay. 
Standard Concentration 
1 500μg/ml 
2 250µg/ml 
3 200µg/ml 
4 150µg/ml 
5 100µg/ml 
6 50µg/ml 
7 25µg/ml 
B DH20 
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Protocol: 
Twenty microlitres of each standard and samples that had been previously 
diluted with DH2O was added to a well. Immediately before use, copper sulphate was 
diluted 50x with BCA solution and 200µl of this added to each well. The plate was then 
incubated at 37oC for 30 minutes before measuring the absorbance at 570nm on the 
spectrophotometer (BMG laboratories, Buckinghamshire, UK). The protein content was 
calculated from the standard curve. Each standard and sample was analysed in 
duplicate.  
2.11. Analysis of MnSOD, catalase and Sirt1 protein content of samples using SDS-
PAGE and western blotting   
 
SDS-PAGE and western blotting is a technique commonly used in research to 
separate and identify proteins in a sample. Proteins are separated in polyacrylamide 
gels and transferred on to a membrane for visualisation. Membranes are firstly blocked 
in milk and then incubated with the antibody for the protein of interest; membranes 
are then incubated with the secondary antibody which has a horseradish peroxide 
(HRP) label. This secondary antibody will bind to the primary antibody. Membranes are 
then placed in an ECL solution; the HRP will form a fluorescent complex that allows 
visualisation with a chemiluminescence imager that will convert the fluorescent signal 
from the HRP-ECL binding into a digital image (Figure 2.5).  
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Figure 2.5 ECL Western blot detection method summary. Primary antibody binds to the 
antigen of the protein of interest. The secondary antibody is conjugated to the enzyme (HRP) 
and binds to the primary antibody. Hydrogen peroxide (H202) activates HRP which will lead to 
the oxidation of luminol, which releases light that can be detected by the chemiluminescence 
imaging system.  
 
2.11.1. Preparation of polyacrylamide gels 
Reagents: 
 Stock acrylamide solution:  
o 30% acrylamide, 0.8% bisacrylamide cross-link, in dH2O (Protogel, 
National Diagnostics, USA) 
 Resolving buffer: 
o  1.5M Tris/HCl, 0.384% SDS, pH 8.8 (Protogel, National Diagnostics, 
USA) 
 Stacking Buffer:  
o 0.5M Tris/HCl, 0.4% SDS, pH 6.8 (Protogel, National Diagnostics, 
USA) 
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 12% acrylamide solution: 
o 8ml stock acrylamide solution 
o 5ml resolving buffer 
o 6.8ml DH2O 
o 4% acrylamide solution: 
o 1.3ml stock acrylamide solution 
o 2.5ml stacking buffer 
o 6.1ml DH2O 
o 10% ammonium persulphate solution (APS, Sigma Aldrich, Dorset, UK, 
Dorset UK)  
o NNN’N-tetramethylethylene-diamine (TEMED, Sigma Aldrich, Dorset, UK, 
Dorset UK) 
o 2-propanol (Sigma Aldrich, Dorset, UK, Dorset UK) 
Protocol: 
Twelve percent and 4% polyacrylamide gels were prepared as described 
above. For the 12% acrylamide solution, gel formation was catalysed by the addition of 
200µl of 10% aqueous ammonium persulphate solution (APS) and 20µl of NNN’N-
tetramethylethylene-diamine (TEMED). Following the addition of APS and TEMED, the 
solution was immediately poured between 2 gel plates (8 x 10cm) with 1.5mm spacers, 
200µl of 2-propanol was added to the top of the gel to ensure the gel was even and 
allowed to set. Following the crosslinking of the 12% gel, 2-propanol was poured off. A 
4% acrylamide solution was prepared, with the addition of 100µl of 10% APS and 25µl 
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of TEMED and was added on top of the 12% resolving gel and a well comb placed in 
position to allow sample loading.  
2.11.2. SDS PAGE  
Reagents: 
 Molecular weight marker (17-225kDA) (Amersham, Buckinghamshire, 
UK) 
 
 Running buffer:  
 
o  10X Tris/Glycine/ SDS (w/v) (National Diagnostics, Hull, UK) 
 
o Distilled water 
 
Protocol: 
Pre-prepared gels were loaded into gel tanks and 1x running buffer added. 
Protein was loaded into the wells in the pre-prepared acrylamide gels and 
electrophoresis carried out. Electrophoresis was carried out using an electrophoresis 
tank (Gene flow, Litchfield, UK) with a power pack (Biorad, Hertfordshire, UK) with a 
constant current of 12mA per gel until the samples had run through the 4% stacking 
gel. The current was then increased to 20mA per gel until the bromophenol blue dye 
had reached the bottom of the resolving gel (2-3 hours). The separated proteins were 
then transferred from the acrylamide gel on to a nitrocellulose membrane by western 
blotting.  
 
103 
 
2.11.3. Western blotting 
Reagents: 
 Anode 1 buffer: 0.3M Tris (Sigma Aldrich, Dorset, UK) in a 20% Methanol    
(Sigma Aldrich, Dorset, UK) solution, pH 10.4 
 Anode 2 buffer: 25mM Tris in a 20% methanol solution, pH 10.4 
 Cathode buffer: 40mM 6-amino n hexanoic acid (Sigma Aldrich, Dorset, 
UK) in a 20% methanol solution, pH 7.6. 
 Ponceau S (Sigma Aldrich, Dorset, UK) 
Protocol: 
The Geneflow blotting system (Gene flow, Litchfield, UK), consists of two 
graphite plate electrodes with Whatman No1 filter paper used as a buffer reservoir 
(Figure 2.1). Following electrophoresis, the acrylamide gel was removed from the glass 
plates and the 4% stacking gel was discarded. The 12% resolving gel was placed on top 
of the nitrocellulose membrane and sandwiched as shown in Figure 2.1 and a current of 
100mA per gel was applied to the system for a minimum of 1H. Following transfer, 
membranes were stained with Ponceau S (Sigma, Dorset, UK) to ensure equal loading 
and transfer of proteins.  
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Figure 2.6 Schematic of western blotting-setup.  
2.11.4. Processing and development of nitrocellulose membrane 
Reagents:  
 PBS tween solution: 0.005% (v/v) polyoxyethylene-sorbitan 
 monolaurate (Tween-20) (Sigma Aldrich, Dorset, UK) in PBS solution 
 Blocking solution: 5% milk powder in 0.005% PBS Tween 
 Primary antibody solution: 1% of milk powder in 0.005% PBS 
 Tween 
 Secondary antibody solution: 3% of milk powder in 0.005% PBS Tween 
 Antibodies (Table 2.2) 
 Chemiluminescence reagent kit (ECL, Thermoscientific, Cheshire, UK) 
Protocol: 
Following electroblotting, membranes were placed in 10ml of a blocking 
solution consisting of 5% milk for 1H. The membrane was washed with PBS tween and 
incubated overnight at 4oC with the appropriate primary antibody (Table 2.2). 
Membranes were washed for 3x5 minute with PBS-Tween and then incubated at room 
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temperature for 1H with the appropriate secondary antibody (Table 2.2). After 3x5 
minute washes, membranes were developed with a chemiluminescence reagent kit 
(ECL, Thermoscientific, Cheshire, UK), placed between acetate sheets and analysed 
using a chemiluminescence imager (Biorad, Hertfordshire, UK). 
2.11.5. Primary antibodies: 
2.11.5.1. MnSOD 
Rabbit polyclonal antibody (Enzo, Exeter, UK) reconstituted in sodium 
phosphate buffer containing 15mg/ml BSA, 0.09% sodium azide, and 50% glycerol. 
Detects a band at approximately 25kDa. 
2.11.5.2. Catalase 
Mouse polyclonal antibody (Sigma Aldrich, Dorset, UK) reconstituted in 0.01M 
phosphate buffered saline, pH7.4, containing 15 mM sodium azide. Detects a band at 
approximately 60kDa.  
2.11.5.3. Sirt1 
Mouse polyclonal antibody (Abcam, Cambridge, UK) reconstituted in 1% BSA 
containing 0.02% Sodium Azide. Detects a band at approximately 120kDa.   
2.11.5.4. Acetylation 
Rabbit polyclonal antibody (Cell signalling, Boston, USA) reconstituted in 
10mM sodium HEPES, 150mM NaCl, 100µg/ml BSA and 50% glycerol. 
  
  
 
 
1
0
6 
Table 2.2 Specific antibody information used for analysis of MnSOD, catalase, Sirt1 and acetylation proteins by western blotting 
Protein Source 
Catalogue 
Number  
Amount 
of protein 
loaded 
(µg) 
Final Primary 
Antibody 
Concentration 
(Dilution 
Used)  
Primary  
diluent 
Final Secondary 
Antibody 
Concentration 
(Dilution Used)  
Secondary 
diluent 
Primary 
host 
MnSOD Enzo ADI-SOD-111 10 
2ng/ml (1 in 
1000) 1% Milk 
0.2μg/ml (1 in 
5000) 3% Milk Rabbit 
Catalase Sigma C-0979 10 
2ng/ml (1 in 
1000) 1% Milk 
0.2μg/ml (1 in 
5000) 3% Milk Mouse 
Sirt1 Abcam Ab7343 25 
1µg/ml (1 in 
1000) 5% BSA 
0.2μg/ml (1 in 
2000) 1% BSA Mouse 
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2.11.6. Western blotting analysis 
Following exposure of membrane, the intensity of each band on the 
nitrocellulose membrane was measured using ImageJ (US National Institutes of Health, 
Maryland, USA). This was then normalised to the intensity of the Ponceau S stain 
(Appendix Section 10.1). This was done by measuring the average intensity of Ponceau 
S across the whole sample.  
2.12. Determination of Atrogin1 and Murf1 expression by quantitative PCR  
Quantitative polymerase chain reaction (qPCR) is a modification of polymerase 
chain reaction (PCR) and is used for the measurement of mRNA levels. For this to 
occur, RNA is made into complimentary DNA (cDNA). cDNA is then added to a master 
mix containing non-specific fluorescent dye and primers. Primers are sequences that 
are complimentary to the gene of interest; each master mix contains both a forward 
and reverse primer, so both the sense and antisense of cDNA will be amplified. qPCR is 
then carried out in a thermal cycler. Firstly cDNA is denatured, the primers are 
annealed and finally extended and this is repeated for a number of cycles. As each 
cycle is carried out the non-specific fluorescent dye is intercalated with the double 
stranded DNA, i.e. when primers have annealed to target sequences, causing a 
fluorescence that is detected by the thermo cycler. This provides each sample with a 
cycle threshold (CT) value. The CT value is the number of cycles at which the 
fluorescent signal from the sample exceeds that of the background fluorescence, so 
the lower the CT value, the more mRNA of the gene of interest is present in the 
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sample. The CT value is then normalised to housekeeping genes CT values to give a 
relative expression value which can then be compared to other samples.  
2.13. Amplex red assay for determining hydrogen peroxide concentrations  
 The enzymatic detection of hydrogen peroxide concentrations can be 
determined using Amplex red (N-acetyl-3, 7-dihydroxyphenoxazine), which has been 
shown to be highly specific and sensitive to hydrogen peroxide (Zhou et al., 1997). 
Amplex Red is a colourless solution that, in the presence of horse radish peroxidase 
(HRP), reacts with hydrogen peroxide at a 1:1 stoichiometry. This reaction of Amplex 
Red and hydrogen peroxide in the presence of HRP produces the highly fluorescent 
resorufin where the intensity of fluorescence can then be detected.  
Reagents: 
 Buffer Z: 
o 110mM K-Mes (2-(N-morpholino) ethanesulfonic acid Sigma 
Aldrich, Dorset, UK) 
 
o 35mM KCl (BDH Prolabo, Leicestershire, UK) 
o 1mM EGTA (Sigma Aldrich, Dorset, UK) 
o 3mM MgCl2  (BDH Prolabo, Leicestershire, UK) 
o 10mM K2HPO4 (BDH Prolabo, Leicestershire, UK) 
 Amplex Red Solution: 
o 50µl SOD (Molecular Probes, Eugene, Oregon) 
o 200µl Amplex Red (Molecular Probes, Eugene Oregon) 
o 10µl of HRP (Molecular Probes, Eugene Oregon) 
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2.13.1. Standard curve for optimisation of settings for Amplex Red analysis 
Standards were generated as shown in Table 2.3. A 2.5µM stock solution of 
hydrogen peroxide was prepared and nine standards prepared using serial dilutions. 
One hundred microlitres of each standard was then added to a black 96 well plate 
(Starlab, Milton Keyes UK) in duplicates. The plate was then read immediately on the 
luminescence reader (BMG laboratories, Buckinghamshire, UK) to set the optimum 
gains to achieve optimum signal to noise for that batch of Amplex Red for further 
experiments to determine concentration of hydrogen peroxide in the media of 
resveratrol treated cells.  
Table 2.3 Concentrations used for construction of standard curve for Amplex Red  
 
 
2.13.2. Determination of H2O2 concentration from media of myotubes treated with 
resveratrol 
 
Fifty microlitres of differentiating media was added to 50µl of Amplex Red 
solution in a black 96 well plate. The plate was read immediately on the luminescence 
reader. The end point value was then normalised to the total protein content of the 
sample. Total protein from cells was determined using the BCA assay (Section 2.10). 
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2.14. Harvesting of cells for RNA extraction  
Reagents: 
 Tri-Reagent (Life technologies, Warrington, UK) 
 
 Chloroform (Sigma Aldrich, Dorset, UK) 
 
 Isoproponal (Sigma Aldrich, Dorset UK) 
 
 Ethanol (Sigma Aldrich, Dorset, UK) 
 
Protocol: 
Myotubes were scraped in 500µl of Tri-Reagent and 200µl of chloroform was 
added. Tri-Reagent and chloroform were thoroughly mixed and samples centrifuged at 
14,000g for 15 minutes. Centrifugation resulted in phase separation and the top clear 
layer containing RNA was transferred to new eppendorfs and 500µl of isopropanol was 
added. Samples were left at room temperature for 10 minutes and centrifuged for 30 
minutes at 14,000g at 4oC. The isopropanol was removed and 200µl of 80% ethanol 
was added and samples centrifuged for a further 2 minutes. The ethanol was then 
removed and RNA pellets were re-suspended in RNAse-free water. One microlitre of 
sample was then added to the Nanodrop (Thermoscientific, Cheshire, UK) to determine 
RNA concentration and purity.  
2.15. cDNA synthesis 
Reagents: 
 Random Hexamers (Sigma Aldrich, Dorset, UK) 
 
 RNA 
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 RNAse free water (Sigma, Dorset, UK) 
 
 Superscript II (Invitrogen, Paisley, UK) 
 
 Deoxynucleotides (DNTP’s, Invitrogen, Paisley, UK) 
 
 Dithiothreitol (DTT, Invitrogen, Paisley, UK) 
 
 
Protocol: 
One hundred nanograms of RNA from each sample were placed in 96 well 
plates and 1µl of random hexamers was added to each sample. RNA was incubated at 
42oC for 10 minutes and placed on ice. Following incubation, 8µl of a master mix 
consisting of 4µl of buffer, 2µl of DTT, 1µl of superscript II and 1µl of dNTPs and 
appropriate amount of RNAse free water to make a final volume of 20µl, was added to 
each well and placed at 65oC for 1H. cDNA was then stored at -20oC. 
Table 2.4 Make-up of master mix for cDNA synthesis.  
 
 
 
 
2.16. Designing of primers 
 
Primers (Table 2.5) were designed using NCBI primer blast.  
 
 
Component Volume 
Random Hexamers 1µl 
First strand 5x buffer 4µl  
DTT 2µl 
DNTP 1µl  
RNAse free water variable 
Total 20µl 
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Table 2.5 Primer sequences for S29 Murf1 and Atrogin1.  
 
 
2.17. Qualitative PCR 
Reagents: 
 cDNA 
 Sybrgreen Master mix (Thermoscientific, Cheshire, UK) 
 Primers (Sigma Aldrich, Dorset, UK) 
Protocol: 
cDNA was diluted 1 in 100 with RNAse free water and 10µl of diluted cDNA 
was added into 96 well plates. A master mix consisting of 25µl of Sybrgreen, 2.5µl of 
forward primer and 2.5µl of reverse primer (Table 2.6) was prepared for each sample 
and 30µl were added to cDNA). Plates were then sealed, pulse centrifuged for 5 
seconds and placed in the thermal cycler (Biorad, Hertfordshire, UK) for thermo cycling 
(Table 2.7) for Atrogin1, S29 and Murf1. Forty five cycles were performed.  
Table 2.6 Reaction mix for qPCR analysis of s29, murf1 and atrogin1 
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Table 2.7 Cycle run for qPCR  
 
Samples were placed at 95oc for 10 minutes and 10 seconds for denaturing, 60oC for 15 
seconds for annealing and 72oC for 20 seconds for extension.  
 
2.17.1. Validation of qPCR products 
Reagents: 
 1% agarose (Sigma Aldrich, Dorset, UK) in TAE Buffer (Life technologies, 
Warrington, UK) 
 Loading dye (Life technologies, Warrington, UK) 
 Midori green (Geneflow, Litchfield, UK)  
Protocol: 
To ensure that the qPCR had amplified the correct products and no primer 
dimers had formed, qPCR products were separated on a 1% agarose gel containing 
20µl of midori green and were visualised using a UV transilluminator light on the 
chemilumiscence (Biorad, Hertfordshire, UK).  
 
Figure 2.7 Example agarose gel showing products of PCR following amplification.  
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2.18. Analysis of cytokine content of cell culture media with luminex assay  
Luminex is a magnetic bead based colour coded multiplex assay that measures 
multiple cytokines, chemokines and growth factors. The luminex assay forms a 
sandwich complex with a magnetic bead containing the capture antibody for the 
biomarker of interest. The biomarker of interest in the sample binds to the capture 
antibody. A biotinylated detection antibody, specific for the biomarker of interest, then 
binds to the complex. Detection is then allowed with addition of the streptavidin-
phycoerythrin (PE) conjugate. The magnetic beads are detected on a bio-plex system. 
The bio-plex system is a dual-laser flow based detected instrument containing two 
lasers, one that classifies the bead and determines which analyte is being detected. 
The secondary laser defines the magnitude of the PE-derived signal, which is in direct 
proportion to the amount of analyte bound (Figure 2.8).  
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Figure 2.8: Brief overview of luminex assay. Magnetic beads are attached to the plate and 
the biomarker of interest will bind to this through the capture antibody. The detection 
antibody will then bind to the streptavidin-phycoerythrin complex and the fluorescence 
detected by the bio-plex system.  
Reagents: 
 Biorad 24 plex rat cytokine assay (Biorad, Hertfordshire, UK): 
o Standards 
o Magnetic beads 
o Antibodies 
o Strepavidin-PE 
o Wash buffer 
o Assay buffer 
 Differentiation medium 
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Protocol: 
The Bio-Plex system was calibrated using calibration beads (Biorad, 
Hertfordshire, UK) before preparation of the plate. Standards were prepared as per 
manufacturer’s instructions; the standard was reconstituted in differentiation medium 
and vortexed thoroughly. Eppendorfs were labelled and the appropriate amount of 
diluent placed in each eppendorf (Table 2.8). Serial dilutions of the reconstituted 
standard were then made as shown in Table 2.8 with 128µl of reconstituted standard 
placed into standard 1 and vortexed thoroughly, 50µl of standard 1 transferred to 
standard 2 and this repeated to get a series of dilutions. Differentiation medium was 
used as a diluent.  
Table 2.8. Serial dilutions of Bioplex standards 
 
Magnetic beads containing capture antibodies were re-suspended in assay 
buffer and 50µl added to each well to place magnetic beads on the plate. All wells were 
then washed twice with 100µl of wash buffer to remove excess beads. Fifty microlitres 
of each sample was pipetted into wells. This was repeated with the standards. Plates 
were then protected from light and left shaking at approximately 300g for 30 minutes. 
All wells were washed 3 times with 100µl of wash buffer. Detection antibody was 
reconstituted and 25µl added to each well. Plates were then protected from light and 
left shaking at approximately 300g for 30 minutes, following incubation; wells were 
washed 3 times with 100µl of wash buffer. Strepavidin-PE was re-suspended ensuring it 
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was protected from light at all times and 50µl was added to each well and plates were 
left shaking at approximately 300g for 10 minutes. Plates were washed for a final 3 
times with 100µl of wash buffer. The plate was then placed on a vortex for 30 seconds 
at approximately 1100g to re-suspend the magnetic beads. Plates were then read at 
High RP1 on the Bio-Plex system (Biorad, Hertfordshire, UK). Plates were protected 
from light at all times.  
2.19. 3D muscle construct studies   
Interest in the measurement of muscle in culture began in the early 90’s when 
Vandenburgh et al constructed “organoids” (Vandenburgh et al., 1991), as a solution to 
measure functional properties of muscle in cell culture. Force was measured using a 
lateral loading and displacement arrangement with a calibrated micro needle. 
However, measurement of force in organoids was criticised due to the possibility of 
lateral loading changing the sarcomere lengths within the organoid (Dennis et al., 
2000). More recently the Tissue Engineering Laboratory at the University of Michigan 
has furthered this technique (Dennis et al., 2000; Dennis et al., 2001; Kosnik et al., 
2001; Baker et al., 2003) to allow functional measurements of 3D muscle constructs 
known as “myooids” and have further aimed to use this technique as a tool for the 
restoration of muscle after acute injury, surgery, or disease. 
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2.19.1. Preparation of culture dishes for 3D constructs 
Reagents: 
 Sylgard elastomer base (Dow Chemical Corporation, Stockport, UK) 
 Sylgard elastomer curer (Dow Chemical Corporation, Stockport, UK) 
 Ethanol 
 DPBS (Sigma Aldrich, Dorset, UK) 
 Laminin (Invitrogen, Paisley, UK) 
 Growth Medium  
Protocol: 
Sylgard was made by mixing sylgard elastomer base with elastomer curer at a 
1 in 10 dilution. Each 60-mm plate was coated with 5ml of Sylgard and left for 3 weeks 
before use. Once ready to use, sylgard coated dishes were soaked in 70% ethanol for 
10 minutes and washed in DPBS. The DPBS was aspirated off and the plates coated 
with a solution of 4ml DPBS containing 2.0μg/cm2 laminin. The plates were left to dry 
overnight in a cell culture hood. Once the laminin was dry, dishes were rinsed with 
DPBS for 10 minutes and each plate was covered with growth medium and stored in a 
37°C, 5% CO2 incubator until use.  
2.19.2. Preparation of 3D constructs 
Reagents: 
 Growth medium (GM) 
 Differentiation medium (DM) 
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 0.025% Trypsin containing EDTA (Sigma Aldrich, Dorset, UK) 
 DPBS 
 Tendon from rat tail  
Protocol: 
Myoblasts were counted and plated at a density of approximately 4x105 on a 
pre-prepared dish in 5ml of growth medium. Once myoblasts had reached 80% 
confluence, the tendon from a rat tail was cut into 3mm sections and two pieces were 
pinned 30mm apart. Media was changed from growth medium to differentiation 
medium and differentiation medium ‘topped up’ every 2 days. Within a few days (3-5 
days) myotubes would then begin to delaminate and roll around the pinned tendon. 
For constructs that did not completely roll up spontaneously, the monolayer was 
manually teased away from the culture dish using a pipette tip to encourage the rolling 
up.  
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Figure 2.9 Stages of 3D construct (a) Cells are plated and once confluent pins were added to 
culture dish. (b and c) Following 3-5 days, cells began to roll up and (d) form a 3D construct. 
This was then attached to a force transducer (e) and force generation was measured. 
 
2.19.3. Measurement of force production by a 3D construct 
Contractile properties were measured the following day after the formation of 
a 3D construct. The pin on one end of the 3D construct was released from the Sylgard 
and attached to a force transducer with wax. Platinum wire electrodes were positioned 
on either side of the construct to allow stimulation of the whole construct. Passive 
baseline force was measured as the average baseline force before the onset of 
stimulation. Twitches were elicited using a single 1.2-ms pulse at 10V and maximum 
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tetanic force was determined at 10, 20, 40, 80 100 and 200Hz. Maximum specific force 
was determined by normalising peak tetanic force to the cross sectional area of the 3D 
construct that was determined by measuring the diameter of the 3D construct 
measured using Nikon TE2000 microscope (Nikon, Kingston upon Thames, UK). 
2.19.4. Haematoxylin and eosin staining of 3D constructs  
Haematoxylin and Eosin use the chemistry of the tissue to differentially colour 
various components of the cell. When in a complex with aluminium salts, Haematoxylin 
is cationic and reacts with negatively charged, basophilic cell components, such as 
nucleic acids in the nucleus. As a consequence of this reaction, these basophilic cell 
components will stain blue. Eosin is anionic and reacts with positively charged, 
acidophilic components in the tissue, for example amino groups in proteins in the 
cytoplasm. As a result of this reaction, these acidophilic components will stain pink. 
Reagents: 
 Tissue embedding medium  
 Liquid nitrogen  
 Haematoxylin (Leica, Milton Keynes, UK) 
 Eosin (Leica, Milton Keynes, UK) 
 Acetic acid 
 Ethanol  
 DPX mountant (Sigma Aldrich, Dorset, UK) 
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Protocol: 
3D constructs were placed on a wooden stick and were covered in tissue 
embedding medium and placed into liquid nitrogen. Frozen constructs were stored at -
80oC until use. Once ready to section, 3D constructs were placed in the cryostat (Leica, 
Milton Keynes UK) for at least 1H before commencing of sectioning. Ten micron 
sections were cut and left to dry for approximately 1H. Sections were placed into 
running tap water for 30 seconds followed by 4 minute incubation in haematoxylin. 
Sections were placed under running tap water 30 seconds, followed by 30 seconds in 
1% acid alcohol. Sections were placed under running tap water for 3 minutes and 
incubated in eosin for up to 4 minutes. Sections were then placed under running water 
for 3 minutes. Sections were then dehydrated in 70% ethanol for 3 minutes followed 
by 3 minutes in 90% ethanol. Sections were then placed in 100% ethanol for a further 3 
minutes. A coverslip was then placed over the sections with DPX mountant and left 
overnight to dry. The following day sections were placed at 4oC until viewing with the 
Nikon Eclipse TE2000 (Nikon, Kingston upon Thames, UK). 
2.20. In vivo studies  
2.20.1. Mouse studies to establish an effective resveratrol treatment  
Reagents:  
 Resveratrol (Sigma Aldrich, Dorset, UK) 
 
 20% DMSO (Sigma Aldrich, Dorset, UK) 
 
 
 
   
123 
 
Protocol: 
Resveratrol was dissolved in 20% DMSO and mice were given 25mg 
resveratrol/kg/day or 125mg resveratrol/kg/day or the equivalent 20% DMSO carrier 
by oral gavage every day for 14 days an additional group of untreated mice was 
studied. On day 15, mice were sacrificed by overdose with pentabarbitone (60mg i.p 
injection) and gastrocnemius muscles collected for HPLC and western blotting analysis 
(Section 2.11.2 and 2.11.3).  
2.20.2. Analysis of resveratrol and metabolites by HPLC 
Gastrocnemius muscles were ground under liquid nitrogen and then sent to 
University of Parma on dry ice where samples underwent HPLC analysis for resveratrol 
and metabolites as described (Bresciani et al., 2014). 
2.20.3. Analysis of MnSOD and Sirt1 in mouse muscle  
Reagents: 
 DPBS 
 Liquid Nitrogen  
 1% SDS   
 Protease inhibitors  
 BCA and copper sulphate  
 Protein loading buffer (Geneflow, Litchfield, UK) 
Protocol: 
Gastrocnemius muscles were ground under liquid nitrogen and placed in 1% 
SDS containing protease inhibitors. Muscles were then homogenised, sonicated and 
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centrifuged at 14000g for 5 minutes at 4oC and supernatants were used for the 
determination of protein content by the BCA method (Section 2.10) and subsequent 
SDS-PAGE (Section 2.11.2) and western blotting (Section 2.11.3) for detection of 
MnSOD and Sirt1 (Section 2.11.5).  
2.20.4. Mouse studies focusing on the effect of resveratrol on muscle force 
generation 
Reagents: 
 Resveratrol 
 DMSO 
 Ketamine 
 Domitor 
 OCT (Merck, UK) 
 Isopentane (Sigma Aldrich, Dorset, UK) 
Protocol: 
Resveratrol was dissolved in 20% DMSO and mice fed with 125mg/kg/day or the 
equivalent DMSO control by oral gavage every day for 14 days. On day 15 mice were 
anaesthetised with an intraperitoneal injection of 0.66mg/kg of ketamine and 
0.55mg/kg of domitor.  
2.20.5. Muscle force measurements in vivo 
Protocol: 
Force measurements were performed according to McArdle et al (2004) with 
assistance from Dr Kasia Whysall. Briefly, the distal tendon was exposed and attached 
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to the lever arm of a servomotor (Cambridge Technology, UK). The lever served as a 
force transducer. The peroneal nerve was exposed, and electrodes placed across the 
exposed nerve. Stimulation voltage and muscle length were adjusted to produce 
maximum twitch force. With the muscle at optimum length, the maximum force was 
determined during 300 msec of voltage stimulation. The maximum force was identified 
by increasing the frequency of stimulation at 2 min intervals until the maximum force 
reached a plateau. Muscle fibre length (Lf) and cross-sectional area were calculated to 
determine specific force of muscle (McArdle et al., 2004). 
Following force measurements mice were culled, the EDL and gastrocnemius 
muscles dissected and weighed. The gastrocnemius muscle was collected for western 
blotting analysis (Section 2.20.3). 
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 EFFECT OF RESVERATROL ON MYOBLAST 3.
VIABILITY IN VITRO 
  
   
127 
 
3.1 Introduction 
Resveratrol is a well-studied polyphenol shown to have potential health 
benefits in numerous diseases such as cancer (Harati et al., 2015) and diabetes 
(Brasnyó et al., 2011). There is some evidence that resveratrol may improve skeletal 
muscle strength. For example, Dolinsky et al (2012) found that resveratrol treatment 
resulted in an increased twitch and tetanic force of the soleus and anterior tibialis 
muscles in 22 week old rats (Dolinsky et al., 2012). 
Considerable work has been carried out examining the effect of resveratrol 
on cell viability and cell number. These studies have shown that the effects of 
resveratrol seems to be cell type specific with resveratrol treatment preserving cell 
viability following serum deprivation in embryotic fibroblasts (Ulakcsai et al., 2015) 
but causing cell death in numerous cancer lines (Ming-Huan et al., 2006; Gomeza et 
al., 2013). The effects of resveratrol have also been shown to be dose dependent; for 
instance low concentrations (1-10µM) of resveratrol led to cell proliferation in the 
prostate cancer cell line PC3 (Chang et al., 2013) whereas higher concentrations (10-
100µM) resulted in decreased cell viability and an increased percentage of apoptotic 
cells (Sheth et al., 2012). Another variable of the effect of resveratrol appears to be 
whether the organism is under stress. A number of studies have suggested that 
resveratrol may only be effective when there is a pre-existing condition for example, 
obesity (Lagouge et al., 2006), but may have little effect in healthy animals (Rogers 
et al., 2015).  
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Resveratrol has been proposed to protect against sarcopenia and a number 
of studies have focused on examining the effect of resveratrol on skeletal muscle 
viability using the skeletal muscle cell line C2C12. These studies have resulted in 
conflicting results. Several studies using C2C12 cells have shown a decrease in cell 
number following treatment of 0.1 and 25µM resveratrol, (Montesano et al., 2013), 
whereas others have shown that resveratrol does not affect myoblast viability until 
concentrations reach 50µM (Higashida et al., 2013). Similar to other cell lines, 
myoblast sensitivity to resveratrol has been shown to be dose dependent. Thus, 
treatment of cells with 10µM of resveratrol resulted in an increase in cell motility 
and fusion, however this effect was inhibited by increasing concentrations of 
resveratrol (20µM, 40µM and 60µM) (Bosutti et al., 2015). No work has been 
undertaken looking at the effect of resveratrol on primary myoblast viability despite 
primary myoblasts being a more physiologically relevant model to study muscle in 
vitro. 
One of the most common and reproducible effects of resveratrol is an 
increase in mitochondrial biogenesis through the upregulation of PGC1-α. The 
mechanism by which this occurs is still unclear. There is some evidence that 
resveratrol directly activates the NAD+ dependent deacetylase Sirt1. Sirtuins are a 
conserved mammalian family of NAD+ dependent deacetylases and ADP-
ribosyltransferases that are involved in numerous processes such as regulation of 
metabolism, repair of DNA and the silencing of genes (Rahman et al., 2011).  
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The direct activation of Sirt1 by resveratrol is supported by the evidence 
that the effects of resveratrol are abolished in cells pre-treated with shRNAs 
targeted against Sirt1 and this work is further supported by studies using mice with a 
Sirt1 deletion (Price et al., 2012).  
This increase in Sirt1 activity has also been implicated in the resveratrol-
induced increase in MnSOD and catalase protein content and activity (Jackson et al., 
2011) through increasing PGC1-α and subsequently NRF-2 (nuclear respiratory factor 
2), leading to increases in mitochondria function. MnSOD and catalase are both 
antioxidant defence enzymes which play a role in the protection of cells against ROS 
(Ji, 1993). 
The aim of this chapter was to identify a concentration of resveratrol that 
would be functional and non-toxic in single skeletal muscle cells (primary myoblasts) 
but was also physiologically achievable by changes in diet. Myoblasts were used to 
determine the effect of resveratrol on myoblast proliferation and further 
experiments will use these data to further optimise a resveratrol treatment to be 
effective during differentiation of muscle (Chapter 4).  
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3.2 Methods  
 
Figure 3.1 A brief overview of the methodology used. Myoblasts were treated with 
different concentrations of resveratrol for different lengths of time and were either 
harvested for western blotting or used for cell counts and live and dead assays.  
3.2.1 Treatment of myoblasts with resveratrol 
Rat primary myoblasts were isolated, cultured and maintained in growth 
medium as described in Section 2.3.1. Myoblasts were plated at a density of 2x104  
per well in 6 well plates. All myoblasts were allowed to adhere overnight and then 
treated with 0, 0.1, 1 or 10µM of resveratrol for 3,6,12, 24 or 48H. Myoblasts were 
treated at passage 1-6. 
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3.2.2 Counting of myoblasts following resveratrol treatment 
Myoblasts were detached from the flask using trypsin and re-suspended in 
1ml of growth medium. Twenty microlitres of cell suspension was added to 20µl of 
trypan blue and 10µl added to each side of the cell counter for use in the automatic 
cell counter (Biorad, Hertfordshire, UK) or 10µl was added to each side of the 
haemocytometer. Myoblasts were counted with both a haemocytometer and 
automatic counter (Biorad, Hertfordshire, UK) to ensure accurate counting of cell 
number. Four measurements were taken from the cell counting slide and 4 
measurements taken from each side of the haemocytometer. All values for each well 
were averaged and the 6 wells pooled together to produce an average value for each 
treatment group.  
3.2.3 Live and Dead staining of resveratrol treated and control myoblasts  
Myoblasts were washed with HBSS and incubated for 15 minutes in a 1ml 
solution with 1 in 500 dilution of both Syto10 and DeadRed (Invitrogen, Paisley, UK) as 
instructed by the manufacturers. Myoblasts were then washed with HBSS, fixed in a 4% 
glutaraldehyde solution for 1H and placed at 4oC until viewing with the Nikon Eclipse 
TE2000 microscope (Nikon Kingston upon Thames, UK).  
3.2.4 Harvesting of resveratrol treated and control cells for western blotting 
Media was removed and cells washed with PBS. Cells were scraped in PBS and 
centrifuged at 14000g for 5 minutes at 4oC and re-suspended in 50µl of 1% SDS 
containing protease inhibitors (Sigma Aldrich, Dorset, UK). Cells were sonicated for 15 
seconds and centrifuged at 14000g for 5 minutes. The pellet was discarded and a BCA 
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assay (Section 2.1.1) was carried out on the supernatant to determine protein 
concentration. Samples were then diluted 1:1 with protein loading buffer (National 
Diagnostics, Hull, UK) in preparation for detection of protein content of MnSOD, 
catalase and Sirt1 (Section 2.12). Following exposure of membranes, the intensity of 
each band was measured using ImageJ (US National Institutes of Health, Maryland, 
USA) and this was normalised to total protein content using Ponceau S (Sigma Aldrich, 
Dorset, UK) staining (Appendix Section 10.1). 
3.2.5 Analysis of MnSOD, catalase and Sirt1 protein concentrations by SDS PAGE 
and western blotting  
Samples were loaded into acrylamide gels and proteins resolved. Following 
transfer of proteins to a nitrocellulose membrane using the Geneflow blotting system 
(Section 2.2.3), membranes were blocked in 5% milk and incubated with primary 
antibodies (Table 2.2) at 4oC overnight. Membranes were washed 3x5 minutes and 
incubated with the secondary antibody (Table 2.2) for 1H at room temperature. 
Membranes were then washed for 3x5 minutes and proteins were visualised using ECL 
with a Chemidoc (Biorad, Hertfordshire, UK). 
3.2.6 Statistical analysis 
Graphpad 5 (Graphpad Software, San Diego, USA) was used to perform a 
One-way ANOVA followed by a Dunnett’s post-test to identify significant differences. 
Data are represented as mean ± SEM.  
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3.3 Results 
3.3.1 Effect of increasing concentrations of resveratrol on number, proliferation 
and viability of primary myoblasts 
3.3.1.1 Effect of increasing concentrations of resveratrol on myoblast number and cell 
proliferation 
 
Myoblast number following treatment with resveratrol is shown in Figures 3.2-
3.6. Treatment of myoblasts with 0.1, 1 and 10µM of resveratrol resulted in decreased 
myoblast number compared with control myoblasts at 3H (Figure 3.2 p<0.01), 6H 
p<0.01), 12H (p<0.05) and 24H (p<0.05) following resveratrol treatment. This was 
accompanied by a premature elongation of resveratrol treated myoblasts compared 
with untreated myoblasts (Figure 3.6). A significant increase in myoblast number 
compared with control was seen 48H following treatment with all concentrations of 
resveratrol (p<0.05). Growth curves show that treatment of myoblasts with resveratrol 
resulted in increased myoblast proliferation (Figure 3.3). This data was validated using 
two methods of cell counting, the automatic cell counter and manual counting, an 
example of this is shown in Figure 3.2. 
   
 
       
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2 Myoblast number at 3H following resveratrol treatment of myoblasts. Myoblast number using a haemocytometer and cell counter 
and (c) a comparison of the two techniques is shown. **p<0.01, ***p<0.001 compared with untreated control by One-way ANOVA. Values 
are mean ±SEM (n=≥3). 
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Figure 3.3 Effect of increasing amounts of resveratrol over a period of time on myoblast number. Myoblast numbers were established using a 
cell counter. *p<0.05 compared with resveratrol treated myoblasts at same time point. One way ANOVA.  
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Figure 3.4 Representative images of myoblasts at (a) 3H (b) 6H (c) 12H (d) 24H and (e) 48H following treatment with 0.1, 1 or 10µM of 
resveratrol compared with control myoblasts. Scale bar is 100µM. 
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3.3.1.2 Effect of resveratrol on cell viability of myoblasts 
Myoblast viability following treatment with increasing amounts of resveratrol 
is shown in Figure 3.5 and Figure 3.6. Treatment of myoblasts with 0.1µM of 
resveratrol resulted in a reduction in cell death at 3H (p<0.05), 6H (p<0.01) and 12H 
(p<0.001) following treatment compared with untreated control myoblasts. Treatment 
of myoblasts with 1µM of resveratrol also resulted in a decrease in cell death at 3H 
(p<0.05), 6H (p<0.001) and 12H (p<0.001) following treatment compared with 
untreated control myoblasts. No difference cell death was identified in myoblasts 
treated with 0.1µM and 1µM of resveratrol at 24H or 48H following treatment 
compared with untreated myoblasts. Treatment of myoblasts with 10µM of resveratrol 
significantly decreased cell death 3H (p<0.05), 6H (p<0.01), 12H (p<0.01), 24H (p<0.01) 
and 48H (p<0.01) following treatment compared with untreated control myoblasts.  
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Figure 3.5 Effect of increasing amounts of resveratrol overtime on myoblast viability over a 48H time course. *p<0.05, **p<0.01, ***p<0.001 
compared with time matched untreated control (0µM) of resveratrol. Values are mean ±SEM (n≥3). One-way ANOVA.  
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Figure 3.6. Representative images of live and dead analyses of myoblasts following a 48H 
time course of treatment with 0, 0.1, 1 and 10µM of resveratrol. Green cells represent live 
myoblasts and red cells are dead myoblasts. Scale bar=10µm.  
 
3.3.2 Effect of increasing concentrations of resveratrol on MnSOD, catalase and 
Sirt1 protein content in primary myoblasts 
3.3.2.1 Effect of resveratrol on MnSOD protein content of myoblasts 
MnSOD protein content in myoblasts following treatment with increasing 
concentrations of resveratrol is shown in Figures 3.11 and 3.12. With the exception 
of a 3H time point (6H-48H) there was a suggestion of a concentration dependent 
increase of MnSOD protein content in myoblasts compared with untreated control 
myoblasts following treatment with 0.1µM, 1 µM and 10 µM of resveratrol (Figure 
3.8a p<0.05). This increase in MnSOD protein content reached significance following 
treatment of myoblasts with 1µM of resveratrol at 3H (p<0.05) and 24H post-
treatment (Figure 3.8 p<0.05), as well as at 12H (p<0.01), 24H (p<0.01) and 48H 
(p<0.05) following treatment of myoblasts with 10µM of resveratrol (Figure 3.8). 
Treatment of myoblasts with 0.1µM (p<0.001) of resveratrol increased MnSOD 
protein content compared with untreated control myoblasts at 3H following 
treatment (Figure 3.8). 
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Figure 3.7 MnSOD protein content expressed as percentage change from untreated control 
myoblasts following treatment with increasing concentrations of resveratrol over a 48H 
time course. *p<0.05, **p<0.01, ***p<0.001 compared with untreated control. Values are 
mean ±SEM (n=3-4) One-way ANOVA. 
 
 
Figure 3.8 MnSOD protein content in myoblasts at (a) 3H (b) 6H (c) 12H (d) 24H (e) and 48H 
following treatment with 0, 0.1, 1 and 10µM of resveratrol.  
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3.3.2.2 Effect of resveratrol on catalase protein content of myoblasts 
Catalase protein content of myoblasts following treatment with increasing 
concentrations of resveratrol is shown in Figure 3.9 and Figure 3.10. Following 
treatment of myoblasts with 0.1, 1 and 10µM of resveratrol, an approximate 
concentration dependent increase in catalase protein content was observed 
compared with untreated control myoblasts. This reached significance up to 6H 
following treatment with 0.1µM of resveratrol (p<0.05) and up to 24H following 1µM 
of resveratrol (p<0.05). This increase in catalase protein content was seen at 48H 
following a treatment of myoblasts with 10µM of resveratrol (p<0.05) compared 
with untreated myoblasts. 
 
Figure 3.9 Catalase protein content expressed as percentage change from untreated control 
following treatment with increasing concentrations of resveratrol over a 48H time course. 
*p<0.05, **p<0.01, ***p<0.001 compared with untreated control. Values are mean ±SEM 
(n=3-4) One-way ANOVA. 
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Figure 3.10 Catalase protein content in myoblasts (a) 3H (b) 6H (c) 12H (d) 24H (e) and 48H 
following treatment with 0, 0.1, 1 and 10µM of resveratrol.  
3.3.2.3 Effect of resveratrol on Sirt protein content of myoblasts 
Sirt1 protein content in myoblasts following treatment with increasing 
concentrations of resveratrol is shown in Figure 3.11 and Figure 3.12. Treatment of 
myoblasts with 0.1, 1 and 10µM of resveratrol resulted in a transient increase in 
Sirt1 protein content compared with untreated control; this increase was significant 
24H (Figure 3.12 p<0.01) following treatment of 0.1µM resveratrol. Treatment of 
myoblasts with 1µM of resveratrol increased Sirt1 protein content 3H (Figure 3.12 
p<0.05) and 12H (Figure 3.12 p<0.05) following treatment compared with untreated 
control myoblasts. Treatment of myoblasts with 10µM of resveratrol resulted in an 
increase in Sirt1 protein content at 6H (Figure 3.12 p<0.01), 12H (Figure 3.12 p<0.05) 
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and 48H (Figure 3.12 p<0.01) following treatment compared with untreated control 
myoblasts.  
 
Figure 3.11 Sirt1 protein content expressed as percentage change from untreated control 
following treatment with increasing concentrations of resveratrol over a 48H time course. 
*p<0.05, **p<0.01 compared with untreated control. Values are mean ±SEM (n=3-4) One-
way ANOVA. 
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Figure 3.12 Sirt1 protein content in myoblasts (a) 3H (b) 6H (c) 12H (d) 24H (e) and 48H 
following treatment with 0, 0.1, 1 and 10µM of resveratrol.  
 
3.4 Discussion 
The aim of this Chapter was to examine the effects of increasing 
concentrations of resveratrol on number and viability of myoblasts and examine the 
effect of resveratrol on the protein content of the predicted target of resveratrol, Sirt1, 
MnSOD and catalase. This would allow identification of a non-toxic, and functional 
concentration of resveratrol to then optimise treatment of differentiated myoblasts 
(myotubes) in future experiments. Data presented here showed that untreated 
myoblasts show some cell death shortly after plating and treatment of myoblasts with 
resveratrol prevented some of this cell death. This increase in viability of myoblasts 
treated with resveratrol was coupled with an initial reduction in cell number that 
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eventually led to an increase in proliferation rate compared with control myoblasts. 
Treatment of myoblasts with resveratrol also resulted in an increase in MnSOD and 
catalase protein content. The effect of resveratrol on Sirt1 protein content varied with 
concentration and time. 
3.4.1 Effect of treatment of myoblasts with resveratrol on cell number  
Data demonstrated a decrease in myoblast number for up to 24H following 
treatment with 0.1, 1 and 10µM of resveratrol compared with untreated myoblasts, 
although this was not evident with 10µM of resveratrol at 24H following treatment. In 
contrast, a dose dependent increase in myoblast number was seen following treatment 
of myoblasts with 0.1, 1 and 10µM of resveratrol at 48H after treatment.  
 The decrease in myoblast number observed following treatment with 
resveratrol at all time points up to 24H following treatment suggests that resveratrol is 
initially damaging to myoblasts; an increase in myoblast number in both untreated 
control and resveratrol treated myoblasts was then seen at 48H following resveratrol 
treatment. The difference in percentage change in myoblast number between the 24H 
and 48H time point was higher in the resveratrol treated myoblasts (586%±33 (0.1µM), 
754%±33 (1µM), 612%±37 (10µM)) compared with the untreated cells (382%±24), 
indicating that in the long term resveratrol treatment did not negatively affect the 
replicative capacity of myoblasts. The acute decrease in myoblast number following 
resveratrol treatment may be due to resveratrol acting to initiate the differentiation of 
myoblasts into myotubes rather than cell replication, as previously suggested 
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(Kaminskia et al., 2012a). This may be due to the ability of resveratrol to control the 
cell cycle regulators, cyclins, p21 (Montesano et al., 2013) and p16 (Rathbone et al., 
2009) allowing early exit from the cell cycle. 
Despite resveratrol treatment resulting in a decrease in myoblast number, 
representative images of myoblasts at each time point appeared to demonstrate 
premature elongation in resveratrol treated myoblasts compared with untreated 
control myoblasts. This has been previously shown 6H following resveratrol treatment 
of C2C12 myoblasts (Kaminskia et al., 2012a). However, it is unlikely that resveratrol 
would initiate differentiation after just a 3H treatment, nor would this explain why the 
effect on myoblast number was reversed at 48H following treatment. Treatment of 
cells with resveratrol has been shown to result in a short term decrease in metabolic 
rate in other cell types, suggesting that resveratrol may inhibit oxidative 
phosphorylation, however, this suppression of cellular metabolism was not maintained 
with a longer term treatment (Robb et al., 2006). 
The increase in myoblast number at 48H following treatment with resveratrol 
compared with untreated control myoblasts suggests that longer term treatment with 
resveratrol increases the proliferative rate of myoblasts, the mechanisms by which this 
occurs is unclear.  
3.4.2 Effect of resveratrol on viability of myoblasts  
Treatment of myoblasts with resveratrol resulted in a decrease in myoblast 
number compared with untreated control myoblasts at 24H following treatment. 
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Despite this, cell viability assays undertaken showed that, compared with untreated 
control myoblasts, treatment of myoblasts with 0.1, 1 and 10µM of resveratrol resulted 
in a significant decrease in myoblast death. It is worth noting that the live and dead 
assay requires removal of the cell media and numerous washing steps. As myoblasts 
are adhesive, any dead myoblasts will eventually lift off the culture dishes and would 
not be seen in the subsequent live and dead assay. Therefore it is possible that the lack 
of evidence of gross myoblast death together with a decrease in myoblast number, 
despite myoblasts initially being seeded at the same density, could be due to rapid 
toxicity of resveratrol which may decrease the adhesiveness of myoblasts. One reason 
for this may be increased migration and fusion of cells that has been previously shown 
as an effect of resveratrol in skeletal muscle cells (Bosutti et al., 2015). 
Data from cell viability assays agrees with previous studies that have shown a 
decrease in cell number but an absence of apoptosis, (Kaminskia et al., 2012a), a 
decrease in the pro-apoptotic p53 and caspase 3 and 9 activities as well as an increase 
in the anti-apoptotic Bcl-2 following treatment of muscle with resveratrol (Jackson et 
al., 2010). Resveratrol has also demonstrated the ability to inhibit the activity of the 
apoptosis related transcription factor, FOXO (Wang et al., 2014). These studies provide 
a potential mechanism by which resveratrol may be able to prevent apoptosis in 
myoblasts.   
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3.4.3 Effect of resveratrol on Sirt1, MnSOD and catalase protein content of 
myoblasts 
An established effect of resveratrol is an increase in the antioxidants MnSOD 
and catalase expression and activity in muscle (Ryan et al., 2010; Jackson et al., 2011) 
and in other cells types (Robb et al., 2006).  
Data in this Chapter demonstrated a dose dependent effect of resveratrol, 
resulting in an increased MnSOD protein content, whereby 0.1µM of resveratrol 
resulted in a significant upregulation of MnSOD protein content in myoblasts at 3H 
following resveratrol treatment. Resveratrol treatment of myoblasts also increased 
MnSOD protein content at 3H and 24H following treatment with 1µM resveratrol and 
at 12H, 24H and 48H following treatment with 10µM resveratrol. Catalase protein 
content was very sensitive to resveratrol treatment and generally the increase seen 
was dose dependent, whereby treatment with 0.1µM of resveratrol resulted in an 
increase in catalase protein content for up to 6H. Treatment of myoblasts with 1µM 
treatment of resveratrol resulted in increased catalase protein content for up to 24H. 
Treatment of cells with 10µM was able to increase catalase protein content for up to 
48H following treatment.  
It has been proposed that the increase in MnSOD and catalase may be through 
indirect actions of resveratrol. For example, resveratrol has been shown to increase 
mitochondrial density (Lagouge et al., 2006) and it is hypothesised that the increase in 
catalase may be due to the addition of polyphenols to cell culture media. The addition 
of polyphenols has been shown to react with constituents of the cell culture media 
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such as pyruvate, leading to the oxidation of the polyphenol and the production of 
hydrogen peroxide (Long et al., 2010). However, unpublished work from our laboratory 
and other studies (Long et al., 2010) have shown that resveratrol treatment does not 
cause an increased hydrogen peroxide in the media from cells. Thus, it is likely that 
resveratrol has a functional effect in myoblasts and the increase in MnSOD and 
catalase production is in direct response to treatment of myoblasts with resveratrol 
and not as a response to the production of hydrogen peroxide in the cell culture media.  
The mechanism through which resveratrol results in an increase in MnSOD 
and catalase protein content in myoblasts is thought to occur through the upregulation 
of the NAD-dependent deacetylase, Sirt1 (Kitada et al., 2011). Despite this, Sirt1 
involvement in mediating the effects of resveratrol is controversial with some data 
showing that increases in Sirt1 activity following resveratrol treatment is an artefact of 
the fluorophore used in these studies (Beher et al., 2009; Pacholec et al., 2010). Data 
presented here showed the potential involvement of Sirt1 in resveratrol mediated 
effects in myoblasts. However, data also shows some temporal effects on Sirt1 when 
myoblasts were treated with different concentrations of resveratrol and at different 
time points. This is in agreement with data suggesting that different concentrations of 
resveratrol may act through different pathways, for example AMPK has also been 
proposed as a target for resveratrol (Centeno-Baez et al., 2011; Higashida et al., 2013), 
and may explain the lack of any clear dose dependent response in Sirt1 protein content 
of myoblasts following treatment with resveratrol. However, in support of a role of 
Sirt1 in the mechanism of action of resveratrol in myoblasts whereby overexpression of 
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Sirt1 in rat myoblasts resulted in increased myoblast proliferation which was 
accompanied by an early G1 to S phase progression of myoblasts (Rathbone et al., 
2009) suggesting that Sirt1 may be involved in resveratrol-mediated increases in 
myoblast proliferation. However as this was not seen until later time points, it may 
suggest that Sirt1 is not a direct target of resveratrol but a part of a downstream 
pathway (Figure 3.13).  
 
Figure 3.13. Potential mechanism of the action of resveratrol through Sirt1 activation in 
primary myoblasts.  
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3.5 Conclusions 
 
Concentrations of resveratrol that are achievable through diet were initially 
damaging to myoblasts but these effects were not long lasting. Resveratrol conferred 
some protective effects against cell death and in the longer term resulted in increased 
myoblast proliferation and potentially early myogenesis. Physiological doses of 
resveratrol resulted in an increase in MnSOD and catalase protein contents of 
myoblasts, indicating functionality of resveratrol in myoblasts. Data suggested that 
resveratrol acted, at least in part, through Sirt1.   
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4. EFFECT OF RESVERATROL ON VIABILITY AND 
HYPERTROPHY OF MYOTUBES IN VITRO 
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4.1 Introduction  
Data presented in the previous Chapter demonstrated that treatment of 
primary myoblasts with 1µM resveratrol resulted in significant changes in Sirt1, 
catalase and MnSOD protein content of myoblasts at 24H following treatment, 
suggesting that at this concentration and time point, resveratrol had functional effects 
on primary myoblasts. Myoblasts are committed muscle precursor cells that are 
generated from muscle stem cells, satellite cells. Myoblasts proliferate and eventually 
fuse with other myoblasts when in close proximity, and these multinuclear cells further 
differentiate to become multinucleated myotubes (Mauro, 1961; Reznik, 1969). This 
process is known as myogenesis and is controlled by myogenic regulatory factors 
(MFRs) such as MyoD, Mrf5 and myogenin. Myotubes are immature muscle fibres and 
are commonly used in tissue culture studies as a model of skeletal muscle.  
Resveratrol has been shown to promote elongation of myoblasts and 
premature differentiation of C2C12 cells (Kaminskia et al., 2012a; Montesano et al., 
2013) and this is supported by data presented in Chapter 3. Resveratrol has also been 
shown to increase the myoblast protein content of muscle specific proteins, MRFs and 
cycle regulators associated with early cell cycle arrest (Montesano et al., 2013).  
Resveratrol has been shown to have differential effects in type I and type II 
skeletal muscle fibres, where resveratrol treatment in rats in vivo resulted in a 
decrease in the protein content of the antioxidant defence enzyme, CuZnSOD in 
primarily type II EDL muscle fibres and increased the content of MnSOD protein 
content in the primarily type I soleus muscle in rats (Chang et al., 2014). Furthermore, 
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resveratrol has previously been shown to affect undifferentiated and differentiated 
cells differently. For example, treatment of the rat adrenal gland cell line, PC12 cells, 
with resveratrol at concentrations of up to 100µM resulted in an increase in cell death 
in undifferentiated cells, but protected against cell death in differentiated PC12 cells 
(Hayakawa et al., 2013). Therefore, it is possible that there may be different effects of 
resveratrol on primary myoblasts and myotubes. To my knowledge; no work on the 
effect of resveratrol on cell viability in primary myotubes has been previously been 
undertaken.  
Skeletal muscle hypertrophy is the process of increased muscle fibre size and 
occurs when muscle is regularly exposed to work that is beyond its existing capacity. 
Hypertrophy can be achieved by an activation of Akt, which leads to the initiation of 
protein synthesis (Bodine et al., 2001a). Studies have shown that resveratrol can 
increase Akt phosphorylation and activation (Wang et al., 2014) as well as increasing 
the myotube diameter (Montesano et al., 2013) in C2C12 myotubes. Treatment of mice 
with resveratrol resulted in increased maximum force production by the soleus and 
anterior tibialis muscles in rodents (Dolinsky et al., 2012; Wu et al., 2013). Although 
treatment with resveratrol has been shown to result in an increase Akt 
phosphorylation in humans platelet cells (Brasnyó et al., 2011) and microarray analysis 
of human muscle biopsies following supplementation with resveratrol demonstrated a 
change in the expression of 489 genes (Timmers et al., 2011), no studies have 
examined the effect of resveratrol on muscle mass and function in humans.  
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Resveratrol has also been shown to prevent the activation of atrophic 
pathways in TNF-α treated C2C12 myotubes (Wang et al., 2014) in cachexia models 
(Shadfara et al., 2011), in a mouse model of muscular dystrophy (Hori et al., 2011) and 
following unloading in rats (Momken et al., 2011). In contrast, there was no effect of 
resveratrol on weight loss in rodent models of cancer (Busquetsa et al., 2007) or on 
muscle mass in healthy adult mice (Menzies et al., 2013). The majority of studies that 
have examined the effect of resveratrol on muscle mass and function have focused on 
the ability of resveratrol to prevent atrophy within a pre-existing condition or following 
a stress rather than the ability to activate hypertrophy in a healthy muscle. 
Data from Chapter 3 and from published studies (Jackson et al., 2010; Ryan et 
al., 2010; Jackson et al., 2011) indicated that antioxidant defence enzymes such as 
catalase and MnSOD are upregulated in myoblasts following treatment with 
resveratrol. Studies concluded that resveratrol can modify the redox status of cells by 
the upregulation of antioxidants (Robb et al., 2008; Jackson et al., 2011).  
Sirt1 is a NAD-dependent deacetylase, which removes acetyl groups from 
proteins resulting in gene silencing. There is evidence for a role for Sirt1 in the effects 
of resveratrol (Jackson et al., 2011; Morita et al., 2012). However, data observed in the 
previous Chapter showed that the changes in protein content of Sirt1 after treatment 
of myoblasts with resveratrol were transient and another study found no difference in 
Sirt1 protein content or activity in the plantaris muscle of rats following resveratrol 
treatment (Bennett et al., 2013). 
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The aim of this Chapter was to optimise a concentration and time frame of 
resveratrol treatment of myotubes that would be non-toxic, achievable with diet and 
functional, to examine the effect of resveratrol on myotubes in vitro. The hypothesis 
was that resveratrol would lead to an increase in the protein content of MnSOD and 
catalase through the upregulation of the deacetylase Sirt1 and that this would also 
result in a decrease in the overall acetylation status of proteins in the resveratrol 
treated cells.  
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4.2 Methods 
 
Figure 4.1 A brief overview of the methodology used. Myotubes were treated with different 
concentrations of resveratrol for different lengths of time and were either harvested for 
western blotting, analysed for cell viability by a live and dead assay or analysed for myotube 
diameter measurements. Media was analysed at 3 days following resveratrol treatment for 
H2O2 analysis by Amplex Red.  
4.2.1 Culturing of rat primary cells 
Rat primary myoblasts were isolated, cultured and maintained in growth 
medium as described in Section 2.3.1. Cells were seeded on to 6 well plates that had 
previously been treated with 500µl of attachment factor (Invitrogen, Paisley, UK) for 
1H at a density of approximately 5x104 per well.  
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4.2.2 Treatment of myotubes with resveratrol  
Once cells had reached 80% confluence, media was changed to differentiation 
media to initiate differentiation into myotubes and differentiation media was 
supplemented with 0, 0.1, 1 or 10µM of resveratrol daily for 3,5, 7 or 10 days.  
4.2.3 Live and Dead staining of resveratrol treated myotubes 
Media was removed and myotubes were washed with HBSS. Myotubes were 
incubated for 15 minutes in a 1ml solution containing Syto10 and DeadRed (Invitrogen, 
Paisley, UK). Stained myotubes were then washed with HBSS, fixed in a 4% 
glutaraldehyde solution for 1H and placed at 4oC until imaging using a Nikon Eclipse 
TE2000 fluorescent microscope (Nikon, Kingston upon Thames, UK). Images were 
analysed and percentage of dead myotubes was calculated using ImageJ (US National 
Institutes of Health, Maryland, USA). 
4.2.4 Harvesting of resveratrol treated myotubes for western blotting 
Media was removed and myotubes were washed with PBS. Myotubes were 
scraped in PBS and centrifuged at 14000g for 5 minutes at 4oC and the cell pellet was 
re-suspended in 50µl of 1% SDS containing protease inhibitors. Cells were sonicated on 
ice for 15 seconds and centrifuged at 14000g for 5 minutes. The pellet was discarded 
and a BCA assay (Section 2.11) was carried out on the supernatant to determine 
protein concentration. Samples were then diluted 1:1 with protein loading buffer in 
preparation for detection of protein levels of MnSOD, catalase and Sirt1 with SDS-PAGE 
western blotting (Section 2.12). Following exposure of membranes, the intensity of 
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each band was measured using ImageJ (US National Institutes of Health, Maryland, 
USA) and this was normalised to total protein content using Ponceau S staining 
(Appendix Section 10.1). 
4.2.5 Analysis of MnSOD, catalase and Sirt1 protein concentrations by SDS-PAGE 
and western blotting   
Samples were loaded onto a pre-prepared acrylamide gel (Section 2.11.1) and 
proteins were resolved. Following transfer onto a nitrocellulose membrane using the 
Geneflow blotting system (Section 2.11.3), membranes were incubated in blocking 
solution (Table 2.2) and then incubated with primary antibodies (Table 2.2) at 4oC 
overnight. The following day, membranes were washed 3x5 minutes and the secondary 
antibody (Table 2.2) was added for 1H at room temperature. Membranes were then 
washed for 3x5 minutes, placed in ECL solution and viewed using a Chemidoc (Biorad, 
Hertfordshire, UK).   
4.2.6 Measurement of myotube diameter  
Control and resveratrol treated myotubes were viewed using a Nikon TE2000 
microscope (Nikon, Kingston upon Thames, UK). Up to 6 random areas from each well 
were imaged. Images were analysed with ImageJ (US National Institutes of Health, 
Maryland, USA). Three measurements were taken at three points along each myotube; 
an average was then obtained for each myotube and then for each treatment group.    
 
 
  
 160   
 
4.2.7 Measurement of H202 production by myotubes following  
The media of myotubes treated with daily doses of 0.1, 1 and 10µM of 
resveratrol for 3 days was subjected to an Amplex Red assay (Section 2.13) to 
determine the effect resveratrol treatment on hydrogen peroxide production of 
myotubes.  
4.2.8 Statistical analysis 
Graphpad 5 (GraphPad software, San Diego, USA) was used to perform One-
way ANOVA followed by a Dunnett’s post-test to identify significant differences. Data 
are represented as mean ± SEM.  
4.3 Results  
4.3.1 Effect of increasing treatment of myotubes with resveratrol on myotube 
viability 
Myotube viability following treatment of myotubes with resveratrol is shown 
in Figure 4.2-4.5. Treatment of myotubes with 0.1, 1, and 10µM resveratrol resulted in 
a concentration dependent increase in cell death at 3 days of treatment (p<0.01) 
compared with untreated control myotubes. Treatment of myotubes with 10µM of 
resveratrol caused an increase in cell death for up to 5 days of treatment (Figure 4.3 
p<0.05). The induction of cell death by resveratrol treatment on myotubes was 
abolished following a 7 day treatment (Figure 4.4).  
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Figure 4.2 Representative images of myotubes treated for 3 days (a) Untreated control cells 
(b) 0.1µM, (c) 1µM and (d) 10µM of resveratrol. Scale bar 50µM. White arrows indicate dead 
cells. 
 
Figure 4.3 Representative images of myotubes treated for 5 days (a) Untreated control cells 
(b) 0.1µM, (c) 1µM and (d) 10µM of resveratrol. Scale bar 50µM. White arrows indicate dead 
cells. 
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Figure 4.4 Representative images of myotubes treated for 7days (a) Untreated control cells 
(b), 0.1µM (c) 1µM (d) and 10µM of resveratrol. Scale bar 50µM. White arrows indicate dead 
cells.
  
  
 
1
6
3
 
 
Figure 4.5. Viability of myotubes following treatment with increasing concentrations of resveratrol over a period of time. * p<0.05, **p<0.01, 
***p<0.001 compared with untreated control myotubes. Values are mean ±SEM (n=≥3).  
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4.3.2 Effect of treatment of myotubes with resveratrol on MnSOD, catalase and 
Sirt1 protein content  
 
4.3.2.1 Changes in MnSOD protein content of primary myotubes following treatment 
with increasing concentrations of resveratrol 
 
MnSOD protein content in myotubes following resveratrol treatment is shown 
in Figure 4.6. MnSOD protein content in myotubes was significantly following 
treatment with 0.1, 1 and 10µM resveratrol daily for 3 days. This increase was 
maintained for up to 7 days of treatment with 1µM and 10µM resveratrol.   
 
Figure 4.6 MnSOD content and representative western blots for MnSOD protein content of 
control myotubes and myotubes following resveratrol treatment with 0, 0.1, 1 or 10µM of 
myotubes for (a) 3 days (b) 5 days and (c) 7 days. Values are mean ±SEM (n=≥3). * p<0.05, 
***p<0.001 compared with untreated control myotubes One-way ANOVA. 
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4.3.2.2 Changes in catalase protein content of primary myotubes following treatment 
with increasing concentrations of resveratrol 
 
Catalase protein content of myotubes following treatment with resveratrol is 
shown in Figure 4.7. Treatment of myotubes with 0.1, 1 and 10µM of resveratrol 
resulted in significant increases in catalase protein content for 3 and 5 (p<0.05) days of 
daily treatments. This increase in catalase protein content in myotubes was maintained 
with 7 days of treatment with 1µM (p<0.05) and 10µM (p<0.05) of resveratrol.  
 
Figure 4.7 Catalase content and representative western blots for catalase protein content of 
control myotubes and myotubes following treatment with 0, 0.1, 1 or 10µM resveratrol for 
(a) 3 days (b) 5 days and (c) 7 days. Values are mean ±SEM (n=≥3). * p<0.05, **p<0.01, 
***p<0.001 compared with untreated control myotubes, One-way ANOVA.  
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4.3.2.3 Changes in Sirt1 protein content of primary myotubes following treatment 
with increasing concentrations of resveratrol.  
 
Sirt1 protein content of myotubes following resveratrol treatment is shown in 
Figure 4.8. Sirt1 protein content of myotubes was decreased at 3 and 5 days following 
daily treatment of myotubes with 0.1µM, 1µM and 10µM of resveratrol (p<0.05). This 
decrease of Sirt1 protein content of myotubes was maintained for 7 days of treatment 
of myotubes daily with 0.1µM of resveratrol (p<0.05). 
 
Figure 4.8 Representative western blots for Sirt1 protein content following resveratrol 
treatment with 0, 0.1, 1 or 10µM of myotubes for (a) 3 days (b) 5 days and (c) 7 days. Values 
are mean ±SEM (n=≥3). * p<0.05,**p<0.01, ***p<0.001 compared with untreated control 
myotubes One-way ANOVA.   
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4.3.3 Effect of treatment of myotubes with increasing concentrations of resveratrol 
on acetylation of cellular proteins 
The protein acetylation status of myotubes following daily treatment with 0.1, 
1 and 10µM resveratrol at 3, 5 and 7 days is shown in Figure 4.9-Figure 4.11. Treatment 
of myotubes with resveratrol resulted in an increase in protein acetylation compared 
with untreated control myotubes following daily treatment with resveratrol for 3 days 
(Figure 4.9). Treatment of myotubes with resveratrol resulted in a decrease in protein 
acetylation in higher molecular weights following daily treatment with resveratrol for 5 
days. Treatment of myotubes with resveratrol had no effect on the acetylation profile 
following 7 days of daily treatment. The acetylation profile was less defined in 
myotubes following 3 days of treatment (Figure 4.9) than following 5 and 7 days of 
resveratrol treatment (Figure 4.10 and Figure 4.11). Histones are typically 11-20kDa, 
data from these images show it is unlikely that the acetylation status of the histones 
has been modified.   
 
Figure 4.9 Representative western blot of acetylation of proteins in untreated control 
myotubes and in myotubes following treatment with resveratrol for 3 days.   
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Figure 4.10 Representative western blot of acetylation of proteins in untreated control 
myotubes and in myotubes following treatment with resveratrol for 5 days.   
 
Figure 4.11 Representative western blot of acetylation of proteins in untreated control 
myotubes and in myotubes following treatment with resveratrol for 7 days.   
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4.3.4 Effect of treatment of myotubes with increasing concentrations of resveratrol 
on myotube diameter 
 
4.3.4.1 Changes in myotube diameter following resveratrol treatment 
 
Myotube diameter following daily treatment with resveratrol for 3, 5, 7 and 10 
days is shown in Figure 4.12. Treatment of myotubes with 0.1, 1 and 10µM of 
resveratrol resulted in an increase in the diameter of myotubes following daily 
treatments for 3 days (p<0.05). This increase in diameter was maintained following 5 
days of treatment with 0.1µM and 1µM (p<0.05) of resveratrol but this effect was lost 
at later time points.   
 
Figure 4.12. Myotube diameter following treatment with increasing concentrations of 
resveratrol following (a) 3 day (b) 5 day (c) 7 day and (d) 10 day treatment. Values are mean 
±SEM (n=≥3). *p<0.05, ***p<0.001 compared with untreated control myotube. One-way 
ANOVA. 
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4.3.4.2 Effect of treatment of myotubes with increasing concentrations of resveratrol 
on hydrogen peroxide production  
Hydrogen peroxide content of the media of myotubes treated daily for 3 days 
with resveratrol is shown in Figure 4.13. Treatment of myotubes with 0.1, 1 and 10µM 
resveratrol for 3 days resulted in a decrease in hydrogen peroxide content of in the 
media of myotubes (p<0.05).  
 
Figure 4.13 Hydrogen peroxide production in media of myotubes following 3 days of 
increasing concentrations of resveratrol.   
 
4.4 Discussion 
The aim of this Chapter was to examine the effects of resveratrol on the 
viability of myotubes and the protein content of Sirt1, MnSOD and catalase. This study 
aimed to identify whether resveratrol led to hypertrophy or atrophy of myotubes. 
Furthermore this study aimed to examine whether resveratrol affected the production 
of hydrogen peroxide by myotubes, in order to identify if the observed increases in 
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catalase protein content following resveratrol treatment were as a direct or indirect 
effect of resveratrol.  
Data demonstrated an acute minor toxic effect of resveratrol by an increase in 
death of myotubes at 3 days of treatment. This cell death was not evident at later time 
points. In myotubes treatment with resveratrol resulted in a significant increase in 
MnSOD and catalase protein content and a decrease in Sirt1 as well as an initial 
increase in myotube diameter, an effect that was lost at later time points. Treatment of 
myotubes with resveratrol also resulted in a decrease in hydrogen peroxide release 
from myotubes.  
4.4.1 Effect of resveratrol treatment on myotube viability 
To examine the effects of resveratrol on viability of myotubes, a Live and Dead 
assay was undertaken at different time points following resveratrol treatment. Data 
demonstrated that myotubes were more susceptible in the long term to cell death 
from resveratrol treatment than myoblasts, with resveratrol causing transient 
increases in myotube death compared with control myotubes. Any differences in effect 
could be due to uptake of resveratrol by myotubes being more efficient than by 
myoblasts as previously shown in C2C12 cells (Kaminskia et al., 2012a) and therefore 
being exposed to higher levels of resveratrol. Despite the initial cell death the 
remaining myotubes were able to overcome these toxic effects suggesting this cell 
death may not be a major concern with chronic treatment.   
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4.4.2 Effect of treatment of myotubes with resveratrol on MnSOD, catalase and 
Sirt1 protein content in myotubes 
Studies have shown that MnSOD and catalase activity and protein content are 
upregulated following treatment of muscle with resveratrol (Ryan et al., 2010; Jackson 
et al., 2011) both in vivo, (Robb et al., 2008) and in vitro (Inglés et al., 2014) as well as 
in other cells and tissues (Morita et al., 2012). Others have also shown the involvement 
of Sirt1 in these resveratrol-induced changes in MnSOD and catalase (Price et al., 
2012). Therefore the protein content of MnSOD, catalase and Sirt1 following 
resveratrol treatment was studied as an indication of resveratrol having an 
transcriptional effect in myotubes. This study has demonstrated that all 3 
concentrations of resveratrol resulted in an increase in MnSOD and catalase protein 
content following a 3 day treatment. Treatment of myotubes for 5 and 7 days with 
1µM and 10µM of resveratrol resulted in an upregulation of MnSOD and catalase. This 
is in agreement with other studies suggesting that resveratrol can act to increase the 
cellular antioxidant defences and alleviate oxidative stress (Jackson et al., 2011).   
Studies have shown modest increases of Sirt1 protein level and activity in 
muscle (Jackson et al., 2011) and in other tissues following treatment with resveratrol 
(Morita et al., 2012). In contrast, the current study demonstrated a decrease in Sirt1 
protein content following treatment of myotubes with resveratrol for 3-5 days. 
Treatment of myotubes with lower concentrations of resveratrol resulted in a decrease 
in Sirt1 protein content after 7 days of treatment. These data agree with other 
published data that suggest Sirt1 is not a direct target of resveratrol (Higashida et al., 
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2013) but provides further evidence that resveratrol may cause early onset of 
myogenesis by down regulation of Sirt1 since Sirt1 has been shown to increase the 
proliferation of satellite cells (Rathbone et al., 2009). Overexpression of Sirt1 has been 
shown to increase proliferation of satellite cells and myoblasts (Rathbone et al., 2009). 
Sirt1 negatively regulates myogenesis by inhibiting MRFs and expression of muscle 
structural proteins. Furthermore, myoblasts overexpressing Sirt1 had impaired 
differentiation (Fulco et al., 2003). This impairment, was reversible with treatment of 
C2C12 cells and human myocytes with shRNA or a NAM (NAD antagonist) (Fulco et al., 
2003). Thus, to facilitate muscle differentiation, decreasing the NAD+/NADPH ratio in 
the myotube prevents Sirt1 activation and allows myogenesis to occur to its full 
potential (Fulco et al., 2003).  
This study found that the lowest concentration (0.1µM) of resveratrol was the 
most efficient at reducing Sirt1 activation. Sirt1 is thought to be beneficial in a number 
of instances. In particular, Sirt1 has been proposed to be life extending (Howitz et al., 
2003; Porquet et al., 2013). However, Sirt1 activity has been shown to be upregulated 
in muscle of old mice (Jackson et al., 2011), suggesting that increased Sirt1 activity may 
not be advantageous to muscle, as higher levels of Sirt1 has been shown to inhibit 
myogenesis (Fulco et al., 2003). Therefore there is a possibility that the increase in Sirt1 
activity in muscle with age may contribute to the poor regenerative potential in the 
muscle of old animals (Gutmann et al., 1976; McArdle et al., 2004). Furthermore, 
treatment of C2C12 myotubes with high concentrations of resveratrol resulted in 
decreased PGC1-α activity, leading to a decline in mitochondria number (Higashida et 
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al., 2013). The difference in dose effects of resveratrol is particularly important, as it 
seems common practice in the majority of studies to use extremely high, non-
physiological concentrations of resveratrol, which cause an increase in Sirt1 protein 
content and activity. Although the high doses of resveratrol and subsequent 
upregulation of Sirt1 may show benefits in other tissues, this may be detrimental to 
muscle, particularly for muscle repair. Resveratrol treatment has been shown to be 
beneficial in diseases such as muscular dystrophy by improving muscle mass and 
partially preventing the infiltration of non-muscular tissue into the muscles (Hori et al., 
2011), further indicating the importance of understanding the effect of different doses 
of resveratrol. This different dose effects could be one of the reasons for the 
discrepancies reported in Sirt1 activation in muscle following resveratrol treatment 
(Jackson et al., 2011; Bennett et al., 2013). To my knowledge, these are the first data 
suggesting a role of resveratrol in decreasing Sirt1 protein content in muscle, as other 
studies have found increases (Jackson et al., 2011) or no effect on protein content of 
Sirt1 (Bennett et al., 2013) in muscle following resveratrol treatment. It is worth noting 
that a number of these studies were undertaken in vivo, which could also account for 
the differences in results for several reasons including the differences in the muscle 
environment or differential effects of the degradation products of resveratrol in vivo 
following degradation in the gut.  
Data presented here suggests that all three doses of resveratrol used in the 
current study have a physiological effect in myotubes and the proposed mechanisms of 
action are shown in Figure 4.14.  
  
 175   
 
 
Figure 4.14 Hypothesised differences in mechanisms of resveratrol in myotubes following 
high and low doses of resveratrol.  
 
4.4.3 Effect of resveratrol treatment on the acetylation status of proteins in 
myotubes 
As protein content does not necessarily translate to a change in activity, the 
acetylation status of the proteins in myotubes following resveratrol treatment was also 
examined. In agreement with the decrease observed in Sirt1 protein content following 
resveratrol treatment in myotubes, there was an indication that acetylation was 
increased in the proteins from resveratrol treated myotubes, particularly at early time 
points following resveratrol treatment. This would suggest that there is a higher 
deacetylase activity in the untreated myotubes compared with resveratrol treated 
cells. It is important to note that there were differences in acetylation states between 
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the higher and lower molecular weight proteins, with high molecular weight proteins 
seemingly highly sensitive to resveratrol and lower molecular weight proteins relatively 
insensitive. These discrepancies could be explained by the presence of a larger number 
of targets on the higher molecular weight proteins. However, previous work has shown 
resveratrol increased acetylation, inhibited acetylation and had no effect on different 
proteins, suggesting that Sirt1 deacetylase activity following resveratrol treatment may 
be substrate selective (Lakshminarasimhan et al., 2012).  
4.4.4 Effect of resveratrol treatment on myotube diameter  
Treatment of myotubes with resveratrol resulted in some acute cell death in 
myotubes, therefore the aim was to identify whether this increase in cell death was 
associated with myotube atrophy. Treatment of myotubes with resveratrol resulted in 
an increase in myotube diameter following 3 and 5 days of daily treatments, however, 
there was no difference in myotube diameter between untreated and resveratrol 
treated myotubes at later time points. Although resveratrol has been shown to induce 
muscle hypertrophy (Montesano et al., 2013), these data provide evidence that instead 
of causing hypertrophy directly, resveratrol may act by initiating early myogenesis, 
causing treated myoblasts to fully differentiate more rapidly and for this reason there 
was an earlier peak in myotube diameter that was absent in the later time points. 
Therefore it would be interesting to investigate at a later time point, when myogenesis 
was complete, in both the control and resveratrol-treated cells, whether the myotube 
protein content of Sirt1 still differ between the untreated control and resveratrol-
treated myotubes.  
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4.4.5 Effects of resveratrol treatment on H202 production by myotubes 
This study aimed to further examine whether the changes in catalase protein 
content in myotubes induced by treatment of resveratrol affected hydrogen peroxide 
release by myotubes. These data has demonstrated that treatment of myotubes with 
all three concentrations of resveratrol resulted in a decrease in hydrogen peroxide 
production by myotubes compared with untreated control myotubes. These data are in 
agreement with the protein content data, which showed that all 3 concentrations of 
resveratrol resulted in increased catalase protein content of myotubes. The data also 
provide evidence that the increase in catalase is likely to be a direct result of the 
resveratrol treatment, resulting in the decrease in hydrogen peroxide generation 
rather than vice versa. This is particularly important as there is increasing amounts of 
evidence that low amounts of ROS act as signalling molecules and the production of 
hydrogen peroxide may be chronically increased in old mammals. Resveratrol may be 
effective in decreasing the levels of ROS. However, the pathway through which 
resveratrol achieves this in muscle in unclear, since data has shown that resveratrol 
treatment also resulted in a decrease in Sirt1 protein content of myotubes.  
Data demonstrated that treatment of myotubes with 1µM of resveratrol for 3 
days was sufficient to increase antioxidant defence enzymes content, myotube 
diameter and decreased levels of hydrogen peroxide release. Therefore this 
concentration of resveratrol that was chosen for use in future experiments. 
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4.5 Conclusion 
Achievable concentrations of resveratrol were initially toxic to myotubes. 
Despite this toxicity, treatment of myotubes with resveratrol initially caused 
hypertrophy and decreased hydrogen peroxide production by myotubes compared 
with control myotubes. Treatment of myotubes with resveratrol resulted in an increase 
in the myotube content of MnSOD and catalase and a decrease in Sirt1 protein as well 
as an increase in overall protein acetylation compared with untreated control 
myotubes. These data suggest that resveratrol may cause pre-mature myogenesis and 
indirectly offers antioxidant protection to myotubes.   
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5. THE EFFECT OF RESVERATROL ON 
INFLAMMATION INDUCED ATROPHY OF 
MYOTUBES IN VITRO 
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5.1 Introduction 
In 1979 Rosenburg defined “sarcopenia” as the decline in muscle mass and 
function (Rosenberg, 1989) and due to the ever increasing life expectancy, it is 
becoming more important to find efficacious therapeutic avenues for prevention and 
treatment of sarcopenia. The development of an effective treatment for or prevention 
of sarcopenia is still a major challenge as the mechanisms responsible for skeletal 
muscle ageing are still undefined and it is likely that there is a multitude of important 
factors involved. One of the major factors proposed to play a role in sarcopenia is 
increases in both systemic circulating pro – inflammatory cytokines such as TNF-α and 
IL6 (Fagiolo et al., 1993) as well a local production in myokines (cytokines released by 
the muscle) such as MCP-1, IL8 (Caldow et al., 2013) and IL1β (Borge et al., 2009).  
The imbalance in important systems such as the proteasomal degradation system 
and autophagy in skeletal muscle during ageing leads to detrimental cellular effects; 
there is an inability of muscle to regenerate as well as usual due to a decrease in the 
number (Gibson et al., 1983) and capacity of satellite cells to self-replenish the reserve 
population, (Shefer et al., 2006; Day et al., 2010). These changes in satellite cells can 
lead to the replacement of muscle fibres with connective tissue (fibrosis) (Brack et al., 
2007) and intramuscular adipose tissue (IMAT) (Borkan et al., 1983; Visser et al., 2005). 
There is a decrease in muscle cross-sectional area type II fibres and furthermore a 
decrease in the ratio of fast type II fibres to slow type I fibres (Lee et al., 2006), as well 
as a decrease in the number of motor neurons (Rowan et al., 2012) and denervation of 
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neuromuscular junctions (Deschenes et al., 2010), all of which subsequently contribute 
to the decrease in muscle mass and force that is seen in sarcopenia 
Studies have shown improvements in satellite cell function and the ability of 
muscle to regenerate when old muscle is placed in a young environment, signifying the 
importance of the environment of the muscle (Carlson et al., 1989; Brack et al., 2007). 
Furthermore, changes have been seen in important inflammatory markers such as NF-
κB (Cai et al., 2004; Hunter et al., 2004; Vasilaki et al., 2006), TNF-α and IL-6 (Pedersen 
et al., 2003) in muscle during ageing. Interferon induced protein 10 (IP10), is a 8.7kDa 
pro-inflammatory chemokine involved in early recruitment of T-helper type 1 cells to 
sites of inflammation (Luster et al., 1985) and is upregulated in response to many 
inflammatory agents such as IFN-γ and TNF-α (Crescioli et al., 2012). Unpublished data 
from our laboratory and other studies have shown an increase in IP10 in the old 
compared with younger counterparts both in rodents (Chen et al., 2003a) and humans 
(Bonfante et al., 2015) although the role of IP10 in ageing associated conditions 
remains unclear.  
Only a small amount of work has been done examining the effects of IP10 on 
skeletal muscle although it is thought that the role of IP10 is pivotal to changes to 
muscle in several situations. A reduction of IP10 has been shown to decrease 
inflammation in muscle in myositis (Kim et al., 2014) and IP10 has shown to be 
upregulated in situations where neuromuscular junction defects are evident (Feferman 
et al., 2005). IP10 was also shown to be linked to the regulatory of the central 
metabolism of genes in skeletal muscle in COPD patients, as well as in a guinea pig 
  
 182   
 
model of COPD (Davidsen et al., 2014). Intrinsic changes that occur within the muscle 
fibre have been shown to also exacerbate systemic ageing (Demontis et al., 2013). 
Therefore, IP10 has the potential to be a therapeutic target for sarcopenia and other 
muscle wasting diseases (Crescioli et al., 2012). No work has been published examining 
the role of IP10 in the development of sarcopenia. 
“Atrogenes” are atrophy related genes, and this term was created from a study 
which identified genes which are changed during various types of atrophy (Sacheck et 
al., 2007). Of all of the established atrogenes, Atrogin1 (muscle atrophy F box/MAFbx) 
and muscle ring finger 1 (Murf1) are two of those most changed during atrophy. 
Atrogin1 and Murf1 are muscle specific ubiquitin ligases involved in the ubiquitin-
proteasome machinery (Section 1.2.3) and are therefore used as indicators of protein 
degradation and thus, muscle atrophy (Gomes et al., 2001; Cohen et al., 2009; 
Fjällström et al., 2014). Atrogin1 and Murf1 are activated during the inflammatory 
response (Cohen et al., 2009; Wu et al., 2011) however, the effect of IP10 on Atrogin1 
and Murf1 expression in skeletal muscle has not been studied. 
Resveratrol is a polyphenol that has been shown to have anti-inflammatory 
properties in many different cell lines and tissues (Hwa Kanga et al., 2009; Zhu et al., 
2011; Amcaoglu Rieder et al., 2012; Tomé-Carneiro et al., 2012), as well as in skeletal 
muscle (Pearson et al., 2008; Centeno-Baez et al., 2011). Thus, resveratrol has been 
proposed as a potential treatment for sarcopenia. Although resveratrol has been shown 
to decrease TNF-α induced Atrogin1 and Murf1 upregulation in skeletal muscle, the 
specific effect of resveratrol on IP10 induced atrophy has not been examined.  
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The aim of this study was to examine the effects that different concentrations 
of IP10 found in the plasma of healthy old compared with adult subjects had on 
myotubes and whether resveratrol was able to attenuate any atrophic effects of IP10. 
The hypothesis was that treatment of myotubes with the relatively high concentrations 
of IP10 seen in serum of old individuals would result in activation of atrophic processes 
in comparison with treatment of myotubes with lower levels of IP10, more consistent 
with the levels seen in younger individuals. In addition, prior treatment of myotubes 
with resveratrol would prevent the atrophic effects of IP10.  
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5.2. Methods  
 
Figure 5.1 A brief overview of the methodology used. Myotubes were treated with or 
resveratrol for 3 days. Myotubes were then treated with 150 or 200pg/ml of IP10. 
Myotube diameter was measured and myotubes used for qPCR analysis of Atrogin1 
at 1,3,5,7 and 10 days following treatment with IP10.  
 
5.2.1. IP10 preparation 
IP10 was dissolved in distilled water at a concentration of 0.1mg/ml and was 
stored at -20oC until use. 
  
 185   
 
5.2.2. Treatment of myotubes with IP10 +/- resveratrol 
Skeletal muscle cells isolated from Wistar rats were grown in culture until they 
reached 80% confluence; cells were counted using TC-20 automatic cell counter 
(Biorad, Hertfordshire, UK) and seeded in 6 well plates at a density of approximately 
5x104 per well. Once cells had reached 80% confluence, media was changed to 
differentiating media containing 0 or 1µM of resveratrol. Resveratrol was added daily 
for 3 days. Following resveratrol treatment, myotubes were treated with 0, 150pg/ml 
or 200pg/ml of IP10 and visualised for 1, 3, 5, 7 or 10 days following treatment using 
the Nikon TE2000 microscope (Nikon, Kingston upon Thames, UK). Myotube diameter 
was measured using ImageJ (US National Institutes of Health, Maryland, USA). For each 
image, every visible myotube was measured 3 times along its length to produce an 
average diameter per myotube, each myotube was then pooled to give an average 
myotube diameter per well. The average myotube diameter per well was then used to 
determine an average for the treatment groups.  
5.2.3. Determination of gene expression in myotubes treated with IP10 +/- 
resveratrol using qPCR  
Myotubes were harvested in TriReagent, RNA extracted from myotube lysates 
(Section 2.14) and 100ng of RNA synthesised into cDNA (Section 2.15). PCR arrays were 
carried out to examine the expression of Atrogin1 as described in Section 2.12. All gene 
CT values were normalised to S29 CT values.  
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5.2.4. Statistics 
Graphpad 5 (Graphpad software, San Diego, USA) was used to perform One-
way ANOVA followed by a Dunnett’s post-test to identify significant differences. Data 
are represented as mean ± SEM.  
5.3. Results 
5.3.1. Effect of IP10 and resveratrol on myotube diameter over time. 
5.3.1.1. The effect of IP10 on myotube diameter 
 
Myotube diameter following treatment of IP10 is shown Figure 5.2. There was 
a transient decrease in myotube diameter following treatment of myotubes with 
150pg/ml IP10 at 3 days following treatment (p<0.05). There was no effect of 
treatment with 150pg/ml IP10 on myotube diameter at 1, 5, 7 or 10 days following 
treatment (Figure 5.2) compared with untreated control myotubes. In contrast, 
treatment of myotubes with 200pg/ml of IP10 resulted in a significant and persistent 
decrease in myotube diameter (Figure 5.2 p<0.05), leading to a 33% reduction in 
myotube diameter compared with untreated control myotubes by 10 days post-
treatment. Treatment of myotubes with 200pg/ml of IP10 resulted in a significant 
reduction in myotube diameter compared with a treatment of myotubes with 
150pg/ml of IP10 at all time points.  
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Figure 5.2 Myotube diameter expressed as percentage change from untreated control 
myotubes at 1, 3, 5, 7 and 10 days following treatment with 150pg/ml and 200pg/ml IP10 
*p<0.05, ***p<0.001 compared with untreated control myotubes One-way ANOVA. Values 
are myoblasts mean ±SEM (n=3-4). 
 
 
 
Figure 5.3 Myotube diameter at 1 day following IP10 treatment. Bright field images showing 
(a) untreated control (b) myotubes treated with 150pg/ml treated or (c) myotubes treated 
with 200pg/ml IP10. 
 
 
a. b. c. 
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Figure 5.4 Myotube diameter at 3 days following IP10 treatment. Bright field images showing 
(a) untreated control (b) myotubes treated with 150pg/ml IP10 or (c) myotubes treated with 
200pg/ml IP10. 
 
 
Figure 5.5 Myotube diameter at 5 days following IP10 treatment. Bright field images showing 
(a) untreated control (b) myotubes treated with 150pg/ml treated or (c) myotubes treated 
with 200pg/ml IP10. 
 
 
Figure 5.6 Myotube diameter at 7 days following IP10 treatment. Bright field images showing 
(a) untreated control (b) myotubes treated with 150pg/ml treated or (c) myotubes treated 
with 200pg/ml IP10. 
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Figure 5.7 Myotube diameter at 10 days following IP10 treatment. Bright field images 
showing (a) untreated control (b) myotubes treated with 150pg/ml treated or (c) myotubes 
treated with 200pg/ml IP10.  
 
5.3.1.2. Effect of resveratrol on IP10-induced atrophy 
 
Myotube diameter following a 3 day pre-treatment with 1µM of resveratrol 
followed by the addition of 150pg/ml or 200pg/ml of IP10 at 1, 3, 5, 7 or 10 days 
following IP10 treatment is shown in Figure 5.8 and Figure 5.9. There was a gradual 
decrease in myotube diameter following treatment with 200pg/ml IP10 for up to 10 
days following treatment, whereas treatment of 150pg/ml only transiently decreased 
myotube diameter compared with untreated control myotubes at 3 days following IP10 
treatment (Figure 5.2). Pre-treatment of myotubes with resveratrol resulted in 
protection against the atrophic effects of treatment of myotubes with both 150pg/ml 
and 200pg/ml of IP10 at all time points following treatment.  
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Figure 5.8 Myotube diameter expressed as percentage change from untreated control 
myotubes following a pre-treatment of resveratrol followed by 200pg/ml IP10 at 1, 3, 5, 7 or 
10 days or a treatment with resveratrol alone *p<0.05, **p<0.01 ***p<0.001 compared with 
untreated control myotubes. One-way ANOVA. Values are mean ±SEM (n=3-4).  
 
 
 
Figure 5.9 Myotube diameter expressed as percentage change from untreated control 
myotubes following a pre-treatment of resveratrol followed by 150pg/ml IP10 at 1, 3, 5, 7 or 
10 days or a treatment with resveratrol alone *p<0.05, **p<0.01 ***p<0.001 compared with 
untreated control myotubes One-way ANOVA. Values are mean ±SEM (n=3-4). 
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Figure 5.10 Representative images of myotubes pre-treated with resveratrol on changes in 
myotube diameter induced 1 day following IP10. Bright field images showing (a) untreated 
control myotubes and myotubes treated with (b) resveratrol + 150pg/ml IP10 (c) resveratrol 
+ 200pg/ml IP10 (d) 1µM of resveratrol alone. Scale bar is 50µm. 
 
 
 
 
 
 
 
 
 
 
Figure 5.11 Representative images of myotubes pre-treated with resveratrol on changes in 
myotube diameter induced 3 day following IP10. Bright field images showing (a) untreated 
control myotubes and myotubes treated with (b) resveratrol + 150pg/ml IP10 (c) resveratrol 
+ 200pg/ml IP10 (d) 1µM of resveratrol alone. Scale bar is 50µm. 
 
a b
c d
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Figure 5.12 Representative images of myotubes pre-treated with resveratrol on changes in 
myotube diameter induced 5 day following IP10. Bright field images showing (a) untreated 
control myotubes and myotubes treated with (b) resveratrol + 150pg/ml IP10 (c) resveratrol 
+ 200pg/ml IP10 (d) 1µM of resveratrol alone. Scale bar is 50µm. 
 
 
 
 
Figure 5.13 Representative images of myotubes pre-treated with resveratrol on changes in 
myotube diameter induced 7 day following IP10. Bright field images showing (a) untreated 
control myotubes and myotubes treated with (b) resveratrol + 150pg/ml IP10 (c) resveratrol 
+ 200pg/ml IP10 (d) 1µM of resveratrol alone. Scale bar is 50µm. 
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Figure 5.14 Representative images of myotubes pre-treated with resveratrol on changes in 
myotube diameter induced 10 day following IP10. Bright field images showing (a) control 
myoblasts and myoblasts treated with (b) resveratrol + 150pg/ml IP10 (c) resveratrol + 
200pg/ml IP10 (d) 1µM of resveratrol alone. Scale bar is 50µm. 
 
5.3.2. Effects of treatment of myotubes with IP10 on Atrogin1 mRNA expression and 
effect of pre-treatment with resveratrol  
Atrogin1 levels in myotubes following treatment with 150pg/ml and 200pg/ml 
of IP10 and the effect of a pre-treatment with resveratrol is shown in Figure 5.15-
Figure 5.17. Atrogin1 levels in myotubes were decreased at 1 day following treatment 
of myotubes with 150pg/ml of IP10 (p<0.05) compared with untreated myotubes. 
Treatment of myotubes with 200pg/ml of IP10 resulted in a significant increase in 
Atrogin1 mRNA levels at 1 (p<0.05) and 7 days (p<0.05) following treatment and there 
was a tendency for Atrogin1 mRNA levels to remain elevated 10 days following 
treatment of myotubes with IP10 when compared with untreated myotubes.  
Any increase in Atrogin1 mRNA levels in myotubes induced by IP10 treatment 
was generally prevented with a pre-treatment of myotubes with resveratrol. However, 
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Atrogin1 mRNA levels were increased in myotubes pre-treated with resveratrol and 
treated with 150pg/ml of IP10 at 10 days following treatment compared with 150pg/ml 
IP10 treatment (p<0.05). Atrogin1 mRNA levels were not changed from untreated 
control myotube levels following a treatment with resveratrol alone.  
 
Figure 5.15 Changes in Atrogin1 mRNA levels in myotubes compared with untreated control 
myotubes (con) at 1 days following IP10 treatment with 150pg/ml (150) or 200pg/ml (200) of 
IP10 +/- a pre-treatment (200+res/150+res) with 1µM of resveratrol or treatment resveratrol 
alone (res) (n≥3) *p<0.05 compared with untreated control myotubes. One way ANOVA.  
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Figure 5.16 Changes in Atrogin1 mRNA levels in myotubes compared with untreated control 
myotubes (con) at 7 days following IP10 treatment with 150pg/ml (150) or 200pg/ml (200) of 
IP10 +/- a pre-treatment (200+res/150+res) with 1µM of resveratrol or treatment resveratrol 
alone (res) (n≥3) *p<0.05 compared with untreated control myotubes, ++p<0.01 compared 
with 200pg/ml. One-way ANOVA. 
 
Figure 5.17 Changes in Atrogin1 mRNA levels in myotubes compared with untreated control 
myotubes (con) at 10 days following IP10 treatment with 150pg/ml (150) or 200pg/ml (200) 
of IP10 +/- a pre-treatment (200+res/150+res) with 1µM of resveratrol or treatment 
resveratrol alone (res) (n≥3) ∆p<0.01 compared with 150pg/ml. One-way ANOVA. 
 
 
 
5.4. Discussion 
The aim of this Chapter was to examine the effects of IP10 on myotubes and 
to identify whether there were differential effects of different concentrations of 
circulating IP10 found in either old (200pg/ml) or adult (150pg/ml) healthy individuals. 
A secondary aim of the study was to identify whether resveratrol was able to prevent 
any negative effects of IP10 treatments in myotubes. Data showed different effects of 
the different concentrations of IP10 on myotubes. Treatment of myotubes with a 
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concentration of 200pg/ml of IP10 resulted in a chronic decrease in myotube diameter, 
whereas treatment of myotubes with 150pg/ml resulted in a transient decrease in 
myotube diameter detected only at 3 days following treatment. Pre-treatment of 
myotubes with resveratrol generally prevented any atrophic effects of both 
concentrations of IP10. Data from myotube diameter were reflected in data examining 
the effect of IP10 and resveratrol on the mRNA levels of the atrogene, Atrogin1. 
Treatment of myotubes with 200pg/ml of IP10 resulted in increased mRNA expression 
of Atrogin1 at 1 and 7 days and a pre-treatment of myotubes with resveratrol 
prevented this increase. Treatment of myotubes with 150pg/ml of IP10 resulted in a 
decrease in Atrogin1 expression 1 day following treatment. A pre-treatment of 
myotubes with resveratrol followed by a 1 day treatment of 150pg/ml of IP10 further 
decreased Atrogin1 expression, making levels undetectable. Pre-treatment of 
myotubes with resveratrol prior to treatment with 150pg/ml IP10 resulted in an 
increased Atrogin1 expression at 10 days following treatment above the levels seen in 
150pg/ml IP10 alone. Treatment of myotubes with resveratrol alone had no effect on 
Atrogin1 mRNA expression. Furthermore, neither IP10 nor resveratrol had an effect on 
Murf1 mRNA expression (data shown in appendix Section 10.2).  
5.4.1. Effects of IP10 on myotube diameter 
Sarcopenia is the loss of muscle mass and function as we age. One major 
contributor to the development of sarcopenia is the atrophy of individual muscle fibres 
in older individuals. Therefore, some aspects of this can be studied in cell cultures using 
a decrease in myotube diameter as an indicator of atrophy. Studies of different 
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atrophic situations have shown that mechanisms through which myotubes decrease 
myotube diameter include a lower fusion index, increased expression of the ubiquitin 
ligase Atrogin1 as well a decrease in protein synthesis through the IGF-1/Akt pathway 
(Stitt et al., 2004; Pomies et al., 2015). IP10 is a chemokine involved in the early stages 
of the inflammatory response and has been shown to be increased with age in various 
tissues (Chen et al., 2003a; Bonfante et al., 2015). Studies from our laboratory have 
demonstrated that levels of IP10 in plasma of older individuals are approximately 
200pg/ml and 150pg/ml in the plasma of healthy younger individuals (Ford et al, 
unpublished). In the current study, treatment of myotubes with 200pg/ml of IP10 
resulted in a chronic decrease in myotube diameter, suggesting an atrophic effect of 
this concentration of IP10. Treatment of myotubes with 150pg/ml had little effect on 
myotube diameter, although a transient decrease in myotube diameter was seen 3 
days following treatment, suggesting an acute but reversible effect. It is well known 
that as we age there is an increase in the inflammatory state, and it is widely 
hypothesised that this plays an important role in both systemic ageing and sarcopenia. 
The contrasting effects of different levels of IP10 offers further evidence that the 
environment may play an important role in the onset of age-related muscle weakness 
and for the first time provides potential evidence for a role of serum changes of IP10 in 
sarcopenia. 
Very little work has been carried out examining the role of IP10 in the 
development of sarcopenia with a PubMed search for IP10/CXCL0 and sarcopenia 
returning 0 results. Data in this Chapter suggests that treatment of myotubes with IP10 
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at the levels found in old individuals, decrease in myotube diameter is persistent, 
suggesting that at these levels IP10 may contribute to sarcopenia. IP10 has been shown 
to be undetectable in untreated muscle and other cells (Torvinen et al., 2007; Crescioli 
et al., 2012) and low levels of IP10 have been shown to inhibit numerous types of 
cancer (Zhang et al., 2005; Wang et al., 2013), induce migration and proliferation of 
smooth muscle cells (Wang et al., 1996) and pericytes (Bonacchi et al., 2001) and have 
been shown to play an important role in the uptake of pluripotent stem cells following 
liver injury (Chan et al., 2012), suggesting that low levels of IP10 can be beneficial to 
cells and may play important roles in signalling pathways. The absence of long term 
effects of 150pg/ml of IP10 on myotubes suggests that these beneficial effects may 
extend to skeletal muscle. Further data show that IP10 is upregulated in early 
myogenesis (Griffin et al., 2010) suggesting that lower levels IP10 may also be required 
for myogenesis and muscle regeneration. However, the persistent atrophic effects 
caused by higher concentrations of IP10 suggest that IP10 may be involved in 
sarcopenia and provides further evidence of the importance of understanding the 
dysregulation of IP10, as increased IP10 levels are correlated with numerous diseases 
such as asthma (Medoff et al., 2002), infection (Tanaka et al., 2009) and lung cancer 
(Siva et al., 2014). Thus, a study in patients with Hepatitis C has shown that serum 
levels of ≤150pg were considered low level risk with no requirement for treatment 
(Grebel et al., 2013) these data are particularly interesting as they suggest a new 
potential target for sarcopenia rather than the more commonly studied TNF-α and IL6 
(Visser et al., 2002; Pedersen et al., 2003). 
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5.4.2. Effects of IP10 on markers of atrophy 
Atrogin1 and Murf1 are muscle specific ligases, that have been shown to be 
upregulated in numerous types of atrophy (Gomes et al., 2001) and are part of a group 
of genes known as atrogenes – atrophy related genes. Preliminary experiments were 
performed to examine mRNA expression of Atrogin1 and Murf1 at 1 day following IP10 
treatment as a potential mechanism for the observed decrease in myotube diameter. 
Treatment of myotubes with 150pg/ml of IP10 had no effect on Atrogin1 mRNA levels, 
whereas treatment of myotubes with 200pg/ml of IP10 resulted in an increase in 
Atrogin1 expression. None of the treatment groups had any effect on Murf1 mRNA 
expression (appendix Section 10.2). The difference in effects on of IP10 treatment 
Atrogin1 and Murf1 mRNA expression were not surprising as this has been shown to be 
the case in other studies (Stefanetti et al., 2014). Due to this lack of effect of IP10 and 
resveratrol on Murf1 expression further work focused on the effect of IP10 on Atrogin1 
expression. 
Treatment of myotubes with 200pg/ml of IP10 resulted in an increase 
Atrogin1 expression both 1 day and 7 days following treatment when myotube atrophy 
was evident. In contrast, treatment of myotubes with 150pg/ml of IP10 decreased 
Atrogin1 mRNA levels from untreated control myotubes 1 day following treatment, and 
Atrogin1 levels in myotubes were significantly decreased compared with the level in 
myotubes following treatment with 200pg/ml of IP10 7 days following treatment. The 
increase in Atrogin1 mRNA levels following treatment of myotubes with 200pg/ml of 
IP10 is in agreement with the decrease in myotube diameter established in this study 
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and further supports the hypothesis that the levels of IP10 found in old individuals may 
contribute to sarcopenia. This data also provides a possible mechanism through which 
the subsequent upregulation of Atrogin1 occurs leading to increased degradation of 
muscle proteins and thus atrophy. Due to the absence of detection of Atrogin1 in 
untreated control myotubes and in myotubes at 3 and 5 days following of IP10 
treatments, these data suggests that there may be an acute and chronic response to 
IP10 treatment. The absence of the atrophic effects of treatment of myotubes with 
150pg/ml of IP10 provides evidence for IP10 involvement in sarcopenia. 
As discussed only a sparse amount of work on IP10 during atrophy has been 
undertaken, therefore the mechanism responsible for IP10 increases in Atrogin1 mRNA 
levels remains unknown. TNF-α is a strong inducer of IP10 expression (Fang et al., 
2012) and therefore it is likely that IP10 is a downstream effector of TNF-α. TNF-α 
treatment of C2C12 myotubes demonstrated an increase Atrogin1 expression through 
the inhibition of the FOXO/mTOR/AKT/S6k pathway (Wang et al., 2014). Furthermore, 
IFN-γ, a known activator of IP10, also resulted in a decrease in the Akt activation 
leading to increased Atrogin1 levels in C2C12 myotubes (Smith et al., 2007). Therefore 
it may be speculated that IP10 acts through the same pathway. However further 
investigation is required.  
5.4.3. Effects of resveratrol on IP10 induced atrophy 
Pre-treatment of myotubes with resveratrol was able to prevent the decrease 
in myotube diameter and increase in Atrogin1 mRNA expression caused by treatment 
of myotubes with 200pg/ml dose of IP10. Interestingly, the increase in myotube 
  
 201   
 
diameter induced by daily treatments of myotubes for 3 days with resveratrol seen in 
Chapter 4 was not evident 1 day after the cessation of resveratrol treatment, 
suggesting the effects of resveratrol, are not long lasting. This is not unexpected as 
resveratrol is known to be metabolised very fast in humans following oral ingestion 
(Wenzel et al., 2005; Almeida et al., 2009) and in cell cultures of liver cells (Lançon A et 
al., 2007) and therefore it is likely that the half-life of resveratrol in myotube cultures is 
also short. Resveratrol alone had no effect on Atrogin1 expression. These data suggest 
that resveratrol prevents the atrophic effects of IP10 by preventing the increase in 
Atrogin1. Resveratrol has been shown to increase Akt activation in C2C12 myotubes 
and Akt is able to inhibit Atrogin1 (Stitt et al., 2004; Wang et al., 2014), suggesting a 
potential mechanism by which resveratrol may prevent an increase in Atrogin1, 
however further work is needed.  
The absence of effects on Atrogin1 by resveratrol alone offers further evidence 
that resveratrol is only effective when there is an existing dysfunction within the cells 
(Lagouge et al., 2006). Furthermore, the increase in Atrogin1 mRNA levels in myotubes 
at 10 days following treatment with 150pg/ml of IP10 which had been pre-treated with 
resveratrol also offers support to previous work that has shown that resveratrol may 
exacerbate some (Sato et al., 2013a) and may be potentially harmful or at least 
ineffective in healthy subjects. These data suggest caution when considering the use of 
resveratrol in healthy individuals and thus suggesting that resveratrol would only be 
useful as a treatment for sarcopenia and not as a preventative measure.  
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5.5. Conclusions 
Evidence of atrophy in myotubes following treatment with an IP10 
concentration similar to that found in older healthy individuals has provided evidence 
for a potential role of increased IP10 levels in the development of sarcopenia. IP10 
induced increases in the ubiquitin ligase Atrogin1 suggest this as a potential 
mechanism by which IP10 induces atrophy. Pre-treatment of myotubes with 
resveratrol was able to prevent the atrophic effects of IP10, providing a potential 
treatment for muscle fibre atrophy developed sarcopenia. However, the induction of 
atrophic pathways following the compounded effect of treatment of myotubes with 
150pg/ml IP10 when pre-treated with resveratrol signifies a need for caution when 
using resveratrol, particularly in young, healthy subjects.   
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 THE EFFECT OF RESVERATROL ON CYTOKINE 6.
PRODUCTION BY MYOTUBES IN VITRO 
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6.1. Introduction  
The inflammatory response is a series of cellular processes, characterised by 
the secretion of inflammatory mediators such as IL6, C-reactive protein (CRP), TNF-α 
(Ballou et al., 1992; Bartlett et al., 2012) and other cytokines, from damaged, infected 
or immune cells which result in the chemotaxis of immune cells, in an attempt to 
achieve resolution of the disease state. The inflammatory response is vital for the 
protection of cells against foreign invading bodies. However, as we age it is well known 
that there is an overall decrease in the production of anti-inflammatory cytokines 
coupled with an increase in circulating pro-inflammatory cytokines that leads to a 
chronic low grade systemic inflammation in the plasma of older people (Miles et al., 
2008; Cartier et al., 2009). This will potentially have serious detrimental effects on 
many different systems in the body. This phenomena has been termed ‘inflamm-
ageing’ (Franceschi et al., 2000) and is supported by heterochronic parabiosis studies 
that show that some aspects of tissue ageing can be reversed when placed into the 
environment of a younger host (Ruckh et al., 2012; Villeda et al., 2014). The increase in 
the baseline cytokine levels has been correlated with numerous age-related 
pathologies such as obesity-related diabetes (Xu et al., 2003), Alzheimer’s disease (Leea 
et al., 2008), cardiovascular disease (Cuff et al., 2001) and sarcopenia (Schaap et al., 
2006).  
The underlying mechanisms responsible for sarcopenia are still poorly 
understood, however, it is proposed that an increase in cytokine levels is likely to play a 
role in the age-related loss of muscle mass and function (Degens, 2010; Lightfoot et al., 
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2014), particularly now as it is recognised that muscles are also able to release 
cytokines, named myokines (Sorby Borge et al., 2009).  
Interest in myokines first began during the late 1990’s when it was noted that 
‘factors’ that had a functional importance were released from muscle following 
exercise. Interleukin 6 was the first myokine to be described following contraction 
(Ostrowski et al., 1998). Furthermore, there is evidence that contracting muscle can act 
as an endocrine organ with data showing muscle secretion of numerous different 
cytokines such as IL15 and IL8 (Pedersen, 2011). Myokine release has been shown to 
be involved in hypertrophic processes and myokines are proposed to play a role in 
some of the beneficial effects of exercise (Jung et al., 2015). However, myokine 
secretion has also been shown in atrophy, for example; IL6 has been shown to cause 
muscle atrophy (Haddad et al., 2005). However, this is controversial as IL6 has also 
been shown to be beneficial to muscle with evidence of a role in myogenesis and 
satellite cell proliferation (Serrano et al., 2008). Thus the role of myokines in muscle 
atrophy and sarcopenia is sparsely studied and unclear.  
A potential role for changes in myokine and cytokine levels in sarcopenia is 
supported by heterochronic parabiosis studies that showed improved proliferation 
capacity and regeneration capability of satellite cells in muscles of old mice when 
exposed to a younger environment (Conboy et al., 2005). The foundations for this were 
demonstrated by seminal transplantation studies in the 1980s, which indicated that 
the age of the host determines the outcome of muscle regeneration and function. 
Specifically, muscle from old rats transplanted into a young rat displayed successful 
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regeneration, whereas muscles taken from young rats transplanted into an old host did 
not (Carlson et al., 1989). These findings exemplify the importance of the environment 
in skeletal muscle regeneration and atrophy and have provided further evidence for a 
role of inflamm-ageing as an important mediator of sarcopenia. Furthermore, the 
deposition of adipose tissue into muscle is an additional hallmark of ageing (Song et al., 
2004) and is reported to play a compounding role in the age-related loss of muscle 
mass and function (Visser et al., 2005). Adipocytes are able to secrete a number of 
different cytokines, such as TNF-α (Hotamisligil et al., 1995; Sopasakis et al., 2005) 
therefore it is hypothesised that this intramuscular adipose tissue (IMAT) may 
contribute to age-related increases in local skeletal muscle production of cytokines. 
This is evidenced in a study by Schapp et al (2009) showing that when adjusted for fat 
mass, systemic inflammation is attenuated (Schaap et al., 2009) and in other studies 
which show muscle IL6 levels correlate with IMAT (Addison et al., 2014). 
Increases in levels of cytokines are a good indicator of a risk for functional 
decline in skeletal muscle; IL6 shows a linear association with loss in muscle strength 
(Schaap et al., 2006) and is correlated with muscle atrophy (Haddad et al 2005). Higher 
levels of TNF-α, CRP and IL1 are correlated with sarcopenia and muscle related 
disorders such an insulin sensitivity (Marques-Vidal et al., 2013), aerobic fitness (Kohut 
et al., 2006), strength and physical functionality (Visser et al., 2002).  
Studies on systemic and muscle ageing have focused on common cytokines 
such as CRP, IL6 and TNF-α. Unpublished work from our laboratory and work from 
other groups (Bonfante et al., 2015) has found an age-related increase in plasma levels 
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of the pro-inflammatory chemokine IP10. Furthermore, a study that took into 
consideration other co-morbidities showed that plasma levels of IP10 were still 
significantly upregulated in the blood of older people, whereas many cytokines that are 
usually associated with ageing were not (Miles et al., 2008). These findings suggest that 
IP10 may play a role in ageing, thus it may be reasonable to hypothesise that other 
cytokines which are described in the context of “inflamm-ageing” may be derived from 
confounding comorbidities. 
Chapter 5 demonstrated that treatment of myotubes with concentrations of 
IP10 found in the plasma of healthy old subjects (200pg/ml) resulted in a decrease in 
myotube diameter coupled with an increase in the mRNA expression of the atrogene, 
Atrogin1 (Chapter 5). There was no effect on myotube diameter or Atrogin1 expression 
when myotubes were treated with concentrations of IP10 generally found in the 
plasma of young adults (150pg/ml). These results suggested higher concentrations of 
IP10 are associated with atrophic effects and therefore suggest a potential role of IP10 
in sarcopenia.  
Considerable work has focused on the effect of exercise on inflammation as a 
potential therapeutic intervention to sarcopenia and studies have shown that different 
types of exercise are successful in decreasing inflammation in skeletal muscle (Gielen 
et al., 2003; Zanchi et al., 2010; Lightfoot et al., 2016). However, exercise may not be 
well tolerated or appropriate and some older people are reluctant to implement 
exercise protocols whereas others are physically unable to carry out such activities. 
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Recent research has moved towards developing potential pharmacological or 
nutritional interventions to combat sarcopenia.  
Polyphenols are plant extracts that have been shown to have beneficial effects 
in many different tissues and disease states (Klein et al., 2002; Sies et al., 2005; Porquet 
et al., 2014). Resveratrol is a commonly studied and used polyphenol and work in 
Chapter 5 demonstrated that pre-treatment of myotubes with a low concentrations of 
resveratrol (1µM) was able to prevent some of the atrophic effects of IP10 on 
myotubes. The prevention of both the decrease in myotube diameter and the increase 
in the ubiquitin ligase Atrogin1, suggests that resveratrol may have a role as a potential 
therapeutic agent against sarcopenia. However the mechanisms by which these effects 
occur remain unclear.  
Resveratrol has been shown to have anti-inflammatory effects through 
decreasing pro-inflammatory cytokines and inflammatory cell infiltration as well as 
increasing anti-inflammatory cytokines (Bereswill et al., 2010), both systemically (Yong 
et al., 2014) and in tissues (Palmieri et al., 2011; Lv et al., 2015). A decrease in IP10 
levels was seen in human epithelial cells (Abengózar-Vela et al., 2015) and mouse 
macrophages (Chung et al., 2011) that had been treated with resveratrol. Some studies 
have shown that resveratrol has anti-inflammatory effects in skeletal muscle (Bereswill 
et al., 2010), as well as decreasing inflammatory cell infiltrates in the muscles of MDX 
model of muscle dystrophy (Gordon et al., 2013). However other studies have shown 
that even when resveratrol was able to attenuate muscle wasting, there was no effect 
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on cytokine levels in the muscle (Momken et al., 2011), suggesting that another 
mechanism may be involved. 
The ubiquitin ligase, Atrogin1, is upregulated in muscle during the 
inflammatory response (Ramirez et al., 2011); therefore it is possible that a resveratrol-
mediated decrease in Atrogin1 mRNA levels downstream of elevated cytokines is a 
potential mechanism by which resveratrol provides protection. 
The aim of this Chapter was to examine the effects of IP10 at concentrations 
found in the older (200pg/ml) and younger population (150pg/ml) on the content of 24 
cytokines released by myotubes into the media and whether a pre-treatment of 
myotubes with resveratrol (Chapter 4) had any effect on IP10 induced changes in the 
media content of these cytokines (Table 6.2). 
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6.2. Methods 
 
 
Figure 6.1 A brief overview of experiments; Myotubes were pre-treated daily with 1µM or 0µM 
(control) of resveratrol for 3 days and then treated with 0, 150 or 200pg/ml of IP10 and luminex 
analyses carried out on media of myotubes.  
 
6.2.1. IP10 preparation 
Murine recombinant IP10 was dissolved in distilled water at a concentration of 
0.1mg/ml and was stored at -20oC.  
6.2.2. Treatment of myotubes with IP10 +/- resveratrol 
Skeletal muscle myoblasts were isolated from Wistar rats and cultured until 
myoblasts had reached 80% confluency; cells were counted using TC-20 automatic cell 
counter (Biorad, Herefordshire, UK) and plated in 6 well plates at a density of 
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approximately 5x104. Once cells had reached 80% confluency, media was changed to 
differentiation media alone (control) or containing 1µM of resveratrol. Resveratrol was 
added every 24H for 3 days. Myotubes were then treated with 0, 150pg/ml or 
200pg/ml and media examined 1, 3, 5, 7 or 10 days following treatment.  
Table 6.1 Timetable of treatment of myotubes 
 
6.2.3. Luminex analysis for determination of cytokine levels following IP10 and 
resveratrol treatment  
The concentration of a panel of cytokines (Table 6.2) in media from primary 
rat myotubes treated with IP10 +/- resveratrol was determined using Bioplex 
multibead analysis as described in Section 2.18.  
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Table 6.2 List of cytokine examined and their inflammatory function 
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6.2.4. Statistics 
Graphpad 5 (Graphpad Software, San Diego, USA) was used to perform One-
way ANOVA test followed by a Dunnett’s post-test to identify significant differences 
between data with 3 or more groups; a T Test was used to identify significant 
differences between data between 2 groups. Data are represented as mean ± SEM.  
6.3. Results 
6.3.1. Effect of IP10 and resveratrol on cytokine content in the media of myotubes 
Cytokine content into the media by myotubes following treatment of IP10 and 
resveratrol is shown in Figure 6.2-Figure 6.13. Overall treatment of myotubes with both 
concentrations of IP10 led to significant changes in the inflammatory cytokine profile in 
the media of myotubes and the addition of resveratrol reduced some of the effects of 
the IP10 treatments. Of the 24 cytokines studied, 11 (EPO, GM-CSF, GCSF, IFN-γ, IL-1α, 
IL-1B, IL-4, IL-10, IL12p, IL-18, Rantes) were not detected in the media either prior to or 
following treatment of myotubes and there was no difference in media content on M-
CFS before or after treatments.  
6.3.1.1. Effect of resveratrol and IP10 on VEGF content of the media of 
myotubes  
VEGF content of the media of myotubes at 1-10 days following treatment with 
IP10+/- resveratrol is shown in Figure 6.2. Ten days following treatment of myotubes 
with 150pg/ml of IP10, VEGF content in the media of myotubes was significantly 
increased (p<0.05); a pre-treatment of myotubes with resveratrol prevented this 
increase (Figure 6.2c). A treatment of myotubes with 200pg/ml of IP10 increased VEGF 
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content in the media of myotubes at 3 days following treatment (p<0.01). A pre-
treatment of resveratrol prevented this increase, but caused an increase in VEGF 
content in the media of myotubes 5 (p<0.05) and 10 days (p<0.05) following treatment 
(Figure 6.2d). Resveratrol alone increased the content of VEGF in the media of 
myotubes 3 days following treatment (p<0.05) and decreased VEGF content in the 
media of myotubes 10 days after treatment (p<0.01 Figure 6.2b). 
Table 6.3 Summary of effects of IP10 and resveratrol on VEGF content of media of myotubes.  
 
X denotes no effect compared with untreated control, arrows denote effect of treatment 
compared with untreated control. Y (yes) denotes to the ability of a pre-treatment of 
myotubes with resveratrol to prevent IP10 induced effects and N (no) denotes to the inability 
of a pre-treatment of myotubes with resveratrol to prevent IP10 induced effects.  
 
Days post 
IP10 
treatment 
Average 
levels in 
control 
myotubes 
(pg/ml) 
Effect of 
150pg/ml 
compared 
with 
untreated 
control? 
Effect of 
150pg/ml 
IP10 
modified by 
pre-
treatment 
with 
resveratrol? 
Effect of 
200pg/ml  
compared 
with 
untreated 
control 
Effect of 
200pg/ml 
IP10 
modified by 
pre-
treatment 
with 
resveratrol? 
Effect of  
resveratrol 
alone  
compared 
with 
untreated 
control 
1 1152 X N/A X N/A X 
3 1710 X N/A ↑ Y ↑ 
5 1117 X N/A X N/A (↑) X 
7 1903 X N/A X X X 
10 3060 ↑ Y X N/A(↑) ↓ 
  
 
 
2
1
5
 
 
 
Figure 6.2 VEGF content in the media of myotubes following treatment of myotubes with (a) 150pg/ml and 200pg/ml of IP10, (b) 1µM of 
resveratrol (c) treatment with resveratrol prior to treatment with 150pg/ml of IP10 and (d) treatment with resveratrol prior to treatment 
with 200pg/ml of IP10. *p<0.05, **p<0.01, +p<0.05 compared with pre-treatment with resveratrol (One-way Anova/T Test). Values are 
presented as mean ±SEM. 
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6.3.1.2. Effect of resveratrol and IP10 on GRO-KC content of the media of 
myotubes  
GRO-KC content in the media of myotubes at 1-10 days following treatment 
with IP10+/- resveratrol is shown in Figure 6.3. Treatment of myotubes with 150pg/ml 
of IP10 resulted in a decrease in GRO-KC content in the media of myotubes at 1 
(p<0.05) and 5 days (p<0.05) following treatment. Pre-treatment of myotubes with 
resveratrol prevented this decrease (Figure 6.3c). Treatment of myotubes with 
200pg/ml of IP10 resulted in a decrease in GRO-KC content in the media of myotubes 
at 5 days following treatment and this was prevented by a pre-treatment of myotubes 
with resveratrol (Figure 6.3d). Treatment of myotubes with resveratrol alone had no 
effect on GRO-KC content of the media of myotubes.  
Table 6.4 Summary of effects of IP10 and resveratrol of GRO-KC content in media of 
myotubes.  
X denotes no effect compared with untreated control, arrows denote effect of treatment 
compared with untreated control. Y (yes) denotes to the ability of a pre-treatment of 
myotubes with resveratrol to prevent IP10 induced effects and N (no) denotes to the inability 
of a pre-treatment of myotubes with resveratrol to prevent IP10 induced effects.  
Days 
following 
IP10 
treatment 
Average 
levels in 
control 
myotubes 
(pg/ml) 
Effect of 
150pg/ml 
compared 
with 
untreated 
control? 
 Effect of 
150pg/ml 
IP10 
modified by 
pre-
treatment 
with 
resveratrol? 
Effect of 
200pg/ml  
compared 
with 
untreated 
control 
Effect of 
200pg/ml 
IP10 
modified by 
pre-
treatment 
with 
resveratrol? 
Effect of  
resveratrol 
alone  
compared 
with 
untreated 
control 
1 467 ↓ Y X X X 
3 372 X N/A X X X 
5 451 ↓ Y ↓ Y X 
7 89 X N/A X X X 
10 Not 
detected 
Not 
detected 
Not 
detected 
Not 
detected 
Not  
detected 
Not 
detected 
  
   
 
2
1
7
 
 
Figure 6.3 GRO-KC content of the media of myotubes following treatment of myotubes with (a) 150pg/ml and 200pg/ml of IP10, (b) 1µM of 
resveratrol (c) treatment with resveratrol prior to treatment with 150pg/ml of IP10 and (d) treatment with resveratrol prior to treatment 
with 200pg/ml of IP10. *p<0.05, **p<0.01 compared with untreated controls, +p<0.05 compared with IP10 treatment (One-way Anova/T 
Test). Values are presented as mean ±SEM. 
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6.3.1.3. Effect of resveratrol and IP10 of IL6 content of the media of myotubes  
IL6 content in the media of myotubes at 1-10 days following treatment with 
IP10+/- resveratrol is shown in Figure 6.4. Treatment of myotubes with 150pg/ml of 
IP10 resulted in an increase in the IL6 content of the media of myotubes at 3, 5 and 10 
days following treatment (p<0.05). Pre-treatment of myotubes with resveratrol 
generally reduced this increase (Figure 6.4c). Treatment of myotubes with 200pg/ml of 
IP10 resulted in an increase in IL6 content in the media of myotubes at 3 (p<0.01) and 5 
days (p<0.05) following treatment. Pre-treatment of resveratrol prevented this 
increase at 5 days following treatment, (p<0.05 Figure 6.4d) but not at 3 days. 
Treatment of myotubes with resveratrol alone resulted in an increase in IL6 content of 
the media of myotubes at 5 days following treatment (p<0.01 Figure 6.4b). 
Table 6.5 Summary of effects of IP10 and resveratrol on IL6 content of media of myotubes. 
X denotes no effect compared with untreated control, arrows denote effect of treatment 
compared with untreated control. Y (yes) denotes to the ability of a pre-treatment of 
myotubes with resveratrol to prevent IP10 induced effects and N (no) denotes to the inability 
of a pre-treatment of myotubes with resveratrol to prevent IP10 induced effects.  
Days 
following 
IP10 
treatment 
Average 
levels in 
control 
myotubes 
(pg/ml) 
Effect of 
150pg/ml 
compared 
with 
untreated 
control? 
 Effect of 
150pg/ml 
IP10 
modified by 
pre-
treatment 
with 
resveratrol? 
Effect of 
200pg/ml  
compared 
with 
untreated 
control 
Effect of 
200pg/ml 
IP10 
modified by 
pre-
treatment 
with 
resveratrol? 
Effect of  
resveratrol 
alone  
compared 
with 
untreated 
control 
1 700 X N/A X N/A X 
3 370 ↑ Y ↑ Y X 
5 564 ↑ Y ↑ N (↑) ↑ 
7 Not 
detected 
Not 
detected 
Not 
detected 
Not 
detected 
Not detected Not 
detected  
10 950 ↑ Y X X X 
  
 
 
2
1
9 
 
Figure 6.4 IL6 content in the media of myotubes following treatment of myotubes with (a) 150pg/ml and 200pg/ml of IP10, (b) 1µM of 
resveratrol (c) treatment with resveratrol prior to treatment with 150pg/ml of IP10 and (d) treatment with resveratrol prior to treatment 
with 200pg/ml of IP10. *p<0.05, **p<0.01 compared with untreated controls, +p<0.05 compared with IP10 treatment (One-way Anova/T 
Test). Values are presented as mean ±SEM. 
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6.3.1.4. Effect of resveratrol and IP10 of MCP-1 content of the media of 
myotubes  
MCP-1 content in the media of myotubes at 1-10 days following treatment with 
IP10+/- resveratrol is shown in Figure 6.5. Treatment of myotubes with 150pg/ml of 
IP10 resulted in a decrease in MCP-1 content in the media of myotubes at 1 day 
following treatment (p<0.05) and this decrease was prevented by a pre-treatment of 
myotubes with resveratrol (Figure 6.5c). Treatment of myotubes with 200pg/ml of IP10 
resulted in an increase in MCP-1 at 3 and 5 days following treatment and this increase 
was prevented with a pre-treatment of myotubes with resveratrol (p<0.05 Figure 6.5d). 
MCP-1 was undetectable in myotubes treated with resveratrol alone 3 days following 
(Figure 6.5). 
Table 6.6 Summary of effects of IP10 and resveratrol on MCP-1 content of media of 
myotubes.   
X denotes not effect compared with untreated control, arrows denote effect of treatment 
compared with untreated control. Y (yes) denotes to the ability of a pre-treatment of 
myotubes with resveratrol to prevent IP10 induced effects and N (no) denotes to the inability 
of a pre-treatment of myotubes with resveratrol to prevent IP10 induced effects.  
 
Days 
following 
IP10 
treatment 
Average 
levels in 
control 
myotubes 
(pg/ml) 
Effect of 
150pg/ml 
compared 
with 
untreated 
control? 
 Effect of 
150pg/ml 
IP10 
modified by 
pre-
treatment 
with 
resveratrol? 
Effect of 
200pg/ml  
compared 
with 
untreated 
control 
Effect of 
200pg/ml 
IP10 
modified by 
pre-
treatment 
with 
resveratrol? 
Effect of  
resveratrol 
alone  
compared 
with 
untreated 
control 
1 11839 ↓ Y X N/A X 
3 9069 X N/A ↑ Y Not 
detected 
5 9341 X N/A ↑ Y X 
7 1181 X N/A X N/A X  
10 Not 
detected 
Not 
detected 
Not 
detected 
Not 
detected 
Not detected Not 
detected 
  
 
 
2
2
1 
 
 
    
Figure 6.5 MCP-1 content of the media of myotubes following treatment of myotubes with (a) 150pg/ml and 200pg/ml of IP10, (b) 1µM of 
resveratrol (c) treatment with resveratrol prior to treatment with 150pg/ml of IP10 and (d) treatment with resveratrol prior to treatment 
with 200pg/ml of IP10. *p<0.05, **p<0.01 compared with untreated controls ++ compared with IP10 treatment (One-way Anova/T Test). 
Values are presented as mean ±SEM. 
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6.3.1.5. Effect of resveratrol and IP10 of IL2 content in the media of myotubes  
IL2 content in the media of myotubes at 1-10 days following treatment with 
IP10+/- resveratrol is shown in Figure 6.6. Treatment of myotubes with 150pg/ml of 
IP10 resulted in an increase in IL2 content in the media of myotubes at 10 days 
following treatment (p<0.001). A pre-treatment with resveratrol prevented this 
increase (p<0.05 Figure 6.6). Treatment of myotubes with 200pg/ml IP10 had no effect 
on IL2 content in the media of myotubes. Treatment of myotubes with resveratrol 
alone resulted in an increase in IL2 content at 3 days following treatment (p<0.01 
Figure 6.6b).  
 
Table 6.7: Summary of effects of IP10 and resveratrol on IL2 content in the media of 
myotubes  
 
 
X denotes no effect compared with untreated control, arrows denote effect of treatment 
compared with untreated control. Y (yes) denotes to the ability of a pre-treatment of 
myotubes with resveratrol to prevent IP10 induced effects and N (no) denotes to the inability 
of a pre-treatment of myotubes with resveratrol to prevent IP10 induced effects.  
Days 
following 
IP10 
treatment 
Average 
levels in 
control 
myotubes 
(pg/ml) 
Effect of 
150pg/ml 
compared 
with 
untreated 
control? 
Effect of 
150pg/ml 
IP10 
modified by 
pre-
treatment 
with 
resveratrol? 
Effect of 
200pg/ml  
compared 
with 
untreated 
control 
Effect of 
200pg/ml 
IP10 
modified by 
pre-
treatment 
with 
resveratrol? 
Effect of  
resveratrol 
alone  
compared 
with 
untreated 
control 
1 Not  
detected 
Not 
detected 
Not 
detected 
Not 
detected 
Not 
detected 
Not 
detected 
3 6.1 X N X N/A ↑ 
5 23 X N X N/A X 
7 Not 
detected 
Not 
detected 
Not 
detected 
Not 
detected 
Not 
detected 
Not 
detected 
10 21 ↑ N (↑) X N/A Not 
detected 
  
 
 
2
2
3
 
 
Figure 6.6 IL2 content in the media of myotubes following treatment of myotubes with (a) 150pg/ml and 200pg/ml of IP10, (b) 1µM of 
resveratrol (c) treatment with resveratrol prior to treatment with 150pg/ml of IP10 and (d) treatment with resveratrol prior to treatment 
with 200pg/ml of IP10. *p<0.05, **p<0.01, ***p<0.001 compared with untreated control, ++p<0.01 compared with IP10 treated (One-way 
Anova/T Test). Values are presented as mean ±SEM. 
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6.3.1.6. Effect of resveratrol and IP10 of IL5 content of the media of myotubes  
IL5 content of the media of myotubes at 1-10 days following treatment with 
IP10+/- resveratrol is shown in Figure 6.7. Treatment of myotubes with 150pg/ml of 
IP10 resulted in a decrease in the IL5 content of the media of myotubes at 1 (p<0.01) 
and 3 (p<0.05) days following treatment. Pre-treatment with resveratrol prevented this 
decrease, but also resulted in a decrease in IL5 content of the media of IP10 treated 
myotubes at 10 days following treatment (p<0.05 Figure 6.7c). Treatment of myotubes 
with 200pg/ml of IP10 resulted in a transient decrease in IL5 content in the media of 
myotubes at 3 days following treatment (p<0.01) and this decrease was prevented by 
pre-treatment of myotubes with resveratrol (Figure 6.7d). Treatment of myotubes with 
resveratrol alone had no effect on the content of IL5.  
 
Table 6.8 Summary of effects of IP10 and resveratrol on IL5 content of media of myotubes. 
 
X denotes no effect compared with untreated control, arrows denote effect of treatment 
compared with untreated control. Y (yes) denotes to the ability of a pre-treatment of 
myotubes with resveratrol to prevent IP10 induced effects and N (no) denotes to the inability 
of a pre-treatment of myotubes with resveratrol to prevent IP10 induced effects.  
Days 
following 
IP10 
treatment 
Average 
levels in 
control 
myotubes 
(pg/ml) 
Effect of 
150pg/ml 
compared 
with 
untreated 
control? 
 Effect of 
150pg/ml 
IP10 
modified by 
pre-
treatment 
with 
resveratrol? 
Effect of 
200pg/ml  
compared 
with 
untreated 
control 
Effect of 
200pg/ml 
IP10 
modified by 
pre-
treatment 
with 
resveratrol? 
Effect of  
resveratrol 
alone  
compared 
with 
untreated 
control 
1 203 ↓ Y X N/A X 
3 232 ↓ Y ↓ Y X 
5 171 X N/A X N/A X 
7 107 X N/A X N/A X 
10 176 X N/A(↓) X N/A X 
  
 
 
2
2
5 
 
   
 
Figure 6.7 IL5 content of the media of myotubes following treatment of myotubes with (a) 150pg/ml and 200pg/ml of IP10, (b) 1µM of 
resveratrol (c) treatment with resveratrol prior to treatment with 150pg/ml of IP10 and (d) treatment with resveratrol prior to treatment 
with 200pg/ml of IP10. *p<0.05, **p<0.01 compared with untreated control (One-way Anova/T Test). Values are presented as mean ±SEM. 
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6.3.1.7. Effect of resveratrol and IP10 of IL7 content in the media of myotubes  
IL7 content in the media of myotubes at 1-10 days following treatment with 
IP10+/- resveratrol is shown in Figure 6.8. IL7 levels were low and not detected in the 
media of myotubes at 1, 3 or 7 days following treatment. There was no significant 
difference between treatment groups, with the exception of resveratrol alone 
treatment which resulted in a significant decrease in IL7 content of media at 10 days 
following treatment (Figure 6.8b p<0.01). 
Table 6.9 Summary of effects of IP10 and resveratrol on IL7 content of media of myotubes.   
 
X denotes no effect compared with untreated control, arrows denote effect of treatment 
compared with untreated control. Y (yes) denotes to the ability of a pre-treatment of 
myotubes with resveratrol to prevent IP10 induced effects and N (no) denotes to the inability 
of a pre-treatment of myotubes with resveratrol to prevent IP10 induced effects.  
Days 
following 
IP10 
treatment 
Average 
levels in 
control 
myotubes 
(pg/ml) 
Effect of 
150pg/ml 
compared 
with 
untreated 
control? 
 Effect of 
150pg/ml 
IP10 
modified by 
pre-
treatment 
with 
resveratrol? 
Effect of 
200pg/ml  
compared 
with 
untreated 
control 
Effect of 
200pg/ml 
IP10 
modified by 
pre-
treatment 
with 
resveratrol? 
Effect of  
resveratrol 
alone  
compared 
with 
untreated 
control 
1 Not 
detected 
Not 
detected 
Not 
detected 
Not 
detected 
Not detected Not 
detected 
3 33 Not 
detected 
Not 
detected 
Not 
detected 
Not detected Not 
detected 
5 47 X N/A X N/A X 
7 Not  
detected 
Not 
detected 
Not 
detected 
Not 
detected 
Not detected Not 
detected 
10 52 X N/A X N/A ↓ 
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Figure 6.8 IL7 content in the media of myotubes following treatment of myotubes with (a) 150pg/ml and 200pg/ml of IP10, (b) 1µM of 
resveratrol (c) treatment with resveratrol prior to treatment with 150pg/ml of IP10 and (d) treatment with resveratrol prior to treatment 
with 200pg/ml of IP10. *p<0.05, compared with untreated controls (One-way Anova/T Test). Values are presented as mean ±SEM. 
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6.3.1.8. Effect of resveratrol and IP10 of IL13 content in the media of myotubes  
IL13 content of the media of myotubes at 1-10 days following treatment with 
IP10+/- resveratrol is shown Figure 6.9. IL13 levels were relatively low and not 
detectable in any treatment group at 1 and 7 days following treatment. Treatment of 
myotubes with 150pg/ml of IP10 resulted in an increase in IL13 content of the media of 
myotubes at 3 days following treatment (p<0.01) and IL13 was undetectable in the 
media of myotubes at 5 days following treatment. Pre-treatment of myotubes with 
resveratrol prevented both of these effects (Figure 6.9c). Treatment of myotubes with 
200pg/ml of IP10 resulted in IL13 being undetectable in the media of myotubes at 5 
and 10 days following treatment. Pre-treatment of myotubes with resveratrol 
prevented this decrease in IL13 in the media of myotubes and also resulted in a 
reduction in IL13 levels at 3 days following treatment (Figure 6.9d). Treatment of 
myotubes with resveratrol alone resulted in an increase in IL13 content of the media of 
myotubes at 5 days following treatment which became undetectable by 10 days 
following treatment (Figure 6.9b).  
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Table 6.10 Summary of effects of IP10 and resveratrol on IL13 content of media of myotubes. 
 
X denotes no effect compared with untreated control, arrows denote effect of treatment 
compared with untreated control. Y (yes) denotes to the ability of a pre-treatment of 
myotubes with resveratrol to prevent IP10 induced effects and N (no) denotes to the inability 
of a pre-treatment of myotubes with resveratrol to prevent IP10 induced effects.  
Days 
following 
IP10 
treatment 
Average 
levels in 
control 
myotubes 
(pg/ml) 
Effect of 
150pg/ml 
compared 
with 
untreated 
control? 
 Effect of 
150pg/ml 
IP10 
modified by 
pre-
treatment 
with 
resveratrol? 
Effect of 
200pg/ml  
compared 
with 
untreated 
control 
Effect of 
200pg/ml 
IP10 
modified by 
pre-
treatment 
with 
resveratrol? 
Effect of  
resveratrol 
alone  
compared 
with 
untreated 
control 
1 Not  
detected 
Not 
detected 
Not 
detected 
Not 
detected 
Not 
detected 
Not 
detected 
3 5 ↑ Not 
detected 
X Not 
detected 
X 
5 4 Not 
detected 
N/A Not 
detected 
N/A ↑ 
7 Not 
detected 
Not 
detected 
Not 
detected 
Not 
detected 
Not 
detected 
Not 
detected  
10 8 X Not 
detected 
Not 
detected 
N/A Not 
detected 
  
 
 
2
3
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Figure 6.9 IL13 content of the media of myotubes following treatment of myotubes with (a) 150pg/ml and 200pg/ml of IP10, (b) 1µM of 
resveratrol (c) treatment with resveratrol prior to treatment with 150pg/ml of IP10 and (d) treatment with resveratrol prior to treatment 
with 200pg/ml of IP10. *p<0.05, **p<0.01 compared with untreated controls (One-way Anova/T Test). Values are presented as mean ±SEM. 
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6.3.1.9. Effect of resveratrol and IP10 of IL17 content of the media of myotubes  
IL17 content in the media of myotubes at 1-10 days following treatment with 
IP10+/- resveratrol is shown in Figure 6.10. Treatment of myotubes with 150pg/ml of 
IP10 resulted in a decrease in IL17 content of the media of myotubes at 5 and 10 days 
following treatment (p<0.05). This was prevented by a pre-treatment of myotubes with 
resveratrol (p<0.05 Figure 6.10c). A treatment of myotubes with 200pg/ml of IP10 
resulted in a decrease in IL17 content in the media of myotubes at 5 and 10 days 
following treatment (p<0.05), but this was not prevented by a pre-treatment of 
myotubes with resveratrol (p<0.05 Figure 6.10d). Treatment of myotubes with 
resveratrol alone had no effect on IL17 content (Figure 6.10b) 
Table 6.11 Summary of effects of IP10 and resveratrol on IL17 content of media of myotubes. 
X denotes not effect compared with untreated control, arrows denote effect of treatment 
compared with untreated control. Y (yes) denotes to the ability of a pre-treatment of 
myotubes with resveratrol to prevent IP10 induced effects and N (no) denotes to the inability 
of a pre-treatment of myotubes with resveratrol to prevent IP10 induced effects.  
Days 
following 
IP10 
treatment 
Average 
levels in 
control 
myotubes 
(pg/ml) 
Effect of 
150pg/ml 
compared 
with 
untreated 
control? 
 Effect of 
150pg/ml 
IP10 
modified by 
pre-
treatment 
with 
resveratrol? 
Effect of 
200pg/ml  
compared 
with 
untreated 
control 
Effect of 
200pg/ml 
IP10 
modified by 
pre-
treatment 
with 
resveratrol? 
Effect of  
resveratrol 
alone  
compared 
with 
untreated 
control 
1 18 X X X X X 
3 33 X X X X X 
5 48 ↓ Y X N/A X 
7 Not  
detected 
Not 
detected 
Not 
detected 
Not 
detected 
Not detected Not 
detected  
10 52 X N/A(↓) ↓ N(↓) X 
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Figure 6.10 IL17 content in the media of myotubes following treatment of myotubes with (a) 150pg/ml and 200pg/ml of IP10, (b) 1µM of 
resveratrol (c) treatment with resveratrol prior to treatment with 150pg/ml of IP10 and (d) treatment with resveratrol prior to treatment 
with 200pg/ml of IP10. *p<0.05, compared with untreated controls (One-way Anova/T Test). Values are presented as mean ±SEM. 
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6.3.1.10.  Effect of resveratrol and IP10 of Mip-1α content of the media of 
myotubes  
 
Mip-1α content of the media of myotubes at 1-10 days following with IP10+/- 
resveratrol is shown in is shown Figure 6.11. Treatment of myotubes with 150pg/ml of 
IP10 had no significant effect on Mip-1α content of the media but a pre-treatment of 
myotubes with resveratrol resulted in an transient but substantial increase in Mip-1α 
content of the media of myotubes at 3 days following treatment (p<0.05 Figure 6.11c). 
Treatment of myotubes with 200pg/ml of IP10 resulted in a decrease in Mip-1α 
content of the media of myotubes at 5 days following treatment (p<0.05). This effect 
was prevented by pre-treatment of myotubes with resveratrol (Figure 6.11d. 
Treatment of myotubes with resveratrol alone had little effect on media content of 
Mip-1α (Figure 6.11b). 
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Table 6.12 Summary of effects of IP10 and resveratrol on content of Mip-1α media of 
myotubes 
 
 X denotes no effect compared with untreated control, arrows denote effect of treatment 
compared with untreated control. Y (yes) denotes to the ability of a pre-treatment of 
myotubes with resveratrol to prevent IP10 induced effects and N (no) denotes to the inability 
of a pre-treatment of myotubes with resveratrol to prevent IP10 induced effects.  
Days 
following 
IP10 
treatment 
Average 
levels in 
control 
myotubes 
(pg/ml) 
Effect of 
150pg/ml 
compared 
with 
untreated 
control? 
 Effect of 
150pg/ml 
IP10 
modified by 
pre-
treatment 
with 
resveratrol? 
Effect of 
200pg/ml  
compared 
with 
untreated 
control 
Effect of 
200pg/ml 
IP10 
modified by 
pre-
treatment 
with 
resveratrol? 
Effect of  
resveratrol 
alone  
compared 
with 
untreated 
control 
1 2 X N/A X N/A X 
3 8 X N/A(↑) X N/A X 
5 2 X N/A ↓ Y X 
7 1.6 X N/A Not 
detected 
N/A Not 
detected 
10 22 X N/A X N/A X 
  
 
 
2
3
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Figure 6.11 Mip-1α content of the media of myotubes following treatment of myotubes with (a) 150pg/ml and 200pg/ml of IP10, (b) 1µM of 
resveratrol (c) treatment with resveratrol prior to treatment with 150pg/ml of IP10 and (d) treatment with resveratrol prior to treatment 
with 200pg/ml of IP10. *p<0.05, compared with untreated controls (One-way Anova/T Test). Values are presented as mean ±SEM.
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6.3.1.11. Effect of resveratrol and IP10 of Mip-3α content in the media of 
myotubes  
Mip-3α content of the media of myotubes at 1-10 days following treatment of 
myotubes with IP10+/- resveratrol is shown in Figure 6.12. Treatment of myotubes with 
150pg/ml of IP10 resulted in a small but significant decrease in Mip-3α content of the 
media of myotubes at 1 (p<0.05), 5 (p<0.01) and 7 (p<0.05) days following treatment. 
Treatment of myotubes with 150pg/ml of IP10 also resulted in an increase in the 
content of Mip-3α in the media of myotubes 10 days following treatment. These 
effects were generally prevented by a pre-treatment of myotubes with resveratrol 
(p<0.01 Figure 6.12c). Treatment of myotubes with 200pg/ml with or without 
resveratrol or treatment of myotubes with resveratrol alone had no effect on Mip-3α 
content of the media of myotubes (Figure 6.12b/d).  
Table 6.13 Summary of effects of IP10 and resveratrol on content of Mip-3α media of 
myotubes  
 
X denotes no effect compared with untreated control, arrows denote effect of treatment 
compared with untreated control. Y (yes) denotes to the ability of a pre-treatment of 
myotubes with resveratrol to prevent IP10 induced effects and N (no) denotes to the inability 
of a pre-treatment of myotubes with resveratrol to prevent IP10 induced effects. 
Days 
following 
IP10 
treatment 
Average 
levels in 
control 
myotubes 
(pg/ml) 
Effect of 
150pg/ml 
compared 
with 
untreated 
control? 
 Effect of 
150pg/ml 
IP10 
modified by 
pre-
treatment 
with 
resveratrol? 
Effect of 
200pg/ml  
compared 
with 
untreated 
control 
Effect of 
200pg/ml 
IP10 
modified by 
pre-
treatment 
with 
resveratrol? 
Effect of  
resveratrol 
alone  
compared 
with 
untreated 
control 
1 2 ↓ Y X N/A X 
3 9 X N/A X N.A X 
5 3 ↓ Y X N/A X 
7 2 ↓ N(↓) X N/A X 
10 22 ↑ Y X N/A X 
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Figure 6.12 Mip-3α content in the media of myotubes following treatment of myotubes with (a) 150pg/ml and 200pg/ml of IP10, (b) 1µM of 
resveratrol (c) treatment with resveratrol prior to treatment with 150pg/ml of IP10 and (d) treatment with resveratrol prior to treatment 
with 200pg/ml of IP10. *p<0.05, **p<0.01 compared with untreated controls, +p<0.05 compared with IP10 treated (One-way Anova/T Test). 
Values are presented as mean ±SEM. 
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6.3.1.12. Effect of resveratrol and IP10 of TNF-α content in the media of 
myotubes  
TNF-α content of the media of myotubes at 1-10 days following treatment of 
myotubes with IP10+/- resveratrol is shown in Figure 6.13. TNF-α levels were extremely 
low throughout the study. Treatment of myotubes with 150pg/ml of IP10 resulted in a 
decrease in TNF-α content of the media of myotubes at 1 day following treatment 
(p<0.05) and this was not prevented by pre-treatment of myotubes with resveratrol 
(p<0.01 Figure 6.13c). Treatment of myotubes with 200pg/ml of IP10 had no effect on 
TNF-α content in the media of myotubes however pre-treatment of myotubes with 
resveratrol led to a reduction in the TNF-α content of media at 1 day following 
treatment (p<0.05 Figure 6.13d). Treatment of myotubes with resveratrol alone 
resulted in a decrease in TNF-α at content of media at 1 day following treatment 
(p<0.01 Figure 6.13b).  
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Table 6.14 Summary of effects of IP10 and resveratrol on TNF-α content of media of 
myotubes 
X denotes no effect compared with untreated control, arrows denote effect of treatment 
compared with untreated control. Y (yes) denotes to the ability of a pre-treatment of 
myotubes with resveratrol to prevent IP10 induced effects and N (no) denotes to the inability 
of a pre-treatment of myotubes with resveratrol to prevent IP10 induced effects.  
Days 
following 
IP10 
treatment 
Average 
levels in 
control 
myotubes 
(pg/ml) 
Effect of 
150pg/ml 
compared 
with 
untreated 
control? 
 Effect of 
150pg/ml 
IP10 
modified by 
pre-
treatment 
with 
resveratrol? 
Effect of 
200pg/ml  
compared 
with 
untreated 
control 
Effect of 
200pg/ml 
IP10 
modified by 
pre-
treatment 
with 
resveratrol? 
Effect of  
resveratrol 
alone  
compared 
with 
untreated 
control 
1 2 ↓ N(↓) X -(↓) ↓ 
3 Not  
detected 
Not 
detected 
Not 
detected 
Not 
detected 
Not detected Not 
detected 
5 20 X N/A X N/A X 
7 Not  
detected 
Not 
detected 
Not 
detected 
Not 
detected 
Not detected Not 
detected 
10 21 X N/A X N/A X 
  
 
2
4
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Figure 6.13 TNFα content of the media of myotubes following treatment of myotubes with (a) 150pg/ml and 200pg/ml of IP10, (b) 1µM of 
resveratrol (c) treatment with resveratrol prior to treatment with 150pg/ml of IP10 and (d) treatment with resveratrol prior to treatment 
with 200pg/ml of IP10. *p<0.05, compared with untreated controls (One-way Anova/T Test). Values are presented as mean ±SEM. 
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6.3.2. Effect of IP10 and resveratrol on cytokine clustering 
Clustergrams were produced from the cytokine data identifying hierarchical 
clustering of cytokine profiles in the media from primary rat myotubes treated with 
IP10+/- resveratrol and are shown in Figure 6.14 - Figure 6.18. Clustergrams were 
produced using MATLAB, which uses a non-biased mathematical algorithm based on 
Eisen et al (1998) and is a common approach in several genome wide expression 
studies (Eisen et al., 1998). Clustergrams function as an output of hierarchical 
clustering. Overall there was not any clear pattern in the clustering, however TNF-α 
and MIP-3α were continually clustered together in the presence of IL7 at day 5 and 10 
following treatment of myotubes with IP10 and resveratrol (Figure 6.16 and Figure 
6.18). IL5 and VEGF were clustered at days 1, 5 and 7 following treatment of myotubes 
with IP10 and resveratrol (Figure 6.14 - Figure 6.16). GRO-KC and IL13 also showed 
some correlations in the media content of myotubes at days 1 and 5 following 
treatment of myotubes with IP10 and resveratrol (Figure 6.16).  
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Figure 6.14 Clustergrams of cytokine content in the media of untreated control myotubes 
(con), and myotubes treated with 150pg/ml of IP10 with (RIP150) and without (IP150) 
resveratrol, 200pg/ml of IP10 with (RIP200) and without (IP200) resveratrol and resveratrol 
treatment alone (res) at 1 day following treatment.  
 
Figure 6.15 Clustergrams of cytokine content in the media of untreated control myotubes 
(con), and myotubes treated with 150pg/ml of IP10 with (RIP150) and without (IP150) 
resveratrol, 200pg/ml of IP10 with (RIP200) and without (IP200) resveratrol (IP200) 
resveratrol treatment alone (res) at 3 days following treatment. 
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Figure 6.16 Clustergrams of cytokine content in the media of untreated control myotubes 
(con), and myotubes treated with 150pg/ml of IP10 with (RIP150) and without (IP150) 
resveratrol, 200pg/ml of IP10 with (RIP200) and without (IP200) resveratrol and resveratrol 
treatment alone (res) at 5 days following treatment. 
 
Figure 6.17 Clustergrams of cytokine content in the media of untreated control myotubes 
(con), and myotubes treated with 150pg/ml of IP10 with (RIP150) and without (IP150) 
resveratrol (IP150), 200pg/ml of IP10 with (RIP200) and without (IP200) resveratrol and a 
lone resveratrol treatment (res) at 7 days following treatment. 
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Figure 6.18 Clustergrams of cytokine content in the media of untreated control myotubes 
(con), and myotubes treated with 150pg/ml of IP10 with (RIP150) and without (IP150) 
resveratrol, 200pg/ml of IP10 with (RIP200) and without (IP200) resveratrol and resveratrol 
treatment alone (res) at 10 days following treatment. 
6.4. Discussion 
The aim of this Chapter was to identify whether the different levels of IP10 
found in serum of the older and younger human population altered the secretion of 
cytokines by myotubes (myokines) and to identify whether the beneficial effects of 
resveratrol seen in myotubes (Chapter 5) were due to changes in cytokine production 
by myotubes. Data from this Chapter has demonstrated no overall trend but suggest 
that production of cytokines by skeletal muscle is a very complex process.  
6.4.1. Cytokines not released or not affected by IP10 and resveratrol 
Data demonstrated that 11 of the cytokines measured were not present in the 
media of either treated or untreated control myotubes; EPO, GM-CSF, GCSF, IFN-γ, IL-
1α, IL-1, IL-4, IL-10, IL12p, IL-18, and Rantes and there was no effect of treatment of 
the content of M-CFS. This was not unexpected as skeletal muscles have been shown 
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to secrete a limited range of cytokines (Nagaraju et al., 1998; Bortoluzzi et al., 2006; 
Sorby Borge et al., 2009). For example, it has been proposed that IL10 and IFN-γ are 
not expressed in skeletal muscle (Nagaraju et al., 1998), IL4 is proposed to be involved 
in myoblast migration and fusion and so is unlikely to play a major role in differentiated 
myotubes (Horsley et al., 2003), although it may be elevated acutely if damage has 
occurred and myoblasts are activated for repair. In contrast, Rantes, IL1α and ILβ are 
quite commonly reported in skeletal muscle; in particular IL1α has been shown to have 
negative effects on skeletal muscle protein synthesis and cell proliferation (Cooney et 
al., 1999; Neustrom et al., 2009), and so the lack of evidence of secretion of some of 
these cytokines from myotubes into the media was surprising. However, some studies 
have shown that these cytokines are not constituently present in muscle and were only 
detected in skeletal muscle following the addition of TNF-α or IFN-y (De Rossi et al., 
2000; Lightfoot et al., 2015). GM-CSF has been previously shown to be present in low 
basal levels in skeletal muscle and was only upregulated following a pro-inflammatory 
stimuli (Nagaraju et al., 1998). These data suggest that the addition of IP10 may not be 
a strong enough stimulus to increase secretion of these cytokines from myotubes. A 
review by Peake et al (2015) demonstrates the differential release of cytokines 
between humans, other species and skeletal muscle cell lines (Peake et al., 2015), 
which may also explain some of the discrepancies in the data. Furthermore Lightfoot et 
al (2015) demonstrated that myotubes produced from C2C12 cells released substantial 
amounts of Rantes (Lightfoot et al., 2015); however Rantes was not present in the 
media of primary rat myotubes in the current study. There is also the possibility that 
  
246 
 
the considerable increases in cytokines seen in some in vivo studies may be due to 
release from other cells present such as the adipocytes and fibroblasts.  
6.4.2. Effects of resveratrol on cytokine secretion by myotubes by myotubes 
Treatment of myotubes with resveratrol alone resulted in some beneficial 
changes in the inflammatory profile in the media of myotubes. For example, there was 
an increase in the media content of the anti-inflammatory cytokines IL13 and IL2 and a 
decrease in the pro-inflammatory cytokine IL7. Resveratrol treatment of myotubes also 
resulted in an increase in IL6 which has been shown to have both pro and anti-
inflammatory effects. Prior treatment of myotubes with resveratrol was able to 
decrease TNF-α in the media in the short term, this is in contrast to other studies which 
have shown that resveratrol can lead to long term decreases in TNF-α and protect 
against TNF-α induced damage (Zhu et al., 2011; Wang et al., 2014). M-CSF is a 
cytokine which has been shown to have anti-inflammatory effects in muscle and 
accelerate muscle regeneration more rapidly leading to a larger muscle fibre (Dumont 
et al., 2013). Treatment of myotubes with resveratrol led to decreases in M-CSF, paired 
with TNF-α data this gives further evidence that, without a pre-existing condition, 
resveratrol may not act as a major anti-inflammatory agent in muscle (Rogers et al., 
2015) and may be detrimental (Gliemann et al., 2013).  
6.4.3. Effect of treatment of myotubes with IP10 on cytokine content of media of 
myotubes 
Treatment of myotubes with IP10 resulted in significant improvements in the 
profile of the pro-inflammatory cytokines including VEGF, KC, IL2, IL5, IL17 and Mip3-α 
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as well as a transient increase in the anti-inflammatory IL13, suggesting IP10 may be 
protective in skeletal muscle cells. In contrast, treatment of myotubes with IP10 
resulted in significant increases in the content of several pro-inflammatory cytokines in 
the media of myotubes. These included Mip-3α, MCP-1 and IL6. However, with respect 
to MCP-1, greater effects were produced by treatment with 200pg/ml compared with 
150pg/ml of IP10. With respect to Mip-3α, treatment of myotubes with 150pg/ml IP10 
resulted in an acute significant decrease in the release by myotubes of this pro-
inflammatory cytokine, and increases at a later time point. In contrast, no effect was 
seen on Mip-3α release following treatment with 200pg/ml of IP10. With respect to 
IL6, treatment of myotubes with IP10 resulted in increased release of IL6 from 
myotubes into the media with little evidence of any major differential effects of the 
two concentrations of IP10 used.  
6.4.4. Effect of pre-treatment of resveratrol on IP10 effects on content of cytokines 
of the media of myotubes  
Treatment of myotubes with an optimised concentration of resveratrol prior 
to IP10 treatment prevented some of the beneficial effects that were seen following 
IP10 treatment. For example, resveratrol prevented the decrease in the content of pro-
inflammatory cytokines VEGF, GRO-KC, IL5, and IL6 as well as preventing the increase 
in the anti-inflammatory cytokine IL13. In contrast, pre-treatment of myotubes with 
resveratrol also prevented some of the negative effects of IP10 on the cytokine profile 
in the media of myotubes. These included IL6, IL5 and Mip-3α and also resulted in a 
decrease in IL17. Pre-treatment of myotubes with resveratrol also resulted in transient 
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increases in the content of the pro inflammatory cytokines Mip-1α in the media of 
myotubes suggesting some pro-inflammatory effects.  
The data discussed above shows that, in terms of inflammation, IP10 
treatment at concentrations of 150pg/ml and 200pg/ml have generally similar overall 
but different temporal effects, with some differences changes occurring with 
resveratrol pre-treatment. Whether or not resveratrol was pro or anti-inflammatory in 
myotubes was inconclusive from these results as resveratrol treatment showed 
characteristics of both. Furthermore, the lack of changes in cytokine content between 
150pg/ml and 200pg/ml of IP10 suggest that changes in IP10 levels that occur with age 
are not a master regulator of the age-related changes in cytokine levels that are seen in 
sarcopenia.  
Importantly, the majority of cytokines have both anti- and pro-inflammatory 
properties depending on the context they are in (Cavaillon, 2001). For example, both 
concentrations of IP10, were able to upregulate IL6, which is known to have both anti 
and pro inflammatory effects (Sugama et al., 2012) and has also been shown to be vital 
for satellite cell activation (Serrano et al., 2008) and myoblast proliferation (Serrano et 
al., 2008; Zhang et al., 2013); suggesting that the increased secretion caused by IP10 
may be beneficial for skeletal muscle. Similarly, MCP-1, is generally considered a pro–
inflammatory cytokine and is increased in muscle in response to cardiotoxin injury 
(Hirata et al., 2003). However, MCP-1 has also been shown to increase myoblast 
proliferation and promote growth (Yahiaoui et al., 2008). MCP-1 content was 
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decreased at 1 day following 150pg/ml treatment and treatment of myotubes with 
200pg/ml increased MCP-1 secretion at 3 and 5 days following treatment. Therefore, 
whether this translates to 150pg/ml being harmful to muscle (i.e. decreases myoblast 
proliferation) and 200pg/ml being beneficial (i.e. increases myoblast proliferation), or 
alternatively that 150pg/ml reduced inflammation, whereas 200pg/ml resulted in an 
increase in inflammation is unclear from these data.  
VEGF (vascular endothelial factor) is a molecule with a well renown role in 
angiogenesis (Connolly et al., 1989), that had temporal changes in content depending 
on the treatment administered. VEGF mRNA has been shown to be upregulated in 
skeletal muscle 4 hours following training (Breen et al., 1996) in rats as well as after 
electrical stimulation (Jensen et al., 2004) of primary rat skeletal muscle as well as in 
C2C12 cells (Kanno et al., 1999) and C2C12 constructs (Park et al., 2008) following 
contraction, suggesting VEGF is present in the muscle following a stress. Therefore it 
suggests that maybe the effects of the different treatments required different amounts 
of time to have an effect, depending on the stress they put on the myotubes. 
Resveratrol has been shown to prevent increases in VEGF following exercise in humans 
(Gliemann et al., 2014) and in the current study the induction of VEGF with treatment 
of 150pg/ml was prevented by prior resveratrol treatment, but not following treatment 
with 200pg/ml of IP10 or treatment with resveratrol alone which also caused an 
increase, giving further evidence that a lower treatment of IP10 may be beneficial for 
skeletal muscle and is possibly able to mimic exercise which has previously been 
proposed (Momken et al., 2011).  
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6.4.5. Clustergram of cytokine secretion 
Due to the ambiguity of the changes in media content of the different 
cytokines, hierarchal clustering (Eisen et al., 1998) of the different cytokines was 
carried out to examine whether there was a relationship between the changes in any 
of the cytokines studied that could give further insight into the effects of both IP10 and 
resveratrol.  
Data from cluster analysis of content of cytokines in the media of myotubes at 
1 day following treatment showed that changes in MCP-1 content in the media of 
myotubes were not related to any other cytokine changes. MCP-1 plays a major role in 
systemic inflammatory and in skeletal muscle regeneration (Hirata et al., 2003) by 
recruiting macrophages. These data suggests that MCP-1 may be an early regulator of 
the regeneration process and acts as one of the master regulators of the inflammatory 
response. This is further evidenced by a gradual reduction in the content in media of 
myotubes at 7 days following treatment and the subsequent absence of the cytokine at 
10 days following treatment. Similarly to MCP-1, the changes in IL6 content in the 
media was not related to any other cytokines at 3 days following treatment, again this 
was not surprising since IL6 has been shown to have a prominent role in inflammation 
and has been shown to regulate many of the cytokines studied.  
IL5 and VEGF were also clustered together at day 1 and 5 following treatment. 
Correlated expression of these two molecules has been seen in models of pneumonia 
(Nishigaki et al., 2003; Choi et al., 2009), providing evidence that increases in IL5 and 
VEGF may have synergistic roles in various tissues including skeletal muscle.  
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There were also correlations between IL13 and GRO-KC content in the media 
of myotubes at day 1, 3 and 5 following treatment. IL13 and GRO-KC have been shown 
to be involved in myoblast proliferation (Jacquemin et al., 2007; Heredia et al., 2013; 
Iwasaki et al., 2013). A role for IL13 and GRO-KC in proliferation is supported by the 
heat map element of the clustergram analysis that showed there was no overall 
change in the content of IL13 and GRO-KC in the media of untreated control myotubes. 
Furthermore, the heat map also showed an increase in GRO-KC and IL13 content in the 
media of myotubes treated only with resveratrol, this may suggest an increase in 
proliferation of myoblasts by a resveratrol treatment, supporting the findings from 
Chapter 3.  
TNF-α and Mip-3α are well known pro-inflammatory cytokines and were also 
correlated at day 5 and 10 following treatment of myotubes. This only occurred in the 
presence of IL7. IL7 is a pro-inflammatory cytokine that has been shown to effect 
myoblast migration (Haugen et al., 2010). There are no studies which have previously 
reported correlations of these cytokines; however, these data suggest this triplet may 
play a synergistic role in myogenesis. Considering IL7 has been shown to be involved in 
myoblast migration (Haugen et al., 2010) treatment of myotubes with resveratrol alone 
as well as a pre-treatment of myotubes with resveratrol followed by a treatment with 
200mg/ml IP10 resulted in a decrease in IL7 content at 10 days following treatment. 
Furthermore, no differences were seen between any of the other treatment groups. 
These data disagrees with previous data that has shown resveratrol to increase motility 
and migration of myoblasts (Bosutti et al., 2015).  
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Previous data from Chapters 3 and 4 provided evidence that resveratrol may 
cause early myogenesis; therefore this suggests that following the different treatments 
myotubes may be at different stages of maturity and may explain some of the 
temporal changes within the treatment groups. This hypothesis is supported by 
another study which showed differences in cytokine responses in myoblasts and 
myotubes (Podbregar et al., 2013). Furthermore, there is a lot of variance within 
treatment groups, which would be expected in primary cell cultures, particularly here 
when there are some fibroblasts also present that may also contribute to cytokine 
secretion, particularly as some of the cytokines found in the media of myotubes have 
not previously been identified as myokines and further work is warranted to clarify 
this.   
It is important to note that although initially the same number of cells was 
plated for each treatment group, experimental design did not allow for protein content 
to be measured and therefore cytokine secretion was not normalized to total protein 
content. Furthermore, data in Chapter 5 showed that Atrogin1 levels were upregulated 
in IP10 treatment groups at days 1, 7 and 10. As Atrogin1 is an ubiquitin ligase that has 
been shown to be upregulated in many models of atrophy, it is possible that this could 
mean there was an increase in cell death; some evidence of this has been shown in 
cardiac muscle were correlations between Atrogin1 and apoptosis were found (Zeng et 
al., 2013). This could mean that there were fewer cells in the 200pg/ml of IP10 treated 
group and therefore cytokine secretion may have been under estimated. However, to 
my knowledge, no link between Atrogin1 and apoptosis has been shown in skeletal 
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muscle and as we were using myotubes, it is unlikely that levels of apoptosis reached 
were that high of an increase that there would be significant difference in myotube 
number.  
6.5. Conclusions 
The data presented in this Chapter suggest that the role of IP10 treatment is 
dose and time dependent. The lack of any major effects of IP10 on the content of 
cytokine in the media of myotubes also suggests that IP10 is not a major regulator in 
the age-related increase in cytokine production by muscle. Furthermore, these data 
and data from other studies (Momken et al., 2011) suggest that there is little evidence 
that resveratrol has major anti-inflammatory properties in muscle. This further 
suggests that beneficial effects of resveratrol on skeletal muscle described in Chapters 
2-4 may not be due to local anti-inflammatory effects of resveratrol on muscle. 
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7. THE EFFECT OF RESVERATROL ON MUSCLE 
FORCE GENERATION IN ADULT AND OLD MICE IN 
VIVO AND OPTIMISATION OF 3D MUSCLE 
CONSTRUCTS IN VITRO 
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7.1. Introduction 
Data presented in Chapters 3-6 showed that treatment of primary muscle cells 
isolated from rat with resveratrol resulted in an increase in myoblast proliferation, 
hypertrophy of myotubes and protection of myotubes from IP10 induced atrophy. 
Other studies have also shown beneficial effects of resveratrol in muscle such as 
hypertrophy as well as a reduction in of oxidative stress (Jackson et al., 2011), decrease 
in and protection from inflammation (Gordon et al., 2013; Wang et al., 2014) and well 
characterised increases in mitochondrial biogenesis and function (Price et al., 2012). 
The effect of resveratrol on skeletal muscle function is less clear. In vivo 
studies have shown varied effects of increased resveratrol intake on the ability of 
skeletal muscle to generate force. For example Dolinsky et al (2012) showed that, 
feeding 22-week old rats chow supplemented with resveratrol for 12 weeks; resulted in 
an increase in both the twitch and maximum tetanic force generated by the soleus and 
tibialis anterior muscles (Dolinsky et al., 2012). These effects of resveratrol were similar 
to the effects of exercise (Dolinsky et al., 2012), suggesting that resveratrol may act as 
an exercise mimetic. Oral treatment of 6-week old mice for 21 days with resveratrol 
resulted in an increase in grip strength as well as protection from physical fatigue (Wu 
et al., 2013). Treatment of rats with resveratrol has also been shown to prevent 
unloading induced atrophy (Jackson et al., 2010; Momken et al., 2011; Gordon et al., 
2014). In contrast, other studies show little effects, for example, resveratrol had no 
effect on the maximum peak or twitch force in the anterior crural muscles of 21-month 
old mice that were fed chow supplemented with resveratrol for 7 weeks (Baumann et 
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al., 2015). Furthermore, treatment of rats for 10 months with resveratrol resulted in 
improved markers of oxidative stress but had no effect on the force generation of the 
plantaris muscle (Jackson et al., 2011). In addition, resveratrol treatment prior to 
barium chloride injections had no effect on the force generation by the anterior tibialis 
either before or after injection (Russell et al., 2015). The variable effects of resveratrol 
treatment on muscle function could be due to differences in the methods of 
administration, length of treatments and species and muscles used. The age and health 
status of the subject may also been important in the outcome on benefits of 
resveratrol treatment (Baur et al., 2006).  
The ability to measure muscle cell function/ force generation in cell culture 
would be ideal for a number of reasons. This would allow the effects of a treatment on 
isolated muscle cells to be studied without any confounding factors such as the 
presence of other cells. It would also remove some of the variables that may affect the 
outcome of treatment as discussed above, such as route of administration and 
systemic metabolism of the compound. A major benefit of the establishment of a 3D 
muscle construct is the ability to measure force generation. An additional benefit of 
the use of a muscle 3D construct is the ability to directly test the effect of the parent 
compound, such as resveratrol, on muscle function rather than this being complicated 
by the potential breakdown of the compound in the gut. It also allows identification of 
the functional effect of treatments directly on the isolated muscle cells. Ethically, it 
would considerably reduce the number of animals needed for experimental work.  
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The use of 3D cultures to measure force generation in vitro was carried out by 
Vandenburgh in avian skeletal muscle cells and these were termed “organoids”. 
(Vandenburgh et al., 1991) The use of lateral loading of the muscle in this model which 
could potentially affect the length of the sarcomere and so give inaccurate force 
measurements meant that this model was met with criticism. Later, 3D constructs 
were also designed using artificial matrix (Okano et al., 1997; Shansky et al., 1997). 
Again, these constructs, when used for functional measurements, were criticised as the 
interference of the scaffold has been shown to introduce a large resting tension 
(Delvoye et al., 1991). Since then, 3D constructs made with primary cells from rat 
skeletal muscle without scaffolds have been relatively well established and 
characterised (Kosnik et al., 2001).  
The use of 3D skeletal muscle constructs (also known as myooids) as implants 
offer great promise for treatment of muscular diseases such as muscular dystrophy and 
for regenerative medicine. Studies have already been carried out using implantation of 
skeletal muscle constructs into rodents and this had led to restoration of function 
(Machingal et al., 2011). Despite the benefits for using 3D constructs in research, 3D 
cell culture models are still only minimally used. 
Thus, the use of 3D constructs in culture and studies in vivo provide 
complimentary approaches to determine the effects of supplementation on muscle 
function whereby 3D constructs can be used to determine the direct effects of 
treatment and in vivo studies incorporate the potential interactions of the compound 
with other tissues, including the gut.   
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The aim of this Chapter is twofold:  
1) To identify a dose of resveratrol which results in known transcriptional 
response in muscle and then to determine the effects of this dose on muscle function 
in adult (6 months old) and old (24 months old) mice in vivo and  
2) To optimise the formation of 3D muscle constructs that could be used to 
measure force generation in vitro for future studies.  
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7.2. Methods 
7.2.1. Preparation of resveratrol 
Resveratrol was dissolved in 20% DMSO solution and stored at 4oC.  
7.2.2. Mice 
C57BL6/J adult and old mice were used and housed as described in Section 
2.2.3. 
7.2.3. Treatment of mice with resveratrol or DMSO  
A pilot study was undertaken to potentially inform a larger study to determine 
the effects of supplementation of adult and old mice with resveratrol on muscle 
function.  
Study 1: Male mice were split into four groups: 
Group 1, treated with 25mg resveratrol/kg/day by oral gavage daily for 14 
days (n=5), group 2, treated with 125mg resveratrol/kg/day by oral gavage daily for 14 
days (n =3), group 3, treated with DMSO vehicle by oral gavage daily for 14 days. (n=5) 
and group 4 , an untreated control group (n=3).  
Study 2: Once a dose of resveratrol which had resulted in changes in Sirt1 and 
MnSOD content of muscle was identified from Study 1, adult and old mice were split 
into two groups each; one group was treated with 125 resveratrol (n=5) mg/kg/day and 
the other treated with DMSO vehicle (n=6) by oral gavage daily for 14 days.  
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Figure 7.1 Overview of studies 1 and 2, to determine the effect of resveratrol on biochemical 
markers and muscle function in adult and old mice in vivo. 
 
7.2.4. HPLC analysis (Study 1) 
Twenty four hours following the final resveratrol treatment, mice were culled 
with overdose of anaesthetic and gastrocnemius muscles were removed, frozen in 
liquid nitrogen and stored at -80oC until analysis. One of the gastrocnemius muscles 
was ground under liquid nitrogen and sent to Dr Bresciani at the University of Parma, 
Italy for HPLC analysis for determination of content of resveratrol and its metabolites; 
dihydroresveratrol aglycone, dihydroresveratrol sulfate, dihydroresveratrol 
glucuronide, resveratrol disulfate, and dihydroresveratrol sulfo-glucoronide. The other 
gastrocnemius muscle was subjected to western blot analysis for determination of 
Sirt1 and MnSOD protein content (Section 2.11).   
7.2.5. Preparation of skeletal muscle for SDS-PAGE and western blotting  
Muscle samples were ground under liquid nitrogen and were sonicated on ice 
for 15 seconds and centrifuged at 14000g for 5 minutes. The pellet was discarded and a 
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BCA assay (Section 2.10) was carried out on the supernatant to determine total protein 
concentration. Fifty micrograms of protein was diluted 1:1 with protein loading buffer 
in preparation for SDS-PAGE (Section 2.11). Western blotting for MnSOD and Sirt1 
contents was performed as described in Sections 2.11.3 and 2.11.4. 
7.2.6. Determination of the effect of resveratrol on force production by EDL muscles 
of mice in vivo (Study 2) 
Following treatment of mice with resveratrol or DMSO carrier, force 
generation by the EDL muscles was measured as described in Section 2.20.4. Briefly, 
adult and old mice were anaesthetised. The knee of the right hind-limb was fixed. The 
distal tendon was exposed and attached to the lever arm of a servomotor (Cambridge 
Technology, UK). The lever served as a force transducer. The peroneal nerve was 
exposed, and electrodes were placed across the nerve. Stimulation voltage and muscle 
length were each adjusted to produce maximum twitch force. The optimal length for 
maximum twitch force is also the optimal length (L0) for the development of maximum 
tetanic force (P0) (Brooks et al., 1988). Optimal length was determined by increasing 
the length of the muscle until optimal twitch force was reached. With the muscle at L0, 
the P0 was determined during 500 msec of voltage stimulation. The P0 was identified by 
increasing the frequency of stimulation at 2-min intervals until the maximum force 
plateaued. Muscle fibre length (Lf) and cross-sectional area were calculated (Brooks et 
al., 1988). Following the final measurement, mice were killed by cervical dislocation. 
The EDL and gastrocnemius muscles were removed and weighed. The specific P0 was 
calculated as the absolute P0/total muscle cross-sectional area (Brooks et al., 1988).  
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7.2.7. Preparation of 3D muscle constructs using primary rat myotubes 
Following isolation and expansion in culture (Section 2.3), myoblasts were 
plated on pre-prepared laminin coated sylgard plates at a density of approximately 
4x105. Once myoblasts had reached 80% confluence, small pieces of tendon from rat 
tail were placed into the petri dish (Section 2.19) and media changed to differentiation 
media to initiate myotube formation. Within 3-5 days, myotubes began to delaminate 
and roll around the pinned tendon. A full 3D construct was formed approximately 7 
days following plating of myoblasts (Figure 7.2). 
 
 
Figure 7.2 Stages of construction of a 3D muscle construct.  
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7.2.8. Measurement of force generation by 3D muscle constructs   
Contractile properties were measured the following day after the formation of 
a 3D construct. The anchor of one end of the 3D construct was released from the 
Sylgard and attached to a force transducer with wax. Platinum wire electrodes were 
positioned on either side of the construct to allow stimulation of the whole construct. 
Passive baseline force was measured as the average baseline force before the onset of 
stimulation. Twitches were elicited using a single 1.2-ms pulse at 10V and maximum 
tetanic force was determined at 10, 20, 40, 80 100 and 200Hz. Maximum specific force 
was determined by normalising peak tetanic force to the cross sectional area of the 3D 
construct that was determined by measuring the diameter of the 3D construct 
measured using Nikon TE2000 microscope (Nikon, Kingston upon Thames, UK). 
7.2.9. Statistics 
Graphpad 5 (Graphpad Software, San Diego, USA) was used to perform One-
way ANOVA test followed by a Dunnett’s post-test to identify significant differences 
between data in Study 1. A two-way ANOVA followed by a Bonferonni post-test was 
used to identify significant differences between data in Study 2. Data are represented 
as mean ± SEM.  
7.3. Results 
7.3.1. Study 1: HPLC analysis of muscle for resveratrol and its metabolites. 
Resveratrol or resveratrol metabolites were undetectable in the 
gastrocnemius of DMSO and resveratrol treated mice (data not shown).  
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7.3.2. Study 1: Effect of treatment of resveratrol on MnSOD and Sirt1 protein 
content of in vivo 
MnSOD and Sirt1 protein contents of the gastrocnemius muscle of mice 
following treatment with resveratrol with either 25 or 125mg resveratrol/kg/day are 
shown in Figure 7.3 and Figure 7.4. MnSOD (Figure 7.3 p<0.01) and Sirt1 (Figure 7.4 
p<0.01) protein content was significantly increased following treatment with 125mg 
resveratrol/kg/day compared with the DMSO vehicle group. The protein contents of 
MnSOD and Sirt1 in untreated mice and mice treated with 25mg resveratrol/kg/day did 
not show any changes compared with the DMSO vehicle mice.  
 
 
Figure 7.3 MnSOD content of the gastrocnemius muscles of adult mice following treatment 
with 125mg resveratrol/kg/day (125), 25mg resveratrol /kg/day (25), compared with 
untreated control (con) and DMSO vehicle treated control (dcon). **p<0.01 One-way 
ANOVA. Values are presented as mean ±SEM.  
  
265 
 
 
 
Figure 7.4 Sirt1 content of the gastrocnemius muscles of adult mice following treatment with 
125mg resveratrol/kg/day (125), 25mg resveratrol /kg/day (25), compared with untreated 
control (con) and DMSO vehicle treated control (dcon). **p<0.01 One-way ANOVA. Values 
are presented as mean ±SEM. 
 
7.3.3. Effect of treatment of adult and old mice with resveratrol on muscle mass of 
EDL and gastrocnemius muscles 
Data for twitch force, maximum force, muscle masses and CSA and maximum 
specific force, of muscles of adult and old mice following treatment with 125mg 
resveratrol/kg/day is shown in Figure 7.5-Figure 7.13.  Thus, no significant effect of age 
was seen on absolute muscle mass (Figure 7.5 and Figure7.7) although a significant 
decline was seen when muscle mass was expressed as a percentage of body weight 
(Figure 7.6 and Figure 7.8). There was a non-significant ~20% reduction in maximum 
tetanic force (Figure 7.11), which became significant when muscle CSA was accounted 
for in the specific force data (Figure 7.13). 
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No difference in maximum tetanic force was seen in EDL muscles of mice 
treated with resveratrol although a small but significant reduction in muscle CSA was 
seen in adult mice treated with resveratrol compared with DMSO controls (p>0.05 
Figure 7.12). Similar patterns were seen in muscles of old mice treated with resveratrol 
compared with DMSO treated old mice. Thus, no effect of resveratrol was seen on 
maximum tetanic force, CSA or maximum specific force generation between old mice 
treated with resveratrol and old mice treated with DMSO vehicle (Figure 7.11, Figure 
7.12 and Figure 7.13).  
 
 
Figure 7.5 Mass of EDL muscles from adult and old mice treated with 125mg 
resveratrol/kg/day or DMSO for 14 days. Values are presented as mean ±SEM. 
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Figure 7.6 Mass of EDL muscles normalised to body mass of adult and old mice treated with 
125mg resveratrol/kg/day or DMSO for 14 days. *p<0.05 compared with same treatment in 
adult. Two way ANOVA. Values are presented as mean ±SEM. 
 
 
Figure7.7 Mass of gastrocnemius muscles of adult and old mice treated with 125mg 
resveratrol/kg/day or DMSO for 14 days. Values are presented as mean ± SEM. 
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Figure 7.8 Mass of gastrocnemius muscles normalised to body mass of adult and old mice 
treated with 125mg resveratrol/kg/day or DMSO for 14 days. **p<0.01 compared with same 
treatment in adult. Two-way ANOVA. Values are presented as mean ±SEM. 
 
   
Figure 7.9 Maximum twitch force of EDL muscles from adult and old mice treated with 125mg 
resveratrol/kg/day or DMSO for 14 days. Values are presented as Mean ± SEM. 
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Figure 7.10 Maximum twitch force normalised to CSA of EDL muscles from adult and old mice 
treated with 125mg resveratrol/kg/day or DMSO for 14 days. Values are presented as mean 
±SEM. 
 
 
Figure 7.11 Maximum tetanic force generation by EDL muscles from adult and old mice 
treated with 125mg resveratrol/kg/day or DMSO for 14 days. Values are presented as mean 
±SEM. 
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Figure 7.12 Cross sectional area of EDL muscles of adult and old mice treated for 14 days with 
125mg resveratrol /kg/day or DMSO. **p<0.01 compared with adult +p<0.05 compared with 
DMSO control. Two-way ANOVA. Values are presented as mean ±SEM. 
 
 
Figure 7.13 Specific force generation of EDL muscles from adult and old mice treated with 
125mg resveratrol/kg/day or DMSO for 14 days. Values are presented as mean ±SEM Two-
way ANOVA. 
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7.3.4. Establishment of 3D muscle construct  
Representative images of 3D constructs are shown in Figure 7.14 and Figure 
7.15. The maximum and specific force generation of a single 3D construct was 76.4μN 
and 10.9N/mm2 respectively. Haematoxylin staining of 3D constructs revealed the 
congregation of fibroblasts around the outer layer with differentiated myotubes 
occupying the middle of the construct (Figure 7.15).  
 
Figure 7.14 Representative images at different stages of 3D construct formation; (a) following 
plating of cells and insertion of anchors, cells start to delaminate (b) and a 3D construct will 
be fully formed within approximately 1 week. (c) Following formation of 3D constructs, (d) 
forces are measured using a force transducer.  
 
 
Figure 7.15 Cross section of 3D construct stained with H&E. Fibroblasts occupy the outside 
layer of construct and the middle area consists of myotubes. 
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7.4. Discussion 
Data from this Chapter showed that resveratrol and its metabolites were 
undetectable in the gastrocnemius muscle of adult mice treated with resveratrol for 14 
days. Despite this, resveratrol was able to have a transcriptional effect in the muscle of 
mice, demonstrated by the upregulation of the muscle protein content of MnSOD and 
Sirt1. This increase in MnSOD and Sirt1 protein content was seen following a treatment 
with a 125mg resveratrol/kg/day whereas treatment of mice with 25mg 
resveratrol/kg/day had no effect on the muscle protein content of Sirt1 or MnSOD. 
Consequently, 125mg resveratrol/kg/day was chosen as the optimum treatment for a 
pilot study (Study 2) aiming to determine the effects of this dose of resveratrol on 
muscle function in adult and old mice in vivo. 
Data comparing muscles of adult and old mice showed a reduction in CSA and 
specific force generation and in the gastrocnemius muscle when muscle mass was 
expressed as a percentage of body weight. This is in agreement with other studies 
suggesting a significant reduction in lean body mass and muscle function. 
No significant effects were observed on maximum tetanic force generation, 
CSA and specific force generation when examining the effect of resveratrol on muscles 
of adult or old mice, or when comparing muscles of adult mice treated with resveratrol 
with adult mice treated with DMSO vehicle or between old mice treated with 
resveratrol and old mice treated with DMSO vehicle. Treatment of mice with 
resveratrol resulted in a significant decrease in muscle CSA in muscles of both old and 
adult mice. However, there was no major effect on tetanic force generation, this 
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resulted in an apparent (non-significant) increase in specific force generation in both 
adult (approximately 25%) and old (approximately 15%) mice when compared with the 
adult and old mice treated with DMSO vehicle, suggesting that caution is required 
when interpreting such data since treatment with resveratrol seems to have induced 
some muscle atrophy, particularly in adult mice. In addition, treatment of old mice with 
resveratrol had no effect on the gastrocnemius mass when normalised to body weight, 
further suggesting that resveratrol was not effective in preserving muscle mass in older 
mice.    
Therefore these data suggest that resveratrol treatment at this dose has little 
beneficial effect on muscle function in adult and old mice.  
7.4.1. Optimisation of resveratrol treatment in vivo 
Resveratrol has been shown to have numerous health benefits in vitro. 
However, due to the rapid absorption and break down of the compound, HPLC studies 
have shown that only 1% of ingested resveratrol reaches the plasma with the rest 
being metabolised (Wenzel et al., 2005). Therefore whether the effects that have been 
seen in cell culture studies are achievable in vivo is debatable (Boocock et al., 2007). 
Concentrations used as well as length and route of administration of 
resveratrol vary widely between studies. Therefore, this work focused on identifying a 
treatment of mice with resveratrol that would have known transcriptional effects, 
demonstrating that resveratrol, or its metabolites had reached the muscle. Based on 
published data, mice were treated with two different concentrations of resveratrol; 
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25mg resveratrol/kg/day and 125mg resveratrol/kg/day for 14 days where resveratrol 
treatment resulted in increased grip strength and decreased markers of fatigue (Wu et 
al., 2013). Resveratrol was administrated via oral gavage to ensure that all mice 
received equal doses. 
Resveratrol or resveratrol metabolites were not detected by HPLC in the 
gastrocnemius muscle from mice treated with either 25mg resveratrol/kg/day or 
125mg resveratrol/kg/day. Muscles were removed at 24H following the final 
resveratrol treatment, therefore the absence of resveratrol in the muscle may be due 
to the fast metabolism of resveratrol (Wenzel et al., 2005). Resveratrol has been shown 
to be present in muscle following administration of 5.9mg/kg/day in the pig (Azorin-
Ortuno et al., 2011). However, this study collected muscle at 6 hours following 
treatment and resveratrol was also administrated intragastrically. A study by Andres-
Lacueva et al (2012) detected a small number of resveratrol metabolites in muscle 
following a 6-week treatment of rats with 6, 30 or 60mg resveratrol/kg/day in their 
normal chow however others were undetectable, (Andres-Lacueva et al., 2012). This 
indicates that skeletal muscle may not be very efficient at absorbing resveratrol and in 
order to determine resveratrol absorption by muscle, collection of tissue should be 
undertaken over a time course of less than 24 hours. These data also suggest that, in 
particular, different routes of administration and studies in different species may also 
affect the outcome of the resveratrol study. Despite the lack of detection of resveratrol 
or it’s metabolites in muscle, known transcriptional targets of resveratrol, MnSOD and 
Sirt1 protein content in the muscle were increased following treatment of mice with 
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125mg resveratrol/kg/day. These data showed that although resveratrol was 
undetectable by HPLC analysis, treatment of mice with resveratrol at a higher dose was 
still able to have an effect on translation of known targets in muscle. Sirt1 as a direct 
target for resveratrol is controversial (Beher et al., 2009). Some studies have shown 
that Sirt1 is activated following resveratrol treatment (Howitz et al., 2003; 
Lakshminarasimhan et al., 2012; Price et al., 2012). However, data from Chapter 4 
showed that, following resveratrol treatment, Sirt1 protein content was decreased in 
primary myotubes from rat and this was associated with increased myotube diameter 
compared with untreated myotubes. Sirt1 has been shown to inhibit myogenesis 
(Rathbone et al., 2009) and so the hypothesis was that the decrease in Sirt1 was 
beneficial to muscle cells as it resulted in initiation of differentiation. Although some 
studies have shown beneficial effects of Sirt1 in other tissues, Sirt1 may be inhibitory 
during muscle development (Rathbone et al., 2009). In contrast to our in vitro findings 
in Chapters 3 and 4, resveratrol treatment in vivo resulted in an increase in Sirt1 
protein content of muscle, suggesting that Sirt1 may be mediating the effects of 
resveratrol, particularly in the reduction of muscle CSA seen in muscles of adult mice, 
which is in agreement with published data by Price and colleagues (Price et al., 2012).  
7.4.2. Effect of resveratrol on cross-sectional area of EDL muscles from adult and old 
mice 
A significant decrease in CSA was seen in muscles of resveratrol treated adult 
mice compared with DMSO vehicle treated adult mice. These data may provide some 
evidence of the hypothesis that resveratrol may be detrimental to muscle of healthy 
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individuals (Chapter 5). Previous Chapters have indicated that treatment of healthy 
muscle with resveratrol may be detrimental. For instance; a pre-treatment of 
resveratrol followed by a non-detrimental treatment of IP10 led to increases in the 
muscle specific ubiquitin ligase, Atrogin1 (Figure 5.17). Resveratrol treatment of 
myotubes also resulted in an increase in some pro inflammatory cytokines in the media 
of myotubes (Figure 6.3).  
In agreement with others (Russell et al., 2015) treatment of mice with 
resveratrol decreased the CSA of muscles of old mice. This was in contrast to other 
studies that have shown that treatment with resveratrol resulted in increases the CSA 
of muscles of old animals (Bennett et al., 2013; Ballak et al., 2016). Discrepancies in 
these data may also be due to the health state of the animals used for these studies. In 
the study by Ballak et al (2016), mice were 25-months old and the rats used in the 
study by Bennett et al (2013) had undergone unloading, further agreeing with previous 
data in this Chapter suggesting that resveratrol may be more beneficial in older 
animals with a more severe sarcopenic phenotype.  
7.4.3. Effect of treatment of mice with resveratrol on muscle force generation  
The decrease in muscle mass and force generation with age is well 
characterised in rodents (Brooks et al., 1994; McArdle et al., 2004) and humans 
(Bemben et al., 1991) and was also shown in this study as well as a significant decrease 
in gastrocnemius and EDL mass when expressed relative to body mass was seen in old 
mice when compared with adult mice which is in agreement with published data 
(Brooks et al., 1994; McArdle et al., 2004). 
  
277 
 
Published data has previously shown that resveratrol administration resulted 
in an increased force generation in muscles of adult animals (Dolinsky et al., 2012; Wu 
et al., 2013), however in the current study, resveratrol treatment caused no significant 
increase in muscle mass and function in adult mice when compared with data from 
adult DMSO vehicle treated mice. Despite studies demonstrating that treatment of 
mice with resveratrol resulted in an increased force generation by muscles of adult 
animals (Dolinsky et al., 2012; Wu et al., 2013) and showing some beneficial effects on 
the muscle of sarcopenic animals, such as a decrease in ROS generation (Jackson et al., 
2010), this study and others have been unable to show the ability of resveratrol to 
attenuate the loss of force with age has not been demonstrated (Jackson et al., 2011). 
Data from this study and others have suggested that resveratrol may need a pre-
existing condition to have beneficial effects (Baur et al., 2006), therefore resveratrol 
treatment may be more beneficial in older mice with a more severe sarcopenic 
phenotype.  
7.4.4. Optimisation of 3D construct  
Additional studies were aimed at optimising the formation of 3D muscle 
constructs that could be used to measure force generation in vitro for future studies 
which would allow us to examine the direct effects of resveratrol and its metabolites 
on skeletal muscle in culture and therefore further understand any different effects of 
interventions reported in vivo compared with in culture. In addition, this model 
provides a novel technique for manipulating the environment of the muscle cells to 
examine the effects of specific treatments directly on muscle cells.  
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I was trained in techniques to assess contractile function in 3D muscle 
constructs by Professor Lisa Larkin (University of Michigan, Ann Arbor, USA) who has 
developed these functional skeletal muscle constructs in vitro. Upon my return from 
the University of Michigan, I spent a substantial amount of time optimising this 
technique. 3D muscle constructs are extremely fragile and break easily when they are 
attached to the force transducer. In addition, delamination of cells from the substrate 
and rolling into a cylinder can also be problematic, therefore 3D muscle constructs are 
not always formed properly. Nevertheless, a small number of 3D muscle constructs 
were successfully produced and force generation from one construct demonstrated. 
The maximum force measurement from the 3D construct in this study was comparable 
to published data (Larkin et al., 2006). The construct requires additional 
standardisation since myotubes were enclosed within a fibroblast surrounding in a 
similar manner to published data (Dennis et al., 2000). These preliminary data 
demonstrate the feasibility of this technique and future work will allow the use of this 
model to measure the effect of resveratrol and other compounds directly on skeletal 
muscle function.  
7.5. Conclusions 
Data from this Chapter identified an effective concentration of resveratrol in 
muscle in vivo and these data will be used to power future studies although the 
functional effects of resveratrol were disappointing. This study was also able to 
successfully produce 3D muscle constructs in vitro and future work will allow use of 
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this model to measure the effect of resveratrol and other compounds directly on 
skeletal muscle function.  
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8. DISCUSSION 
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8.1 Summary of main findings  
The initial aims of the work reported in this thesis were to: 
 
1. Establish an in vitro model to test the effects of resveratrol on primary muscle 
cells in culture and identify a concentration of resveratrol that was effective in 
both undifferentiated (myoblasts) and differentiated (myotubes) primary 
skeletal muscle cells. 
2. Establish an in vitro model to study the effect of increased levels of IP10 on 
muscle cell atrophy and inflammation. 
3. Examine whether a treatment of primary myotubes with resveratrol is able to 
protect against IP10 induced effects on skeletal muscle cell atrophy or 
inflammation. 
4.  Identify an effective dose of resveratrol in mice in vivo and examine the effect 
of this concentration on skeletal muscle force generation in adult and old mice. 
5. Establish a 3D muscle construct model that could potentially be used to study 
the direct effects of compounds on skeletal muscle function in vitro. 
The major findings of the work were: 
1. Data have shown that concentrations of resveratrol achievable by diet showed 
some initial toxicity but were non-toxic to myoblasts in the longer term, conferred 
some protective effects against cell death, increased cell proliferation and potentially 
caused early myogenesis. Physiological concentrations of resveratrol resulted in 
increases in MnSOD and catalase protein contents in myoblasts, indicating that 
resveratrol is functional of primary rat myoblasts. Data suggested that a potential 
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mechanism for this was through upregulation of the NAD-dependent deacetylase Sirt1, 
however results were inconclusive.   
2. Data from primary rat myotubes demonstrated that treatment of myotubes 
with concentrations of resveratrol achievable by diet initially caused an increase in cell 
death, which was associated with an increase in myotube diameter and decreased 
hydrogen peroxide production of the remaining cells. Data suggest that the increase in 
myotube diameter was likely through the decrease in the myogenesis inhibitor Sirt1 
thus allowing early progression of myogenesis. The decrease in hydrogen peroxide 
production was likely due to the increase in the antioxidant defence enzymes MnSOD 
and catalase; however, these data suggest that, in myotubes, this does not occur 
through the upregulation of Sirt1.  
3. Data from primary rat myotubes treated with concentrations of IP10 found in 
old individuals led to decreases in myotube diameter and increases in the muscle levels 
of specific ubiquitin ligase Atrogin1. Treatment of myotubes with levels of IP10 found 
in young individuals had no effect on markers of atrophy. Treatment of myotubes with 
both concentrations of IP10 had some subtle effects on the cytokine profile in the 
media of myotubes. These data suggest that the age-related changes in serum IP10 
concentrations likely contributes to sarcopenia but are unlikely to have a major role in 
the age-related increase in cytokine production by muscle. 
4. Data from myotubes treated with resveratrol demonstrated that resveratrol 
treatment alone had anti-inflammatory effects by inducing IL13, IL2 and reducing levels 
of IL7. Treatment of myotubes with resveratrol prior to treatment with IP10 was able 
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to prevent IP10-induced decreases in myotube diameter and was able to inhibit the 
IP10-induced increases in the muscle specific ubiquitin ligase Atrogin1. Pre-treatment 
of myotubes with resveratrol was able to partly reduce some of the IP10-induced pro 
inflammatory cytokine levels in the media but also prevented some of the anti-
inflammatory effects of IP10. Thus resveratrol may be a potential treatment for 
sarcopenia; however it is unlikely these effects are mediated through anti-
inflammatory properties.  
5. Data from force measurements demonstrated that treatment of mice with 
125mg resveratrol/kg/day resulted in increased muscle content of antioxidant 
defences but had little effect on age-related changes in force generation. It is possible 
that that a longer term treatment and a more severe sarcopenic phenotype is required 
to produce a beneficial effect with resveratrol. 
6. The study successfully established a 3D muscle construct which can be used to 
study the direct effects of compounds such as resveratrol or its metabolites on muscle 
function in vitro.  
8.2 General discussion of the data presented  
A number of general areas for discussion are highlighted by these data: 
During ageing, the function and mass of skeletal muscle declines and this is 
known as sarcopenia (Rosenberg, 1989). In a large number of cases sarcopenia leads to 
a loss of mobility resulting in the loss of independence and a poor quality of life as well 
as an increase in the likelihood of development other diseases and mortality (Landi et 
al., 2013). The poor prognosis of individuals with sarcopenia coupled with the ever 
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increasing lifespan means that sarcopenia is becoming a huge economic burden for 
society (WHO, 2014).  
The mechanisms responsible for sarcopenia are unclear, however it is 
accepted that the increased state of inflammation that occurs with ageing (Fagiolo et 
al., 1993; Sorby Borge et al., 2009; Caldow et al., 2013) is likely to play a major role. 
Some other factors thought to contribute to sarcopenia include; changes in the 
production and effect of ROS (Harman, 1956), mitochondrial dysfunction (Short et al., 
2005), changes in autophagy (Cuervo et al., 2000) and ubiquitin-proteasomal pathways 
(Ponnappan et al., 1999; Chondrogiannia et al., 2000) and anabolic resistance (Welle et 
al., 1993). Changes to important systems during ageing results in the complete loss of 
muscle fibres, inability of muscles to regenerate (Gibson et al., 1983) (Shefer et al., 
2006; Day et al., 2010), a decrease in type II fibre numbers and cross sectional area 
(Lee et al., 2006), a decrease in the number of motor neurons (Rowan et al., 2012), 
denervation of neuromuscular junctions, (Deschenes et al., 2010), infiltration of 
connective tissue (Brack et al., 2007) and fat (Borkan et al., 1983; Visser et al., 2005) all 
of which subsequently contribute to the decrease in muscle mass and function that is 
seen in sarcopenia. 
Polyphenols are plant extracts and resveratrol is one of the most studied 
polyphenols, due to the beneficial effects shown in a number of diseases (Jang et al., 
1997; Brasnyó et al., 2011; Harati et al., 2015). Resveratrol has also been proposed to 
have beneficial effects in sarcopenia (Dolinsky et al., 2012).  
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The overall aim of this study was to identify a concentration of resveratrol that 
could be functional in skeletal muscle and identify whether resveratrol could be a 
useful therapeutic for sarcopenia.  
8.2.1 Effect of resveratrol on myoblast and myotube viability  
Treatment of myoblasts with 0.1, 1 and 10µM of resveratrol for up to 24H 
resulted in a decrease in the number of myoblasts, suggesting that a short term 
treatment of resveratrol may be toxic to myoblasts. Similar results were seen in human 
lung cells, were treatment with resveratrol resulted in a decrease in metabolic rate 
suggesting inhibition of oxidative phosphorylation (Robb et al., 2006). Despite this 
initial decrease in cell number, at 48H following treatment with 0.1, 1 and 10µM of 
resveratrol, an increase in the proliferation rate of myoblasts, pre-mature elongation 
and fusion in resveratrol-treated myoblasts could be seen in agreement with other 
studies and demonstrating that resveratrol can increase proliferation and cause early 
myogenesis (Kaminskia et al., 2012a; Montesano et al., 2013).  
Taken together, these data suggest that resveratrol is not chronically toxic to 
myoblasts. The initial decrease in myoblast number may be due to the ability of 
resveratrol to affect the motility of myoblasts which has previously been shown 
(Bosutti et al., 2015).  
Treatment of myotubes with 0.1, 1 and 10µM of resveratrol also resulted in an 
initial increase in cell death seen at 3 days following treatment and this effect was 
extended until 5 days following treatment with 10µM of resveratrol. However this cell 
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death was not evident at later time points. This suggests that myotubes may be more 
susceptible to death than myoblasts and may be due to myotubes having a higher 
uptake of resveratrol than myoblasts (Kaminskia et al., 2012a), although this was not 
determined in this study. However, as myotube specific staining was not carried out it 
is possible that the cell death that was detected may have occurred in myoblasts that 
did not differentiate into myotubes or fibroblasts that are also present in primary 
muscle cultures, therefore, in future, elimination of fibroblasts would be useful. 
These data agrees with existing data that resveratrol may initially cause some 
damage to skeletal muscle however in the long term, resveratrol is relatively non-toxic. 
Furthermore, data also suggest that resveratrol is able to induce fusion and thus early 
differentiation to myotubes (Kaminskia et al., 2012a; Montesano et al., 2013) which 
may be beneficial in certain condition such as muscles of older people recovering from 
damage.  
8.2.2 Effect of resveratrol on antioxidant defence enzyme content in myoblasts and 
myotubes 
Increases in the protein levels and activity of the antioxidant defence enzymes 
MnSOD and catalase were seen following resveratrol treatment of muscle (Jackson et 
al., 2010; Ryan et al., 2010; Bennett et al., 2013). Treatment of myoblasts with 
resveratrol resulted in a transient upregulation of MnSOD protein content in 
myoblasts; whereby 0.1µM of resveratrol to increased MnSOD content at 3H after 
treatment; 1µM upregulated MnSOD content for up to 24H after treatment and 10µM 
for up to 48H. The different concentrations had different temporal effects suggesting 
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that they may function through different pathways (Centeno-Baez et al., 2011; Bosutti 
et al., 2015).  
Treatment of myoblasts with resveratrol resulted in a dose dependent 
increase in catalase protein content with 0.1µM of resveratrol increasing catalase 
content for up to 6H, 1µM for up to 24H and 10µM for up to 48H. These data show 
that resveratrol is able to have functional effects in myoblasts and the longer 
maintenance of MnSOD upregulation with 10µM resveratrol treatment, also agrees 
with data from Chapter 3 where cell viability assays identified that treatment of 
myoblasts with 10µM of resveratrol provided a longer term protection than the lower 
concentrations of resveratrol. The increase in MnSOD and catalase protein content in 
the myoblasts also suggests a potential mechanism by which resveratrol is able to 
protect myoblasts from cell death (Figure 3.8).  
In a similar manner to myoblasts, treatment of myotubes with resveratrol 
resulted in increases in MnSOD and catalase protein content for up to 7 days following 
treatment with 1µM and 10µM of resveratrol. Treatment of myotubes with 0.1µM of 
resveratrol resulted in an increase in MnSOD protein content in myotubes for up to 3 
days and catalase for up to 5 days. These data suggested that resveratrol is able to 
have a functional effect on myotubes.  
Some would argue that the increases in antioxidant defence enzymes 
following a polyphenol treatment are predictable as polyphenols have been shown to 
react with components in cell culture media to produce hydrogen peroxide (Long et al., 
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2010). However unpublished data from our lab and other data showed that the 
addition of resveratrol to the media used in these studies did not result in hydrogen 
peroxide production. Furthermore, this study demonstrated that treatment of 
myotubes with resveratrol led to a decrease in hydrogen peroxide production by 
myotubes (Figure 4.12). This is likely to be due to the increase in the antioxidant 
MnSOD and catalase protein content and suggests that the increases in MnSOD and 
catalase is a likely to be direct effect of the resveratrol treatment.  
8.2.3 Effect of resveratrol on Sirt1 protein content in myoblasts and myotubes.  
Sirt1 is a deacetylase involved in silencing of gene transcription and has been 
shown to be the direct target of resveratrol in numerous tissues as well as in skeletal 
muscle (Price et al., 2012). It is through the increase in Sirt1 the activation of the 
mitochondrial master regulator PGC1-α is thought to occur. Despite the evidence for a 
role of Sirt1, the activation of Sirt1 following resveratrol treatment is highly debated 
(Beher et al., 2009; Pacholec et al., 2010). Therefore, the aim was to examine the effect 
of a treatment of resveratrol on Sirt1 protein content of rat primary skeletal muscle 
cells.  
Treatment of myoblasts with 0.1,1 and 10µM of resveratrol for up to 48H 
resulted in temporal increases in Sirt1 protein content that did not correlate with 
antioxidant defence enzyme protein content and was therefore inconclusive as to 
whether Sirt1 was involved in resveratrol- mediated effects on myoblasts.  
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Treatment of myotubes with 0.1, 1 and 10µM of resveratrol resulted in a 
decrease in Sirt1 protein content following 3 and 5 days of treatment. This was 
supported by data showing more acetylation of proteins in resveratrol treated 
myotubes than in untreated myotubes. These data support other studies that suggest 
Sirt1 is not a direct target for resveratrol (Pacholec et al., 2010). However, as Sirt1 has 
been shown to inhibit myogenesis (Fulco et al., 2003), the decreases in Sirt1 in 
resveratrol treated myotubes that were observed in this study also support a role for 
resveratrol as an initiator of early myogenesis. These data suggests that resveratrol 
may cause early myogenesis by decreasing Sirt1 activity and thus preventing the Sirt1 
mediated inhibition of myogenesis (Rathbone et al., 2009).   
8.2.4 Hypertrophic effects of resveratrol on myotubes 
Hypertrophic and atrophic effects are studied in cell culture by measuring the 
diameter of myotubes, with increases in myotube diameter suggesting hypertrophic 
effects and decreases showing atrophic effects. Treatment of myotubes with 0.1, 1 and 
10µM of resveratrol resulted in an increase myotube diameter following 3 days of 
treatment suggesting that resveratrol has hypertrophic effects in skeletal muscle. This 
is supported by other studies that have found hypertrophic effects (Montesano et al., 
2013) and increases in force production (Dolinsky et al., 2012) following resveratrol 
treatment in skeletal muscle. Other studies have also shown that, as well as preventing 
the increase in proteasomal degradation, resveratrol is able to upregulate the Akt 
pathway (Wang et al., 2014), which is responsible for hypertrophy in skeletal muscle. 
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This suggests a potential mechanism for the increase in myotube diameter seen in 
resveratrol treated myotubes. However this was not considered in the current study.  
Treatment of myotubes with 10µM of resveratrol resulted in an increased 
myotube diameter treatment for up to 3 days and this effect was still seen following a 
5 day treatment with 0.1µM and 1µM of resveratrol however any further treatment 
with resveratrol did not illicit any effects. The absence of any long term increases in 
myotube diameter following resveratrol treatment suggests that resveratrol does not 
maintain a hypertrophic response in skeletal muscle myotubes. However, it does 
further support the theory that resveratrol causes early myogenesis. It is possible 
therefore that resveratrol treated myotubes reach peak diameter earlier than control 
myotubes, and thus explains the absence of any differences in myotube diameter at 
later time points when myogenesis would be complete.  
These data provide further evidence for resveratrol increasing myogenesis and 
also highlights the advantageous effects of the lower concentrations of resveratrol on 
skeletal muscle. 
8.2.5 Effect of IP10 on markers of atrophy in myotubes, role of resveratrol 
The increase in inflammation during ageing is well characterised and recently 
the chemokine IP10 has been shown to be a major contributor to this age-related 
increase in inflammation (Miles et al., 2008). Only a sparse amount of work has been 
carried out examining the effect of IP10 on muscle. Data in this thesis have shown that 
treatment of myotubes with doses of IP10 found in the old (200pg/ml) resulted in a 
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decrease in myotube diameter. In contrast, treatment of myotubes with IP10 at levels 
found in younger individuals (150pg/ml) had no major effect on myotube diameter. 
Pre-treatment of myotubes with resveratrol prevented this IP10-induced decrease in 
myotube diameter. These data suggest that the increase in levels of IP10 during ageing 
may contribute to skeletal muscle atrophy and therefore may play an important role in 
sarcopenia, particularly as data demonstrated more detrimental effects with more 
chronic treatment. A role for IP10 in the development of sarcopenia is further 
supported by the absence of atrophic effects on muscle using levels of IP10 found in 
the younger individuals.  
It should be noted that it is possible that the ability of a resveratrol pre-
treatment with IP10 in preventing the decrease in myotube diameter following 
treatment was due to the ability of resveratrol to increase myotube diameter and thus 
the myotubes may have a larger diameter at the time of IP10 treatment. However, this 
is unlikely, as no differences where seen in the diameter of myotubes treated with IP10 
at lower concentrations found in the young with or without a pre-treatment with the 
same concentration of resveratrol.   
Treatment of myotubes with IP10 resulted in temporal increases in the mRNA 
expression of the muscle specific ubiquitin ligase Atrogin1. This suggested an increase 
in proteasomal degradation as a mechanism responsible for the atrophic effects of 
IP10. This theory is further supported by the fact that a pre-treatment of myotubes 
with resveratrol prevented both the decrease in diameter and the increase in Atrogin1 
mRNA expression caused by treatment of myotubes with IP10. 
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Data from this study showed that a pre-treatment of resveratrol followed by a 
10 day treatment with IP10 at concentrations found in the young also resulted in an 
increase in Atrogin1 mRNA expression that was absent in myotubes treated with the 
lower level of IP10 alone. These data suggest that, at least in skeletal muscle, 
resveratrol supplementation of a healthy subject could be detrimental. It also 
highlights the possibility that resveratrol should only be used as a treatment for 
sarcopenia when there is a pre-existing condition and not as a preventative to retain 
skeletal muscle. Furthermore, these data support other studies that show the health 
status of the subject dictates the outcome of the resveratrol treatment (Lagouge et al., 
2006) and that if no pre-existing condition is present, a treatment of resveratrol may 
be detrimental, at least in skeletal muscle.  
8.2.6 Effect of IP10 and resveratrol on muscle inflammation  
Treatment of myotubes with resveratrol alone led to anti-inflammatory effects 
with an increase in IL13 and IL2 and decreasing IL7. Treatment of myotubes with IP10 
had only subtle effects on the inflammatory profile in the media of myotubes, 
treatment of myotubes with levels of 150pg/ml and 200pg/ml of IP10 surprisingly 
showing changes in both pro and anti-inflammatory cytokines. There was also no major 
difference in the effects of the two concentrations of IP10 on the cytokine profile in the 
media of myotubes. Similarly, pre-treatment of myotubes with resveratrol prior to IP10 
treatment had both pro and anti-inflammatory effects; treatment with resveratrol was 
able to prevent some of the increases in pro-inflammatory cytokines however, pre-
treatment with resveratrol also prevented some of the IP10-induced anti-inflammatory 
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effects in the media of myotubes. Although the data were relatively ambiguous, data 
provided no evidence for a major anti-inflammatory role of resveratrol in skeletal 
muscle and suggest that the beneficial effects seen in skeletal muscle following 
resveratrol treatment in Chapters 3-4 were not due to anti-inflammatory effects. 
Furthermore, the lack of differential effects with a treatment of IP10 at 150pg/ml or 
200pg/ml suggest that the increases in IP10 during ageing are not a major regulator of 
the changes in the cytokine profile of skeletal muscle that occur with ageing.  
Clustergram analysis of the cytokine content of the media of myotubes 
following treatment with IP10, suggested that MCP-1 and IL6 may be major regulators 
of skeletal muscle inflammation in this situation. Data also provided evidence that 
resveratrol affects myoblast proliferation by the clustering of IL13 and GRO-KC, as well 
as affecting IL7 content in the media of myotubes. Similarly to previous data in this 
study, clustergram data showed temporal effects, suggesting a potential role of the 
stage of myogenesis in the differences observed in cytokine production.  
8.2.7 Effect of resveratrol on muscle function in vivo 
Daily oral treatments of mice with 125mg resveratrol/kg/day for 14 days 
demonstrated that in contrast to in vitro studies, Sirt1 was upregulated in vivo 
following resveratrol treatment. Daily oral treatments of resveratrol for 14 days 
resulted in no significant effect on force generation in adult or old mice. The lack of 
statistical differences may be due to the lack of gross sarcopenia in old mice and 
furthermore, the low number of animals used in this pilot study. Therefore, future 
studies would utilise these data for a powered study if appropriate.  
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8.2.8 Resveratrol as a therapeutic compound for sarcopenia 
Data have shown that resveratrol can be beneficial to skeletal muscle and can 
result in the upregulation of antioxidant defence enzymes to protect against increases 
in ROS, as well as a decrease in proteasomal degradation. This leads to an increase in 
myotube diameter of myotubes in culture as well as preventing the atrophic effects 
induced by an IP10. Furthermore, data demonstrated that resveratrol was able to 
increase proliferation of satellite cells and initiate early myogenesis, suggesting that it 
may be a good treatment for injured muscle or following muscle unloading. Functional 
measurements of the effect of resveratrol as a supplementation in vivo were 
disappointing in the pilot study and it is likely that a longer treatment is needed 
possibly with a more severe phenotype of sarcopenia, when inflammation is 
substantially increased to see more benefits.   
In vitro data suggested that treatment with resveratrol may be detrimental to 
‘healthy’ muscle; force measurements in young mice showed no suggestion of this. 
However treatment of adult mice with resveratrol resulted in a decrease in CSA, 
agreeing with cell culture data that resveratrol can be detrimental to skeletal muscle.   
In conclusion this study showed that resveratrol has the potential to be an 
efficient treatment for the alleviation of some of the molecular changes that occur with 
sarcopenia. However, cell culture work suggested that further work is needed and it is 
likely that personalised doses of resveratrol may be required depending on the stage of 
sarcopenia. 
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8.3 Potential future studies  
 
These studies showed that resveratrol has the ability to alleviate IP10 induced 
atrophy and that increases in serum levels of IP10 may contribute to sarcopenia and 
thus propose resveratrol as a potential treatment for sarcopenia as well as IP10 as a 
potential therapeutic target. Several further experiments could be carried out to 
further test these findings.  
Chapter 4 provided evidence that treatment of myotubes with resveratrol 
increases myotube diameter and further prevented the decrease in myotube diameter 
induced by concentrations of IP10 found in the old. Some studies propose that this is 
due to induction of hypertrophy whereas these data suggest that resveratrol initiates 
early myogenesis. Therefore the identification of changes in the Akt pathway and 
myogenesis regulatory factors following treatment of myotubes with IP10 treatment 
+/- resveratrol pre-treatment would identify whether resveratrol was able to cause 
hypertrophy or solely induce pre-mature myogenesis.  
This study has suggested that resveratrol may have some beneficial effects in 
sarcopenic skeletal muscle however; data from Chapter 5 showed that lower levels of 
IP10 such as those seen in healthy adults together with a pre-treatment with 
resveratrol resulted in an increase in Atrogin1 in myotubes. Therefore, future 
experiments identifying the molecular effects of resveratrol on healthy muscle would 
identify any negative effects of such treatment and whether resveratrol could be used 
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as a treatment for sarcopenia or whether caution should be used when using 
resveratrol as a preventative measure.  
Data showed that, in skeletal muscle, resveratrol had functional effects through 
the upregulation of antioxidant defence enzymes, MnSOD and catalase. As there is an 
age-related increase in the muscle content of these enzymes (Vasilaki et al., 2006), cell 
culture studies using siRNA to inhibit or the addition to overexpress these enzymes 
would confirm whether this is the mechanism through which resveratrol was 
functioning and would further allow identification of pathways that resveratrol may be 
functioning through. This would also identify whether resveratrol was able to further 
increase these enzymes when their muscle contents was already at elevated levels 
(Vasilaki et al., 2006).  
  Finally, although this thesis has shown that resveratrol can alleviate some of 
the molecular changes hypothesised to be involved in sarcopenia the study lacks clear 
measurements of muscle function. Therefore using the optimised 3D construct 
(myooid) treated with IP10 and resveratrol or its metabolites followed by 
measurement of force generation would allow identification of the effect of increasing 
levels of IP10 directly on skeletal muscle and therefore validate a role of IP10 in 
sarcopenia as well as the ability of resveratrol or other compounds on muscle function.  
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10.1. Ponceau stain for western blotting 
10.1.1. Three hour resveratrol treated myoblasts Ponceau S 
Ponceau S (Sigma Aldrich, Dorset, UK) staining for normalisation for western 
blot analysis of MnSOD, catalase and Sirt1 protein content at 3H following resveratrol 
treatment (Figure 3.8, Figure 3.10 and Figure 3.12) is shown in Figure 10.1. 
 
Figure 10.1 Ponceau S staining for normalisation for (a) MnSOD and catalase and (b) Sirt1 
content at following 3H resveratrol treatment. 
10.1.2. Six hour resveratrol treated myoblasts Ponceau S 
 Ponceau S (Sigma Aldrich, Dorset, UK) staining for normalisation for western 
blot analysis of MnSOD, catalase and Sirt1 protein content at 6H following resveratrol 
treatment (Figure 3.8, Figure 3.10 and Figure 3.12) is shown in is shown in Figure 10.2 
 
Figure 10.2 Ponceau S staining for normalisation for MnSOD, catalase and Sirt1 protein 
content following 6H resveratrol treatment.  
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10.1.3. Twelve hour resveratrol treated myoblasts Ponceau S 
 Ponceau S (Sigma Aldrich, Dorset, UK) staining for normalisation for western 
blot analysis of MnSOD, catalase and Sirt1 protein content following 12H resveratrol 
treatment (Figure 3.8, Figure 3.10 and Figure 3.12) is shown in is shown in Figure 10.3 
 
Figure 10.3 Ponceau S staining for normalisation for (a) MnSOD, catalase and (b) Sirt1 protein 
content following 12H resveratrol treatment.  
10.1.4. Twenty four hour resveratrol treated myoblasts Ponceau S 
 Ponceau S (Sigma Aldrich, Dorset, UK) staining for normalisation for western 
blot analysis of MnSOD, catalase and Sirt1 protein content following 24H resveratrol 
treatment (Figure 3.8, Figure 3.10 and Figure 3.12) is shown in is shown in Figure 10.4. 
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Figure 10.4 Ponceau S staining for normalisation for (a) MnSOD, (b)catalase and (c) Sirt1 
protein content following 24H resveratrol treatment. 
 
10.1.5. Forty eight hour resveratrol treated myoblasts Ponceau S 
Ponceau S (Sigma Aldrich, Dorset, UK) staining for normalisation for western 
blot analysis of MnSOD, catalase and Sirt1 protein content following 48H resveratrol 
treatment (Figure 3.8, Figure 3.10 and Figure 3.12) is shown in is shown in Figure 10.5. 
 
Figure 10.5 Ponceau S staining for normalisation for MnSOD, catalase and Sirt1 protein 
content following 48H resveratrol treatment.  
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10.1.6. Three day resveratrol treated myotube Ponceau S 
 Ponceau S (Sigma Aldrich, Dorset, UK) staining for normalisation for western 
blot analysis of MnSOD, catalase and Sirt1 protein content following 3 day resveratrol 
treatment (Figure 4.6, Figure 4.7 and Figure 4.8) is shown in is shown in Figure 10.6. 
 
Figure 10.6 Ponceau S staining for normalisation for MnSOD, catalase and Sirt1 protein 
content following 3 day resveratrol treatment.  
10.1.7. Five day resveratrol treated myotube Ponceau S  
Ponceau S (Sigma Aldrich, Dorset, UK) staining for normalisation for western 
blot analysis of MnSOD, catalase and Sirt1 protein content following 5 day resveratrol 
treatment (Figure 4.6, Figure 4.7 and Figure 4.8) is shown in is shown in Figure 10.7. 
 
Figure 10.7 Ponceau S staining for normalisation for MnSOD, catalase and Sirt1 protein 
content following 5 day resveratrol treatment.  
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10.1.8. Seven day resveratrol treated myotube Ponceau S  
Ponceau S (Sigma Aldrich, Dorset, UK) staining for normalisation for western 
blot analysis of MnSOD, catalase and Sirt1 protein content following 7 day resveratrol 
treatment (Figure 4.6, Figure 4.7 and Figure 4.8) is shown in is shown in Figure 10.8. 
 
Figure 10.8 Ponceau S staining for normalisation for MnSOD, catalase and Sirt1 protein 
content following 7 day resveratrol treatment.  
10.2. Effect of resveratrol and IP10 treatment on Murf1 expression in myotubes 
The effect of a 24H 150pg/ml and 200pg/ml of IP10 with and without a 
resveratrol treatment on Murf1 mRNA levels is shown in Figure 10.9. 
 
Figure 10.9 Effect of IP10 and resveratrol on Murf1 mRNA levels following a 1 day IP10 
treatment +/- a 7 day resveratrol pre-treatment.  
